Systems and methods for generating lipid nanoparticles

By controlling the generation of lipid nanoparticles through a conduit and static mixer system, the problems of uneven particle size and distribution were solved, and efficient nucleic acid delivery was achieved.

CN123124967APending Publication Date: 2026-11-17RECODE THERAPEUTICS INC
View PDF 4 Cites 0 Cited by

Patent Information

Application Number
CN202580027729.4
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Priority Date
2024-12-20
Filing Date
2025-02-14
Publication Date
2026-11-17

AI Technical Summary

Technical Problem

Existing lipid nanoparticle generation technologies struggle to effectively control particle size and distribution, resulting in low delivery efficiency.

Method used

By employing a conduit and static mixer system, and configuring the conduit inlet and outlet, and using the static mixer to mix nucleic acid and lipid components, the polydispersity index and Reynolds number of the mixture fluid are controlled to generate lipid nanoparticles with uniform diameter.

Benefits of technology

This achieved uniformity and efficient delivery of lipid nanoparticles, improving the delivery efficiency of therapeutic nucleic acids.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN123124967A_ABST
    Figure CN123124967A_ABST
Patent Text Reader

Abstract

This disclosure provides systems and methods for generating lipid nanoparticles. The system may include a conduit comprising a first inlet configured to introduce nucleic acids. The conduit may further include a second inlet configured to introduce one or more lipid components of the lipid nanoparticles. The conduit may further include an outlet where the nucleic acid and one or more lipid components converge. The system may further include a static mixer. The nucleic acid and one or more lipid components may be mixed in the static mixer to generate a mixture fluid. The polydispersity index of the mixture fluid may be no greater than about 0.25.
Need to check novelty before this filing date? Find Prior Art

Description

[0001] Cross-referencing This application claims the benefits of U.S. Provisional Application No. 63 / 554,054, filed February 15, 2024, and U.S. Provisional Application No. 63 / 737,069, filed December 20, 2024, each of which is incorporated herein by reference in its entirety. Background Technology

[0002] Therapeutic nucleic acids, such as those capable of gene silencing, expression, and editing, have great potential for use as gene therapies. Lipid nanoparticles (LNPs) can be used to deliver nucleic acids to treat or prevent a variety of diseases and conditions. Summary of the Invention

[0003] This document provides a system for generating lipid nanoparticles. In some embodiments, the system includes a conduit; a static mixer in which nucleic acids and one or more lipid components are mixed to generate a mixture fluid; and a high-performance liquid chromatography (HPLC) pump. In some embodiments, this document provides a system for generating lipid nanoparticles, the system including a conduit and a static mixer in which nucleic acids and one or more lipid components are mixed to generate a mixture fluid, wherein the system reaches a pressure not exceeding 8 psig when the nucleic acids and one or more lipid components converge in the static mixer. In some embodiments, the conduit includes a first inlet configured to introduce nucleic acids. In some embodiments, the conduit includes a second inlet configured to introduce one or more lipid components of lipid nanoparticles. In some embodiments, the conduit includes an outlet in which nucleic acids and one or more lipid components converge. In some embodiments, the conduit includes a third inlet configured to introduce either nucleic acids or one or more lipid components of lipid nanoparticles. In some embodiments, the conduit includes a fourth inlet configured to introduce either nucleic acids or one or more lipid components of lipid nanoparticles. In some embodiments, the static mixer includes multiple elements in which each element of the static mixer undergoes a 270° twist per 1 / 8 inch. In some embodiments, the system includes a channel that houses a static mixer configured to mix nucleic acids and one or more lipid components, wherein the channel is square and undergoes a -180° twist every 1 / 8 inch. In some embodiments, the conduit is T-shaped. In some embodiments, the conduit is Y-shaped. In some embodiments, the conduit further includes a cut ties. In some embodiments, the conduit is L-shaped. In some embodiments, the length of the static mixer is less than about 40 millimeters (mm). In some embodiments, the length of the static mixer is less than about 10 mm. In some embodiments, the length of the static mixer is less than about 5 mm. In some embodiments, the length of the static mixer is about 4.8 mm. In some embodiments, the static mixer has an inner diameter of about 1 / 16 inch to about 1 / 2 inch. In some embodiments, the inner diameter is about 1 / 4 inch. In some embodiments, the inner diameter is about 1 / 8 inch. In some embodiments, the polydispersity index of the mixture fluid is about 0.05 to about 0.25. In some embodiments, the polydispersity index of the mixture fluid is about 0.1 to about 0.2. In some embodiments, the polydispersity index of the mixture fluid is not greater than about 0.1. In some embodiments, the Reynolds number of the mixture fluid is from about 150 to about 1000. In some embodiments, the Reynolds number is from about 500 to about 1000. In some embodiments, the Reynolds number is about 1000. In some embodiments, the diameter of the lipid nanoparticles is not greater than about 100 nanometers (nm). In some embodiments, the diameter of the lipid nanoparticles is from about 50 nm to about 100 nm.In some embodiments, the diameter of the lipid nanoparticles is about no greater than about 50 nm. In some embodiments, the flow rate ratio of the lipid component to the nucleic acid is about 1:2 to about 1:5. In some embodiments, the flow rate ratio of the lipid component to the nucleic acid is about 1:2. In some embodiments, the flow rate ratio of the lipid component to the nucleic acid is about 1:3. In some embodiments, nucleic acid and one or more lipid components are mixed to generate a mixture fluid, thereby encapsulating the nucleic acid in one or more lipid components to generate lipid nanoparticles. In some embodiments, the static mixer includes eight or more elements. In some embodiments, the static mixer includes 12 or more elements. In some embodiments, the static mixer includes 16 or more elements. In some embodiments, the static mixer includes 24 or more elements. In some embodiments, the static mixer is downstream of the catheter.

[0004] The aspects disclosed herein relate to a system for generating lipid nanoparticles, the system comprising: a conduit including: a first inlet configured to introduce nucleic acids; a second inlet configured to introduce one or more lipid components of the lipid nanoparticles; an outlet in which the nucleic acids and one or more lipid components converge; and a static mixer in which the nucleic acids and one or more lipid components are mixed to generate a mixture fluid, and wherein the polydispersity index of the mixture fluid is not greater than about 0.25. In some embodiments, the conduit is T-shaped. In some embodiments, the conduit is Y-shaped. In some embodiments, the conduit further includes a cut cable tie. In some embodiments, the conduit is L-shaped. In some embodiments, the length of the static mixer is less than about 40 millimeters (mm). In some embodiments, the length of the static mixer is less than about 10 mm. In some embodiments, the length of the static mixer is less than about 5 mm. In some embodiments, the length of the static mixer is about 4.8 mm. In some embodiments, the static mixer has an inner diameter of about 1 / 16 inch to about 1 / 2 inch. In some embodiments, the inner diameter is about 1 / 4 inch. In some embodiments, the inner diameter is about 1 / 8 inch. In some embodiments, the polydispersity index is from about 0.05 to about 0.25. In some embodiments, the polydispersity index is from about 0.1 to about 0.2. In some embodiments, the polydispersity index is not greater than about 0.1. In some embodiments, the Reynolds number of the mixture fluid is from about 150 to about 1000. In some embodiments, the Reynolds number is from about 500 to about 1000. In some embodiments, the Reynolds number is about 1000. In some embodiments, the lipid nanoparticles are not larger than about 100 nanometers (nm). In some embodiments, the lipid nanoparticles are from about 50 nm to about 100 nm. In some embodiments, the lipid nanoparticles are not larger than about 50 nm. In some embodiments, the flow rate ratio of the lipid component to the nucleic acid is from about 1:2 to about 1:5. In some embodiments, the flow rate ratio of the lipid component to the nucleic acid is about about 1:2. In some embodiments, the flow rate ratio of the lipid component to the nucleic acid is about 1:3. In some embodiments, nucleic acids and one or more lipid components are mixed to generate a mixture fluid, thereby encapsulating the nucleic acids within one or more lipid components to generate lipid nanoparticles. In some embodiments, the static mixer comprises eight or more elements. In some embodiments, the static mixer comprises 12 or more elements. In some embodiments, the static mixer comprises 16 or more elements. In some embodiments, the static mixer comprises 24 or more elements. In some embodiments, the static mixer is downstream of the catheter. In some embodiments, the system reaches a pressure not exceeding 8 psig.In some implementations, the system further includes a high-performance liquid chromatography (HPLC) pump configured to deliver nucleic acids and one or more lipid components at a specified flow rate.

[0005] This document discloses a method for generating lipid nanoparticles, the method comprising: providing a conduit and a static mixer, the conduit including: a first inlet; a second inlet; an outlet; introducing nucleic acid into the first inlet; introducing one or more lipid components of the lipid nanoparticles into the second inlet; converging the nucleic acid and one or more lipid components at the outlet; and mixing the nucleic acid and one or more lipid components using the static mixer to generate a mixture fluid, wherein the polydispersity index of the mixture fluid is not greater than about 0.25. In some embodiments, the conduit is T-shaped. In some embodiments, the conduit is Y-shaped. In some embodiments, the conduit further includes a cut cable tie. In some embodiments, the conduit is L-shaped. In some embodiments, the length of the static mixer is less than about 40 mm. In some embodiments, the length of the static mixer is less than about 10 mm. In some embodiments, the length of the static mixer is less than about 5 mm. In some embodiments, the length of the static mixer is about 4.8 mm. In some embodiments, the static mixer has an inner diameter of about 1 / 16 inch to about 1 / 2 inch. In some embodiments, the inner diameter is about 1 / 4 inch. In some embodiments, the inner diameter is about 1 / 8 inch. In some embodiments, the polydispersity index is from about 0.05 to about 0.25. In some embodiments, the polydispersity index is from about 0.1 to about 0.2. In some embodiments, the polydispersity index is not greater than about 0.1. In some embodiments, the Reynolds number of the mixture fluid is from about 150 to about 1000. In some embodiments, the Reynolds number is from about 500 to about 1000. In some embodiments, the Reynolds number is about 1000. In some embodiments, the lipid nanoparticles are not greater than about 100 nm. In some embodiments, the lipid nanoparticles are from about 50 nm to about 100 nm. In some embodiments, the lipid nanoparticles are not greater than about 50 nm. In some embodiments, the flow rate ratio of the lipid component to the nucleic acid is from about 1:2 to about 1:5. In some embodiments, the flow rate ratio of the lipid component to the nucleic acid is about about 1:2. In some embodiments, the flow rate ratio of the lipid component to the nucleic acid is about 1:3. In some embodiments, nucleic acids and one or more lipid components are mixed to generate a mixture fluid, thereby encapsulating the nucleic acids within one or more lipid components to generate lipid nanoparticles. In some embodiments, the static mixer comprises eight or more elements. In some embodiments, the static mixer comprises 12 or more elements. In some embodiments, the static mixer comprises 16 or more elements. In some embodiments, the static mixer comprises 24 or more elements. In some embodiments, the static mixer is downstream of the catheter. In some embodiments, the system reaches a pressure not exceeding 8 psig.In some implementations, the system further includes a high-performance liquid chromatography (HPLC) pump configured to deliver nucleic acids and one or more lipid components at a specified flow rate.

[0006] The aspects disclosed herein relate to a system for generating lipid nanoparticles, the system comprising: a conduit and a static mixer, the conduit including: a first inlet configured to introduce nucleic acids; a second inlet configured to introduce one or more lipid components of the lipid nanoparticles; a junction site where the first and second inlets intersect; and the static mixer being configured to mix the nucleic acids and one or more lipid components, wherein the nucleic acids and one or more lipid components do not contact each other before entering the junction site. In some embodiments, the conduit is T-shaped. In some embodiments, the conduit is Y-shaped. In some embodiments, the conduit further includes a cut tie. In some embodiments, the conduit is L-shaped. In some embodiments, the length of the static mixer is less than about 40 mm. In some embodiments, the length of the static mixer is less than about 10 mm. In some embodiments, the length of the static mixer is less than about 5 mm. In some embodiments, the length of the static mixer is about 4.8 mm. In some embodiments, the static mixer has an inner diameter of about 1 / 16 inch to about 1 / 2 inch. In some embodiments, the inner diameter is about 1 / 4 inch. In some embodiments, the inner diameter is about 1 / 8 inch. In some embodiments, nucleic acids and one or more lipid components are mixed to generate a mixture fluid, wherein the polydispersity index of the mixture fluid is from about 0.05 to about 0.25. In some embodiments, the polydispersity index is from about 0.1 to about 0.2. In some embodiments, the polydispersity index is not greater than about 0.1. In some embodiments, the Reynolds number of the mixture fluid is from about 150 to about 1000. In some embodiments, the Reynolds number is from about 500 to about 1000. In some embodiments, the Reynolds number is about 1000. In some embodiments, the lipid nanoparticles are not larger than about 100 nm. In some embodiments, the lipid nanoparticles are from about 50 nm to about 100 nm. In some embodiments, the lipid nanoparticles are not larger than about 50 nm. In some embodiments, the flow rate ratio of the lipid component to the nucleic acid is from about 1:2 to about 1:5. In some embodiments, the flow rate ratio of the lipid component to the nucleic acid is about about 1:2. In some embodiments, the flow rate ratio of the lipid component to the nucleic acid is about 1:3. In some embodiments, nucleic acids and one or more lipid components are mixed to generate a mixture fluid, thereby encapsulating the nucleic acids within one or more lipid components to generate lipid nanoparticles. In some embodiments, the static mixer comprises eight or more elements. In some embodiments, the static mixer comprises 12 or more elements. In some embodiments, the static mixer comprises 16 or more elements. In some embodiments, the static mixer comprises 24 or more elements. In some embodiments, the static mixer is downstream of the conduit. In some embodiments, the system reaches a pressure not exceeding 8 psig.In some implementations, the system further includes a high-performance liquid chromatography (HPLC) pump configured to deliver nucleic acids and one or more lipid components at a specified flow rate.

[0007] This document discloses a method for generating lipid nanoparticles, the method comprising: providing a conduit and a static mixer, the conduit including a first inlet; a second inlet; a junction site downstream of the first and second inlets; wherein the static mixer is disposed distal to the junction site; introducing a nucleic acid into the first inlet; introducing one or more lipid components of the lipid nanoparticles into the second inlet; converging the nucleic acid and one or more lipid components at the junction site; and mixing the nucleic acid and one or more lipid components using the static mixer, wherein the nucleic acid and one or more lipid components do not contact each other before entering the junction site. In some embodiments, the conduit is T-shaped. In some embodiments, the conduit is Y-shaped. In some embodiments, the conduit further includes a cut tie. In some embodiments, the conduit is L-shaped. In some embodiments, the length of the static mixer is less than about 40 mm. In some embodiments, the length of the static mixer is less than about 10 mm. In some embodiments, the length of the static mixer is less than about 5 mm. In some embodiments, the length of the static mixer is about 4.8 mm. In some embodiments, the static mixer has an inner diameter of about 1 / 16 inch to about 1 / 2 inch. In some embodiments, the inner diameter is about 1 / 4 inch. In some embodiments, the inner diameter is about 1 / 8 inch. In some embodiments, nucleic acids and one or more lipid components are mixed to generate a mixture fluid, wherein the polydispersity index of the mixture fluid is about 0.05 to about 0.25. In some embodiments, the polydispersity index is about 0.1 to about 0.2. In some embodiments, the polydispersity index is not greater than about 0.1. In some embodiments, the Reynolds number of the mixture fluid is about 150 to about 1000. In some embodiments, the Reynolds number is about 500 to about 1000. In some embodiments, the Reynolds number is about 1000. In some embodiments, the lipid nanoparticles are not greater than about 100 nm. In some embodiments, the lipid nanoparticles are about 50 nm to about 100 nm. In some embodiments, the lipid nanoparticles are about not greater than about 50 nm. In some embodiments, the flow rate ratio of the lipid component to the nucleic acid is about 1:2 to about 1:5. In some embodiments, the flow rate ratio of the lipid component to the nucleic acid is about about 1:2. In some embodiments, the flow rate ratio of the lipid component to the nucleic acid is approximately 1:3. In some embodiments, the nucleic acid and one or more lipid components are mixed to generate a mixture fluid, thereby encapsulating the nucleic acid in one or more lipid components to generate lipid nanoparticles. In some embodiments, the static mixer includes eight or more elements. In some embodiments, the static mixer includes 12 or more elements. In some embodiments, the static mixer includes 16 or more elements. In some embodiments, the static mixer includes 24 or more elements. In some embodiments, the static mixer is downstream of the catheter.In some implementations, the system reaches a pressure of no more than 8 psig. In some implementations, the system further includes a high-performance liquid chromatography (HPLC) pump configured to deliver nucleic acids and one or more lipid components at a specified flow rate.

[0008] The aspects disclosed herein relate to a system for generating lipid nanoparticles, the system comprising: a conduit including: a first inlet configured to introduce nucleic acids; a second inlet configured to introduce one or more lipid components of the lipid nanoparticles; an outlet in which the nucleic acids and one or more lipid components converge; and a static mixer in which the nucleic acids and one or more lipid components are mixed to generate a mixture fluid, and wherein the Reynolds number of the mixture fluid is not greater than about 1000. In some embodiments, the conduit is T-shaped. In some embodiments, the conduit is Y-shaped. In some embodiments, the conduit further includes a cut cable tie. In some embodiments, the conduit is L-shaped. In some embodiments, the length of the static mixer is less than about 40 mm. In some embodiments, the length of the static mixer is less than about 10 mm. In some embodiments, the length of the static mixer is less than about 5 mm. In some embodiments, the length of the static mixer is about 4.8 mm. In some embodiments, the static mixer has an inner diameter of about 1 / 16 inch to about 1 / 2 inch. In some embodiments, the inner diameter is about 1 / 4 inch. In some embodiments, the inner diameter is about 1 / 8 inch. In some embodiments, the polydispersity index of the mixture fluid is from about 0.05 to about 0.25. In some embodiments, the polydispersity index is from about 0.1 to about 0.2. In some embodiments, the polydispersity index is not greater than about 0.1. In some embodiments, the Reynolds number is from about 150 to about 1000. In some embodiments, the Reynolds number is from about 500 to about 1000. In some embodiments, the Reynolds number is about 1000. In some embodiments, the lipid nanoparticles are not greater than about 100 nm. In some embodiments, the lipid nanoparticles are from about 50 nm to about 100 nm. In some embodiments, the lipid nanoparticles are about not greater than about 50 nm. In some embodiments, the flow rate ratio of the lipid component to the nucleic acid is from about 1:2 to about 1:5. In some embodiments, the flow rate ratio of the lipid component to the nucleic acid is about about 1:2. In some embodiments, the flow rate ratio of the lipid component to the nucleic acid is about 1:3. In some embodiments, nucleic acids and one or more lipid components are mixed to generate a mixture fluid, thereby encapsulating the nucleic acids within one or more lipid components to generate lipid nanoparticles. In some embodiments, the static mixer comprises eight or more elements. In some embodiments, the static mixer comprises 12 or more elements. In some embodiments, the static mixer comprises 16 or more elements. In some embodiments, the static mixer comprises 24 or more elements. In some embodiments, the static mixer is downstream of the catheter. In some embodiments, the system reaches a pressure not exceeding 8 psig.In some implementations, the system further includes a high-performance liquid chromatography (HPLC) pump configured to deliver nucleic acids and one or more lipid components at a specified flow rate.

[0009] In some embodiments, this document provides a method for generating lipid nanoparticles, the method comprising: providing a conduit and a static mixer; providing nucleic acid and one or more lipid components of the lipid nanoparticles to a high-performance liquid chromatography (HPLC) pump configured to provide the nucleic acid and one or more lipid components at a specified flow rate; introducing the nucleic acid into a first inlet; introducing one or more lipid components of the lipid nanoparticles into a second inlet; converging the nucleic acid and one or more lipid components at an outlet; and mixing the nucleic acid and one or more lipid components using the static mixer to generate a mixture fluid containing the lipid nanoparticles. In some embodiments, the conduit includes a first inlet. In some embodiments, the conduit includes a second inlet. In some embodiments, the conduit includes a third inlet. In some embodiments, the conduit includes a fourth inlet. In some embodiments, the conduit includes an outlet. In some embodiments, the conduit is T-shaped. In some embodiments, the conduit is Y-shaped. In some embodiments, the conduit further includes a cut cable tie. In some embodiments, the conduit is L-shaped. In some embodiments, the static mixer includes multiple elements, wherein each element of the static mixer undergoes a 270° twist per 1 / 8 inch. In some embodiments, the length of the static mixer is less than about 40 mm. In some embodiments, the length of the static mixer is less than about 10 mm. In some embodiments, the length of the static mixer is less than about 5 mm. In some embodiments, the length of the static mixer is about 4.8 mm. In some embodiments, the static mixer has an inner diameter of about 1 / 16 inch to about 1 / 2 inch. In some embodiments, the inner diameter is about 1 / 4 inch. In some embodiments, the inner diameter is about 1 / 8 inch. In some embodiments, the polydispersity index of the mixture fluid is about 0.05 to about 0.25. In some embodiments, the polydispersity index of the mixture fluid is about 0.1 to about 0.2. In some embodiments, the polydispersity index of the mixture fluid is not greater than about 0.1. In some embodiments, the Reynolds number is about 150 to about 1000. In some embodiments, the Reynolds number is about 500 to about 1000. In some embodiments, the Reynolds number is about 1000. In some embodiments, the diameter of the lipid nanoparticles is not greater than about 100 nm. In some embodiments, the diameter of the lipid nanoparticles is about 50 nm to about 100 nm. In some embodiments, the diameter of the lipid nanoparticles is no greater than about 50 nm. In some embodiments, the flow rate ratio of the lipid component to the nucleic acid is about 1:2 to about 1:5. In some embodiments, the flow rate ratio of the lipid component to the nucleic acid is about 1:2. In some embodiments, the flow rate ratio of the lipid component to the nucleic acid is about 1:3. In some embodiments, nucleic acids and one or more lipid components are mixed to generate a mixture fluid, thereby encapsulating the nucleic acid in one or more lipid components to generate lipid nanoparticles.In some embodiments, the static mixer includes eight or more elements. In some embodiments, the static mixer includes 12 or more elements. In some embodiments, the static mixer includes 16 or more elements. In some embodiments, the static mixer includes 24 or more elements. In some embodiments, the static mixer is downstream of the conduit.

[0010] This document discloses a method for generating lipid nanoparticles, the method comprising: providing a conduit and a static mixer, the conduit including: a first inlet; a second inlet; an outlet; introducing nucleic acid into the first inlet; introducing one or more lipid components of the lipid nanoparticles into the second inlet; converging the nucleic acid and one or more lipid components at the outlet; and mixing the nucleic acid and one or more lipid components using the static mixer to generate a mixture fluid, wherein the Reynolds number of the mixture fluid is not greater than about 1000. In some embodiments, the conduit is T-shaped. In some embodiments, the conduit is Y-shaped. In some embodiments, the conduit further includes a cut cable tie. In some embodiments, the conduit is L-shaped. In some embodiments, the length of the static mixer is less than about 40 mm. In some embodiments, the length of the static mixer is less than about 10 mm. In some embodiments, the length of the static mixer is less than about 5 mm. In some embodiments, the length of the static mixer is about 4.8 mm. In some embodiments, the static mixer has an inner diameter of about 1 / 16 inch to about 1 / 2 inch. In some embodiments, the inner diameter is about 1 / 4 inch. In some embodiments, the inner diameter is about 1 / 8 inch. In some embodiments, the polydispersity index of the mixture fluid is from about 0.05 to about 0.25. In some embodiments, the polydispersity index is from about 0.1 to about 0.2. In some embodiments, the polydispersity index is not greater than about 0.1. In some embodiments, the Reynolds number is from about 150 to about 1000. In some embodiments, the Reynolds number is from about 500 to about 1000. In some embodiments, the Reynolds number is about 1000. In some embodiments, the lipid nanoparticles are not greater than about 100 nm. In some embodiments, the lipid nanoparticles are from about 50 nm to about 100 nm. In some embodiments, the lipid nanoparticles are about not greater than about 50 nm. In some embodiments, the flow rate ratio of the lipid component to the nucleic acid is from about 1:2 to about 1:5. In some embodiments, the flow rate ratio of the lipid component to the nucleic acid is about about 1:2. In some embodiments, the flow rate ratio of the lipid component to the nucleic acid is about 1:3. In some embodiments, nucleic acids and one or more lipid components are mixed to generate a mixture fluid, thereby encapsulating the nucleic acids within one or more lipid components to generate lipid nanoparticles. In some embodiments, the static mixer includes eight or more elements. In some embodiments, the static mixer includes 12 or more elements. In some embodiments, the static mixer includes 16 or more elements. In some embodiments, the static mixer includes 24 or more elements. In some embodiments, the static mixer is downstream of the catheter.In some embodiments, the method further includes providing one or more lipid components of nucleic acid and lipid nanoparticles to a high-performance liquid chromatography (HPLC) pump configured to provide nucleic acid and one or more lipid components at a specified flow rate.

[0011] The aspects disclosed herein relate to a system for generating lipid nanoparticles, the system comprising: a conduit and a static mixer, the conduit including: a first inlet configured to introduce nucleic acids; a second inlet configured to introduce one or more lipid components of the lipid nanoparticles; an outlet in which the nucleic acids and one or more lipid components converge; and the static mixer being configured to mix the nucleic acids and one or more lipid components, wherein the flow rate of the nucleic acids is not greater than about 200 mL / min. In some embodiments, the conduit is T-shaped. In some embodiments, the conduit is Y-shaped. In some embodiments, the conduit further includes a cut cable tie. In some embodiments, the conduit is L-shaped. In some embodiments, the length of the static mixer is less than about 40 mm. In some embodiments, the length of the static mixer is less than about 10 mm. In some embodiments, the length of the static mixer is less than about 5 mm. In some embodiments, the length of the static mixer is about 4.8 mm. In some embodiments, the static mixer has an inner diameter of about 1 / 16 inch to about 1 / 2 inch. In some embodiments, the inner diameter is about 1 / 4 inch. In some embodiments, the inner diameter is about 1 / 8 inch. In some embodiments, nucleic acids and one or more lipid components are mixed to generate a mixture fluid, wherein the polydispersity index of the mixture fluid is from about 0.05 to about 0.25. In some embodiments, the polydispersity index is from about 0.1 to about 0.2. In some embodiments, the polydispersity index is not greater than about 0.1. In some embodiments, the Reynolds number of the mixture fluid is from about 150 to about 1000. In some embodiments, the Reynolds number is from about 500 to about 1000. In some embodiments, the Reynolds number is about 1000. In some embodiments, the lipid nanoparticles are not larger than about 100 nm. In some embodiments, the lipid nanoparticles are from about 50 nm to about 100 nm. In some embodiments, the lipid nanoparticles are not larger than about 50 nm. In some embodiments, the flow rate ratio of the lipid component to the nucleic acid is from about 1:2 to about 1:5. In some embodiments, the flow rate ratio of the lipid component to the nucleic acid is about about 1:2. In some embodiments, the flow rate ratio of the lipid component to the nucleic acid is about 1:3. In some embodiments, nucleic acids and one or more lipid components are mixed to generate a mixture fluid, thereby encapsulating the nucleic acids within one or more lipid components to generate lipid nanoparticles. In some embodiments, the static mixer includes eight or more elements. In some embodiments, the static mixer includes 12 or more elements. In some embodiments, the static mixer includes 16 or more elements. In some embodiments, the static mixer includes 24 or more elements. In some embodiments, the static mixer is downstream of the catheter.In some embodiments, the method further includes providing one or more lipid components of nucleic acid and lipid nanoparticles to a high-performance liquid chromatography (HPLC) pump configured to provide nucleic acid and one or more lipid components at a specified flow rate.

[0012] This document discloses a method for generating lipid nanoparticles, the method comprising: providing a conduit and a static mixer, the conduit including a first inlet; a second inlet; and an outlet; introducing nucleic acid into the first inlet; introducing one or more lipid components of the lipid nanoparticles into the second inlet; converging the nucleic acid and one or more lipid components at the outlet; and mixing the nucleic acid and one or more lipid components using the static mixer, wherein the flow rate of the nucleic acid is not greater than about 200 mL / min. In some embodiments, the conduit is T-shaped. In some embodiments, the conduit is Y-shaped. In some embodiments, the conduit further includes a cut cable tie. In some embodiments, the conduit is L-shaped. In some embodiments, the length of the static mixer is less than about 40 mm. In some embodiments, the length of the static mixer is less than about 10 mm. In some embodiments, the length of the static mixer is less than about 5 mm. In some embodiments, the length of the static mixer is about 4.8 mm. In some embodiments, the static mixer has an inner diameter of about 1 / 16 inch to about 1 / 2 inch. In some embodiments, the inner diameter is about 1 / 4 inch. In some embodiments, the inner diameter is about 1 / 8 inch. In some embodiments, nucleic acids and one or more lipid components are mixed to generate a mixture fluid, wherein the polydispersity index of the mixture fluid is from about 0.05 to about 0.25. In some embodiments, the polydispersity index is from about 0.1 to about 0.2. In some embodiments, the polydispersity index is not greater than about 0.1. In some embodiments, the Reynolds number of the mixture fluid is from about 150 to about 1000. In some embodiments, the Reynolds number is from about 500 to about 1000. In some embodiments, the Reynolds number is about 1000. In some embodiments, the lipid nanoparticles are not larger than about 100 nm. In some embodiments, the lipid nanoparticles are from about 50 nm to about 100 nm. In some embodiments, the lipid nanoparticles are not larger than about 50 nm. In some embodiments, the flow rate ratio of the lipid component to the nucleic acid is from about 1:2 to about 1:5. In some embodiments, the flow rate ratio of the lipid component to the nucleic acid is about about 1:2. In some embodiments, the flow rate ratio of the lipid component to the nucleic acid is about 1:3. In some embodiments, nucleic acids and one or more lipid components are mixed to generate a mixture fluid, thereby encapsulating the nucleic acids within one or more lipid components to generate lipid nanoparticles. In some embodiments, the static mixer includes eight or more elements. In some embodiments, the static mixer includes 12 or more elements. In some embodiments, the static mixer includes 16 or more elements. In some embodiments, the static mixer includes 24 or more elements. In some embodiments, the static mixer is downstream of the catheter.In some embodiments, the method further includes providing one or more lipid components of nucleic acid and lipid nanoparticles to a high-performance liquid chromatography (HPLC) pump configured to provide nucleic acid and one or more lipid components at a specified flow rate.

[0013] The aspects disclosed herein relate to a system for generating lipid nanoparticles, the system comprising: a conduit and a static mixer, the conduit including: a first inlet configured to introduce nucleic acids; a second inlet configured to introduce one or more lipid components of lipid nanoparticles; an outlet in which the nucleic acids and one or more lipid components converge; and the static mixer being configured to mix the nucleic acids and one or more lipid components, wherein the lipid nanoparticles are no larger than about 150 nm. In some embodiments, the conduit is T-shaped. In some embodiments, the conduit is Y-shaped. In some embodiments, the conduit further includes a cut tie. In some embodiments, the conduit is L-shaped. In some embodiments, the length of the static mixer is less than about 40 mm. In some embodiments, the length of the static mixer is less than about 10 mm. In some embodiments, the length of the static mixer is less than about 5 mm. In some embodiments, the length of the static mixer is about 4.8 mm. In some embodiments, the static mixer has an inner diameter of about 1 / 16 inch to about 1 / 2 inch. In some embodiments, the inner diameter is about ¼ inch. In some embodiments, the inner diameter is about 1 / 8 inch. In some embodiments, nucleic acids and one or more lipid components are mixed to generate a mixture fluid, wherein the polydispersity index of the mixture fluid is from about 0.05 to about 0.25. In some embodiments, the polydispersity index is from about 0.1 to about 0.2. In some embodiments, the polydispersity index is not greater than about 0.1. In some embodiments, the Reynolds number of the mixture fluid is from about 150 to about 1000. In some embodiments, the Reynolds number is from about 500 to about 1000. In some embodiments, the Reynolds number is about 1000. In some embodiments, the lipid nanoparticles are not larger than about 100 nm. In some embodiments, the lipid nanoparticles are from about 50 nm to about 100 nm. In some embodiments, the lipid nanoparticles are not larger than about 50 nm. In some embodiments, the flow rate ratio of the lipid component to the nucleic acid is from about 1:2 to about 1:5. In some embodiments, the flow rate ratio of the lipid component to the nucleic acid is about about 1:2. In some embodiments, the flow rate ratio of the lipid component to the nucleic acid is about 1:3. In some embodiments, nucleic acids and one or more lipid components are mixed to generate a mixture fluid, thereby encapsulating the nucleic acids within one or more lipid components to generate lipid nanoparticles. In some embodiments, the static mixer includes eight or more elements. In some embodiments, the static mixer includes 12 or more elements. In some embodiments, the static mixer includes 16 or more elements. In some embodiments, the static mixer includes 24 or more elements. In some embodiments, the static mixer is downstream of the catheter.In some embodiments, the method further includes providing one or more lipid components of nucleic acid and lipid nanoparticles to a high-performance liquid chromatography (HPLC) pump configured to provide nucleic acid and one or more lipid components at a specified flow rate.

[0014] This document discloses a method for generating lipid nanoparticles, the method comprising: providing a conduit and a static mixer, the conduit including a first inlet; a second inlet; and an outlet; introducing a nucleic acid into the first inlet; introducing one or more lipid components of the lipid nanoparticles into the second inlet; converging the nucleic acid and one or more lipid components at the outlet; and mixing the nucleic acid and one or more lipid components using the static mixer, wherein the lipid nanoparticles are no larger than about 150 nm. In some embodiments, the conduit is T-shaped. In some embodiments, the conduit is Y-shaped. In some embodiments, the conduit further includes a cut cable tie. In some embodiments, the conduit is L-shaped. In some embodiments, the length of the static mixer is less than about 40 mm. In some embodiments, the length of the static mixer is less than about 10 mm. In some embodiments, the length of the static mixer is less than about 5 mm. In some embodiments, the length of the static mixer is about 4.8 mm. In some embodiments, the static mixer has an inner diameter of about 1 / 16 inch to about 1 / 2 inch. In some embodiments, the inner diameter is about 1 / 4 inch. In some embodiments, the inner diameter is about 1 / 8 inch. In some embodiments, nucleic acids and one or more lipid components are mixed to generate a mixture fluid, wherein the polydispersity index of the mixture fluid is from about 0.05 to about 0.25. In some embodiments, the polydispersity index is from about 0.1 to about 0.2. In some embodiments, the polydispersity index is not greater than about 0.1. In some embodiments, the Reynolds number of the mixture fluid is from about 150 to about 1000. In some embodiments, the Reynolds number is from about 500 to about 1000. In some embodiments, the Reynolds number is about 1000. In some embodiments, the lipid nanoparticles are not larger than about 100 nm. In some embodiments, the lipid nanoparticles are from about 50 nm to about 100 nm. In some embodiments, the lipid nanoparticles are not larger than about 50 nm. In some embodiments, the flow rate ratio of the lipid component to the nucleic acid is from about 1:2 to about 1:5. In some embodiments, the flow rate ratio of the lipid component to the nucleic acid is about about 1:2. In some embodiments, the flow rate ratio of the lipid component to the nucleic acid is about 1:3. In some embodiments, nucleic acids and one or more lipid components are mixed to generate a mixture fluid, thereby encapsulating the nucleic acids within one or more lipid components to generate lipid nanoparticles. In some embodiments, the static mixer includes eight or more elements. In some embodiments, the static mixer includes 12 or more elements. In some embodiments, the static mixer includes 16 or more elements. In some embodiments, the static mixer includes 24 or more elements. In some embodiments, the static mixer is downstream of the catheter.In some embodiments, the method further includes providing one or more lipid components of nucleic acid and lipid nanoparticles to a high-performance liquid chromatography (HPLC) pump configured to provide nucleic acid and one or more lipid components at a specified flow rate.

[0015] This document discloses a system for generating lipid nanoparticles, the system comprising: a conduit and a static mixer, the conduit including: a first inlet configured to introduce nucleic acids; a second inlet configured to introduce one or more lipid components of lipid nanoparticles; an outlet in which the nucleic acids and one or more lipid components converge; and the static mixer being configured to mix the nucleic acids and one or more lipid components, thereby encapsulating the nucleic acids in one or more lipid components to generate lipid nanoparticles. In some embodiments, the conduit is T-shaped. In some embodiments, the conduit is Y-shaped. In some embodiments, the conduit further includes a cut tie. In some embodiments, the conduit is L-shaped. In some embodiments, the length of the static mixer is less than about 40 mm. In some embodiments, the length of the static mixer is less than about 10 mm. In some embodiments, the length of the static mixer is less than about 5 mm. In some embodiments, the length of the static mixer is about 4.8 mm. In some embodiments, the static mixer has an inner diameter of about 1 / 16 inch to about 1 / 2 inch. In some embodiments, the inner diameter is about 1 / 4 inch. In some embodiments, the inner diameter is about 1 / 8 inch. In some embodiments, nucleic acids and one or more lipid components are mixed to generate a mixture fluid, wherein the polydispersity index of the mixture fluid is from about 0.05 to about 0.25. In some embodiments, the polydispersity index is from about 0.1 to about 0.2. In some embodiments, the polydispersity index is not greater than about 0.1. In some embodiments, the Reynolds number of the mixture fluid is from about 150 to about 1000. In some embodiments, the Reynolds number is from about 500 to about 1000. In some embodiments, the Reynolds number is about 1000. In some embodiments, the lipid nanoparticles are not larger than about 100 nm. In some embodiments, the lipid nanoparticles are from about 50 nm to about 100 nm. In some embodiments, the lipid nanoparticles are not larger than about 50 nm. In some embodiments, the flow rate ratio of the lipid component to the nucleic acid is from about 1:2 to about 1:5. In some embodiments, the flow rate ratio of the lipid component to the nucleic acid is about about 1:2. In some embodiments, the flow rate ratio of the lipid component to the nucleic acid is about 1:3. In some embodiments, the static mixer includes eight or more elements. In some embodiments, the static mixer includes 12 or more elements. In some embodiments, the static mixer includes 16 or more elements. In some embodiments, the static mixer includes 24 or more elements. In some embodiments, the static mixer is downstream of the conduit. In some embodiments, the method further includes providing one or more lipid components of nucleic acid and lipid nanoparticles to a high-performance liquid chromatography (HPLC) pump configured to provide nucleic acid and one or more lipid components at a specified flow rate.

[0016] This document discloses a method for generating lipid nanoparticles, the method comprising: providing a conduit and a static mixer, the conduit including a first inlet; a second inlet; and an outlet; introducing a nucleic acid into the first inlet; introducing one or more lipid components of the lipid nanoparticles into the second inlet; converging the nucleic acid and one or more lipid components at the outlet; and mixing the nucleic acid and one or more lipid components using the static mixer to encapsulate the nucleic acid within one or more lipid components to generate lipid nanoparticles. In some embodiments, the conduit is T-shaped. In some embodiments, the conduit is Y-shaped. In some embodiments, the conduit further includes a cut cable tie. In some embodiments, the conduit is L-shaped. In some embodiments, the length of the static mixer is less than about 40 mm. In some embodiments, the length of the static mixer is less than about 10 mm. In some embodiments, the length of the static mixer is less than about 5 mm. In some embodiments, the length of the static mixer is about 4.8 mm. In some embodiments, the static mixer has an inner diameter of about 1 / 16 inch to about 1 / 2 inch. In some embodiments, the inner diameter is about 1 / 4 inch. In some embodiments, the inner diameter is about 1 / 8 inch. In some embodiments, nucleic acids and one or more lipid components are mixed to generate a mixture fluid, wherein the polydispersity index of the mixture fluid is from about 0.05 to about 0.25. In some embodiments, the polydispersity index is from about 0.1 to about 0.2. In some embodiments, the polydispersity index is not greater than about 0.1. In some embodiments, the Reynolds number of the mixture fluid is from about 150 to about 1000. In some embodiments, the Reynolds number is from about 500 to about 1000. In some embodiments, the Reynolds number is about 1000. In some embodiments, the lipid nanoparticles are not larger than about 100 nm. In some embodiments, the lipid nanoparticles are from about 50 nm to about 100 nm. In some embodiments, the lipid nanoparticles are not larger than about 50 nm. In some embodiments, the flow rate ratio of the lipid component to the nucleic acid is from about 1:2 to about 1:5. In some embodiments, the flow rate ratio of the lipid component to the nucleic acid is about about 1:2. In some embodiments, the flow rate ratio of the lipid component to the nucleic acid is about 1:3. In some embodiments, the static mixer includes eight or more elements. In some embodiments, the static mixer includes 12 or more elements. In some embodiments, the static mixer includes 16 or more elements. In some embodiments, the static mixer includes 24 or more elements. In some embodiments, the static mixer is downstream of the conduit. In some embodiments, the method further includes providing one or more lipid components of nucleic acid and lipid nanoparticles to a high-performance liquid chromatography (HPLC) pump configured to provide nucleic acid and one or more lipid components at a specified flow rate.

[0017] Another aspect of this disclosure provides a non-transitory computer-readable medium containing machine-executable code that, when executed by one or more computer processors, implements any of the methods described above or elsewhere herein.

[0018] Another aspect of this disclosure provides a system comprising one or more computer processors and computer memory coupled thereto. The computer memory contains machine-executable code that, when executed by the one or more computer processors, implements any of the methods described above or elsewhere herein.

[0019] This article provides a system for generating lipid nanoparticles, the system comprising (i) a first inlet configured to introduce nucleic acids, (ii) a second inlet configured to introduce one or more lipid components of the lipid nanoparticles, and (iii) a static mixer configured to mix nucleic acids and one or more lipid components, wherein the system reaches a pressure of no more than 8 psig when the nucleic acids and one or more lipid components are mixed in the static mixer.

[0020] In some embodiments, the length of the static mixer is less than about 40 mm. In some embodiments, the length of the static mixer is less than about 5 mm. In some embodiments, the length of the static mixer is about 4.8 mm. In some embodiments, the static mixer has an inner diameter of about 1 / 16 inch to about 1 / 2 inch. In some embodiments, the inner diameter is about 1 / 4 inch. In some embodiments, the inner diameter is about 1 / 8 inch.

[0021] In some embodiments, the nucleic acid and one or more lipid components in (b) are mixed to generate a mixture fluid, and wherein the polydispersity index of the mixture fluid is from about 0.05 to about 0.25. In some embodiments, the polydispersity index is from about 0.1 to about 0.2. In some embodiments, the polydispersity index is not greater than about 0.1.

[0022] In some embodiments, the Reynolds number of the mixed fluid is from about 150 to about 1000. In some embodiments, the Reynolds number is from about 500 to about 1000. In some embodiments, the Reynolds number is about 1000.

[0023] In some embodiments, the lipid nanoparticles are no larger than about 100 nm. In some embodiments, the lipid nanoparticles are from about 50 nm to about 100 nm. In some embodiments, the lipid nanoparticles are no larger than about 50 nm.

[0024] In some embodiments, the flow rate ratio of the lipid component to the nucleic acid is about 1:2 to about 1:5. In some embodiments, the flow rate ratio of the lipid component to the nucleic acid is about 1:2. In some embodiments, the flow rate ratio of the lipid component to the nucleic acid is about 1:3.

[0025] In some implementations, nucleic acids are mixed with one or more lipid components to generate a mixture fluid, thereby encapsulating the nucleic acids in one or more lipid components to generate lipid nanoparticles.

[0026] In some embodiments, the static mixer includes eight or more components. In some embodiments, the static mixer includes twelve or more components. In some embodiments, the static mixer includes sixteen or more components. In some embodiments, the static mixer includes twenty-four or more components.

[0027] In some embodiments, the method includes diluting the lipid nanoparticles. In some embodiments, the particle size of the lipid nanoparticles differs from the particle size of the lipid nanoparticles before dilution by less than 10%.

[0028] In some embodiments, this document provides a method for generating lipid nanoparticles, the method comprising: (a) providing the system provided herein, (b) introducing a nucleic acid into a first inlet, (c) introducing one or more lipid components of the lipid nanoparticles into a second outlet, (d) converging the nucleic acid and one or more lipid components at the outlet, and (e) mixing the nucleic acid and one or more lipid components using a static mixer to encapsulate the nucleic acid in one or more lipid components to generate lipid nanoparticles, wherein the particle size of the lipid nanoparticles is selected by adjusting the Reynolds number.

[0029] In some implementations, particle size is increased by decreasing the Reynolds number. In other implementations, particle size is decreased by increasing the Reynolds number.

[0030] Other aspects and advantages of this disclosure will become apparent to those skilled in the art from the following detailed description, which shows and describes only illustrative embodiments thereof. As will be appreciated, this disclosure is capable of other and different embodiments, and certain details thereof can be modified in various obvious ways without departing from this disclosure. Therefore, the drawings and descriptions should be considered illustrative in nature and not restrictive.

[0031] Incorporation All publications, patents, and patent applications mentioned in this specification are incorporated herein by reference to the extent that each individual publication, patent, or patent application is expressly and individually indicated to be incorporated by reference. Where a publication, patent, or patent application incorporated by reference contradicts the disclosure contained in this specification, this specification is intended to supersede and / or give precedence to any such contradictory material. Attached Figure Description

[0032] The novel features of this disclosure are set forth in the appended claims. A better understanding of the features and advantages of this disclosure will be obtained by referring to the following detailed description and accompanying drawings (also referred to herein as “Figures”) of illustrative embodiments in which the principles of this disclosure are utilized, in which: Figures 1A-1I illustrate nine test static mixing setups. Figures 1A and 1B show Systems A and B, both using Koflo 24 element 1 / 8” ID disposable static mixers with polypropylene tubing, where System A uses a T-shaped connector and System B uses a Y-shaped connector for inlet confluence before mixing. Figure 1C shows System C, which uses Koflo 12 element 1 / 4” OD mixing element 1 / 4” ID platinum-cured silicone tubing. Figure 1D shows System D, which uses the same mixer and Y-shaped connector as System B, but with the mixer partially pushed into the Y-shaped connector. Figure 1E shows System E, which uses the same mixer and Y-shaped connector as System B, except that some inlet separation is provided by cut cable ties. Figure 1F shows System F, which is the same as System B, but with only 12 mixing elements. Figure 1G shows System G, which uses a custom mixer where three 12 element 1 / 8” mixers are placed together in a 3 / 16” 3 / 4” OD connector. The system is housed in an ID silicone tube. Figure 1H shows System H, a custom mixer with 16 mixing elements, where some of the mixing elements are pushed into a T-shape to allow the lipids and buffer to converge during mixing. Figure 1I shows System I, a custom mixer with 12 mixing elements, where the mixer is pushed into the lipid inlet at a Y-shaped junction.

[0033] Figure 2 Images of food dye tests at Reynolds numbers of 25, 50, and 100 are shown for systems A-C.

[0034] Figures 3A-3B The figure shows the particle diameter relative to the Reynolds number when system B is running at a 1:2 FRR. Figure 3A ),as well as Figure 3A The polydispersity index (PDI) of the same samples shown ( Figure 3B ).

[0035] Figures 4A-4F illustrate six static mixing setups (Systems J-N). All systems were tested at a Re of 1000. Figure 4A shows System J, which is essentially System H (Figure 1H) but with the inlet flow swapped and a higher total flow rate. Figure 4B shows System K, which is essentially System H (Figure 1H) but with a higher total flow rate. Figure 4C shows System L, which is System J but with a 1:3 FRR and no online dilution. Figure 4D shows System M, which is System J but with a 1:5 FRR and no online dilution. Figure 4E shows System N, which is System J but with a shorter connection between the two T-shaped sections and half the number of mixing elements. Figure 4F shows System O, which is similar in design to Systems J-M but without mixing elements.

[0036] Figures 5A-5B The diluted particle diameters of the T-shaped, J-shaped, K-shaped, L-shaped, M-shaped, N-shaped, and O-shaped mixing systems are shown. Figure 5A ) and diluted PDI ( Figure 5B (a bar chart of ).

[0037] Figures 6A-6B The particle diameters are shown after dilution and 15 minutes after mixing. Figure 6A ) and PDI ( Figure 6B (The image is shown.)

[0038] Figures 7A-7C The post-storage particle diameters of the five test compositions are shown. Figure 7A ), Post-storage PDI ( Figure 7B ) and encapsulation efficiency after storage ( Figure 7C The bar chart also shows a comparison of the statically mixed sample with the previously prepared cross-tee sample. Post-storage conditions included storage at approximately 2°C to approximately 8°C and storage at approximately -80°C.

[0039] Figures 8A-8B A splitter insert designed to split the flow before the mixing element to ensure consistent mixing is shown.

[0040] Figures 9A-9C A mixer with a length of 1 inch (25.4 mm) and a diameter of 1 / 8 inch (3.175 mm) is shown. Figure 9A , Figure 9C It includes 8 components ( Figure 9B Each component is 1 / 8 inch (3.175 mm) long and twists 180°. The cross-sectional thickness is approximately 0.0394 inches (1 mm).

[0041] Figures 10A-10B The mixer is shown. Figure 10A) and hybrid simulation ( Figure 10B The mass fraction of ethanol was simulated using Ansys Fluent. The ethanol flow rate was 75.4 mL / min, and the water flow rate was 150.8 mL / min.

[0042] Figures 11A-11C Results for two different viscosity models are shown, the viscosity model being the SST k-ω model ( Figure 11A ) and the transition-SST model, which is more stringent for the transition range Reynolds number ( Figure 11B ). Such as cross-section ( Figures 11A-11B ) and extrapolation plots of the standard deviation of ethanol mass fraction at different cross sections of the mixer ( Figure 11C As shown in the figure, the two models appear similar in terms of mixed estimation.

[0043] Figures 12A-12C Results for two different viscosity models are shown, the viscosity model being the SST k-ω model ( Figure 12A ) and transition-SST model ( Figure 12B The differences between model outputs are more pronounced when comparing shear stress. Figure 12C Overall, the shear stress output by the transition-SST model is about 40% higher than that of the k-ω model.

[0044] Figures 13A-13B A comparison of mixing according to the export is shown. Figure 13A The mass fraction of ethanol in the free outflow is shown. Figure 13B The ethanol mass fraction at the pressure outlet is shown.

[0045] Figures 14A-14B A comparison of shear stresses between outlets is shown. Figure 14A The shear stress of the free outflow is shown. Figure 14B The shear stress at the pressure outlet is shown. The shear stress at the two outlets is approximately the same.

[0046] Figures 15A-15C A mixer with eight mixing elements is shown. Figure 15A A 3D model of a mixer with eight mixing elements is shown, each element undergoing a 180° twist. Figure 15B It shows the result of Figure 15A An example of a hybrid conduit 3D model made from the drawn hybrid elements. Figure 15C It shows Figure 15B The 3D model of the fluid volume / path of the mixing conduit is shown.

[0047] Figures 16A-16B A 3D rendering of the fluid volume of a 0.5 mm orifice cross-shaped mixer is shown. Figure 16A An isometric view is shown. Figure 16B A top view is shown.

[0048] Figures 17A-17C The comparison results of an 8-element static mixer and a 0.5 mm cross-shaped mixer are shown. Figure 17A The standard deviation of ethanol mass fraction is shown between an 8-element static mixer and a 0.5 mm cross-shaped mixer. The time point of zero indicates the first mixing between the ethanol and water flows, and each data point represents the standard deviation on a cross section perpendicular to the flow direction. Figure 17B The comparison of mean shear stress between an 8-element static mixer and a 0.5 mm cross-shaped mixer is shown. Each data point represents the area-weighted mean shear stress on a cross section perpendicular to the flow direction. Figure 17C The maximum system pressures of both the 8-element static mixer and the 0.5 mm cross-shaped mixer are shown.

[0049] Figures 18A-18C A mixer with a length of 0.8 inches (20.32 mm) and a diameter of 1 / 8 inch (3.175 mm) is shown. Figure 18A , Figure 18C It includes 8 components ( Figure 18B Each component is 0.1 inches (2.54 mm) long and twists 180°. The cross-sectional thickness is approximately 0.0394 inches (1 mm).

[0050] Figures 19A-19C A mixer measuring 1.2 inches (30.48 mm) in length and 1 / 8 inch (3.175 mm) in diameter is shown. Figure 19A , Figure 19C It includes 8 components ( Figure 19B Each component is 0.15 inches (3.81 mm) long, with each component twisted 180°. The cross-sectional thickness is approximately 0.0394 inches (1 mm).

[0051] Figures 20A-20C A 3-channel mixer with a length of 1 inch (25.4 mm) and a diameter of 1 / 8 inch (3.175 mm) is shown. Figure 20A , Figure 20C It includes 8 components ( Figure 20B Each element is 1 / 8 inch long and twists 180°. The cross-sectional thickness is 0.0197 inches (0.5 mm) and is Y-shaped.

[0052] Figures 21A-21C A 4-channel mixer with a length of 1 inch (25.4 mm) and a diameter of 1 / 8 inch (3.175 mm) is shown. Figure 21A , Figure 21C It includes 8 components ( Figure 21B Each element is 1 / 8 inch long and twists 180°. The cross-sectional thickness is 0.5 mm and is X-shaped.

[0053] Figures 22A-22C A 90° steering mixer with a length of ½ inch (12.7 mm) is shown. Figure 22A , Figure 22C It includes two channels with a diameter of 1 / 8 inch (3.175 mm). The mixer comprises eight elements ( Figure 22B Each element is 1 / 16 inch (1.59 mm) long and is twisted 90°. The cross-sectional thickness is approximately 1 mm.

[0054] Figures 23A-23C A 270° steering mixer with a length of 1.5 inches (38.1 mm) is shown. Figure 23A , Figure 23C It includes two channels with a diameter of 1 / 8 inch (3.175 mm). The mixer comprises eight elements ( Figure 23B Each element is 3 / 16 inch (4.76 mm) long and twists 270°. The cross-sectional thickness is approximately 1 mm.

[0055] Figure 24 An exemplary static mixing setup with conduit 2401 and mixer 2402 is shown. The conduit may include a first inlet 2403, a second inlet 2404, an outlet 2405, and a junction point 2406. The conduit may have an angle 2407 between the first inlet 2403 and the second inlet 2404. The conduit may have an angle 2408 between the first inlet 2403 and the outlet 2405. The conduit may have an angle 2409 between the second inlet 2404 and the outlet 2405.

[0056] Figures 25A-25C A Koflo analogue mixer (Design 1, A1) is shown, which has two inlets and a helical element, as well as a 180° twist ( Figure 25A ), and cylindrical channels for accommodating components, and including 1 / 8-inch barbs spaced 120° apart ( Figure 25B , Figure 25C ).

[0057] Figures 26A-26D A design mixer (Design 2, No. D10) is shown, which has two inlets and a helical element and a 270° twist ( Figure 26A , Figure 26B ), and a square channel for accommodating the components ( Figure 26C ), and includes -180° twist ( Figure 26D ).

[0058] Figures 27A-27D A design mixer (Design 3, No. D7) is shown, which has 4 inlets and a helical element and a 270° twist ( Figure 27A , Figure 27B ), and a square channel for accommodating the components ( Figure 27C ), and includes -180° twist ( Figure 27D ).

[0059] Figures 28A-28D A design mixer (Design 5, No. D6) is shown, which has 4 inlets and a helical element and a 180° twist ( Figure 28A , Figure 28B ), and a square channel for accommodating the components ( Figure 28C ), and includes -180° twist ( Figure 28D ).

[0060] Figure 29A , Figure 29B and Figure 29C A static mixer as described in this article is shown. Detailed Implementation

[0061] Nucleic acids capable of gene silencing, expression, and editing hold immense potential for use in gene therapy for a wide range of indications, including cancer, genetic disorders, and infectious diseases. Effective application of nucleic acids to the treatment of these conditions typically requires the use of both viral and non-viral delivery methods to facilitate delivery to target cells. Lipid nanoparticles (LNPs) represent a potentially efficient non-viral delivery platform for nucleic acids. Despite advances in this field, this paper recognizes the need for improved synthetic methods for generating nucleic acid-containing LNPs. LNP preparation often faces several challenges, including particle size and dispersion control. The effectiveness of LNPs can be dependent on their size, and consistently preparing particles of various sizes required for different applications can be challenging. Furthermore, LNP preparation can suffer from low reproducibility due to the complex manufacturing processes involved. Cost and scaling up can also hinder the clinical translation of LNPs, as large-scale LNP preparation may encounter reduced homogeneity or altered properties. Currently, LNPs are prepared using various methods, including high-pressure homogenization, microemulsions, solvent emulsification / evaporation, and sonication. These methods each have their own set of advantages and disadvantages, but for enhancing the clinical translation and feasibility of LNPs, a method that allows for reproducible, size-controlled, and monodisperse high nucleic acid load LNPs is preferable.

[0062] This disclosure provides systems and methods for generating LNPs. LNPs can have small particle sizes. LNPs can have low polydispersity indices in solution. The systems and methods provided herein can be low-cost and can be efficiently scaled up. The methods for generating LNPs as described herein may include the use of a conduit having one or more inlets. The conduit may have one or more outlets. The conduit may have a static mixer. Static mixers can offer improved scalability compared to alternative setups, such as T-shaped, cross-shaped, or microfluidic setups. Improved scalability can be significant for commercial-scale manufacturing. Each element can allow the production of LNPs with different component ratios. The methods provided herein can utilize lower flow rates and back pressures and can facilitate better control over the physicochemical properties of the resulting drug product. Using lower flow rate and lower back pressure schemes can provide a wider range of pump options and better control over LNP formation. Using the static mixer provided herein can be a suitable choice for LNP generation. The methods provided herein can allow for reproducible preparation of LNPs with enhanced control over properties such as size, monodispersity, scalability, and drug loading. Furthermore, the method presented in this paper is general and allows for the replacement, addition, or removal of various LNP components (e.g., allowing 3-component LNPs, 4-component LNPs, 5-component LNPs, etc.) without sacrificing control over the aforementioned properties.

[0063] Systems and methods for generating lipid nanoparticles This disclosure provides systems and methods for generating lipid nanoparticles. In some embodiments, the lipid nanoparticles encapsulate nucleic acids. In some embodiments, the nucleic acid can be, for example, deoxyribonucleic acid (DNA), ribonucleic acid (RNA), or a DNA copy of ribonucleic acid (cDNA). The RNA can be, for example, messenger RNA (mRNA), transfer RNA (tRNA), ribosomal RNA (rRNA), guide RNA (gRNA), small nuclear RNA (snRNA), small nucleolar RNA (snoRNA), SmY RNA, splice leader RNA (SLRNA), CRISPR RNA, long non-coding RNA (lncRNA), microRNA (miRNA), or other suitable RNA. The nucleic acid can be RNA. The nucleic acid can be mRNA. The nucleic acid can be DNA.

[0064] catheter Systems disclosed herein may include conduits (e.g., such as...) Figure 24 (As shown in Figure 2401). In some embodiments, the catheter includes one or more inlets (e.g., as shown in Figure 2401). Figure 24 The image shows the first entrance of 2403 and... Figure 24 The image shows the second entry point for 2404, as shown below. Figure 24The image shows the exit for 2405, and as shown... Figure 24 The intersection point shown is 2406.

[0065] In some embodiments, the catheter includes ten or more inlets. In some embodiments, ten or more inlets intersect at a junction. In some embodiments, the catheter includes one to ten (e.g., more) inlets. In some embodiments, the catheter includes one to eight inlets. In some embodiments, the catheter includes one to five inlets. In some embodiments, the catheter includes one to three inlets. In some embodiments, the catheter includes one inlet. In some embodiments, the catheter includes two inlets. In some embodiments, the catheter includes three inlets. In some embodiments, the catheter includes four inlets. In some embodiments, the catheter includes five inlets. In some embodiments, the catheter includes six inlets. In some embodiments, the catheter includes seven inlets. In some embodiments, the catheter includes eight inlets. In some embodiments, the catheter includes nine inlets. In some embodiments, the catheter includes ten inlets.

[0066] In some embodiments, the catheter may be T-shaped, as shown in Figure 1A. In some embodiments, the catheter may be Y-shaped, as shown in Figures 1B-1G and 1I. In some embodiments, the Y-shaped catheter may further include a cut ties, as shown in Figure 1E. In some embodiments, the cut ties may provide an inlet partition. In some embodiments, the cut ties may include a simple shunt. In some embodiments, the catheter may be L-shaped, as shown in Figures 1H and 4A-4F.

[0067] Each inlet of the catheter can be used to introduce one or more components of the lipid nanoparticles. In some cases, each inlet is used to introduce a single component of the lipid nanoparticles. In other cases, the inlets are used to introduce at least two (e.g., three, four, or five) components of the lipid nanoparticles. In some embodiments, the inlet is used to introduce a therapeutic agent (e.g., a nucleic acid), and a second (e.g., or a second, third, fourth, and / or fifth) inlet is used to introduce other components of the lipid nanoparticles.

[0068] The catheter may include a first inlet, such as Figure 24 The diagram shows 2403. The first inlet can be configured to introduce nucleic acids. The first inlet can be configured to introduce one or more lipid components of lipid nanoparticles.

[0069] The catheter may include a second inlet, such as Figure 24 The diagram shows 2404. The second inlet can be configured to introduce nucleic acids. The second inlet can be configured to introduce one or more lipid components of lipid nanoparticles.

[0070] The catheter may include a third inlet. The third inlet may be configured to introduce nucleic acids. The third inlet may be configured to introduce one or more lipid components of lipid nanoparticles.

[0071] The conduit may include a fourth inlet. The fourth inlet may be configured to introduce nucleic acids. The fourth inlet may be configured to introduce one or more lipid components of lipid nanoparticles.

[0072] The catheter may include an outlet, such as Figure 24 The diagram shows 2405. The catheter may include an outlet where nucleic acids and one or more lipid components converge.

[0073] The catheter may include a junctional site where a first inlet and a second inlet intersect, such as... Figure 24 The number shown is 2406. In some embodiments, nucleic acids and one or more lipid components may not come into contact with each other before entering the intersection site.

[0074] The catheter may include the angle between the first inlet and the second inlet, such as... Figure 24 The figure shown is 2407. In some embodiments, the angle between the first inlet and the second inlet may not be greater than 210° (e.g., not greater than 180°, 160°, 140°, 120°, 100°, 90°, 80°, 70°, 60°, 50°, 40°, 30°, 20°, or 10°). In some embodiments, the angle between the first inlet and the second inlet is at least 10° (e.g., at least 15°, 20°, 25°, 30°, 35°, 40°, 45°, 50°, 60°, 70°, 80°, or 90°). In some embodiments, the angle between the first inlet and the second inlet is about 10° to about 90° (e.g., about 10° to about 60°, about 10° to about 45°, about 20° to about 90°, about 30° to about 90°, or about 20° to about 45°). In some embodiments, the angle between the first inlet and the second inlet is approximately 10°, approximately 15°, approximately 20°, approximately 25°, approximately 30°, approximately 35°, approximately 40°, approximately 45°, approximately 50°, approximately 55°, approximately 65°, approximately 70°, approximately 75°, approximately 80°, or approximately 90°. In some embodiments, the angle is less than 100°. In some embodiments, the angle is less than 90°. In some embodiments, the angle is approximately 20° to approximately 100°. In some embodiments, the angle is approximately 30° to approximately 80°.

[0075] The catheter may include the angle between the first inlet and outlet, such as... Figure 24The figure shown is 2408. In some embodiments, the angle between the first inlet and the outlet can be at least 10° (e.g., at least 20°, 30°, 40°, 50°, 60°, 70°, 80°, 90°, 100°, 110°, 120°, 130°, 140°, 150°, 160°, or 170°). In some embodiments, the angle between the first inlet and the outlet is at most 180° (e.g., at most 170°, 160°, 150°, 140°, 130°, 120°, 110°, 100°, 90°, 80°, 70°, 60°, 50°, or 40°). In some embodiments, the angle between the first inlet and the outlet is about 40° to about 180° (e.g., 40° to about 160°, 60° to about 160°, 80° to about 160°, or about 100° to about 150°). In some embodiments, the angle between the first inlet and the second outlet is about 180°, about 170°, about 160°, about 150°, about 140°, about 130°, about 120°, about 110°, about 100°, about 90°, or about 80°. In some embodiments, the angle is at least 90°. In some embodiments, the angle is at least 120°. In some embodiments, the angle is about 100° to about 170°.

[0076] The catheter may include the angle between the second inlet and outlet, such as... Figure 24 The figure shown is 2409. In some embodiments, the angle between the second inlet and the outlet can be at least 10° (e.g., at least 20°, 30°, 40°, 50°, 60°, 70°, 80°, 90°, 100°, 110°, 120°, 130°, 140°, 150°, 160°, or 170°). In some embodiments, the angle between the second inlet and the outlet is at most 180° (e.g., at most 170°, 160°, 150°, 140°, 130°, 120°, 110°, 100°, 90°, 80°, 70°, 60°, 50°, or 40°). In some embodiments, the angle between the second inlet and the outlet is about 40° to about 180° (e.g., 40° to about 160°, 60° to about 160°, 80° to about 160°, or about 100° to about 150°). In some embodiments, the angle between the second inlet and the second outlet is about 180°, about 170°, about 160°, about 150°, about 140°, about 130°, about 120°, about 110°, about 100°, about 90°, or about 80°. In some embodiments, the angle is at least 90°.

[0077] In some implementations, the angle between the first inlet and the outlet and the angle between the second inlet and the outlet are the same. In other implementations, the angle between the first inlet and the outlet and the angle between the second inlet and the outlet are different.

[0078] In some embodiments, the angle between the inlet (e.g., first inlet, second inlet, third inlet, fourth inlet, fifth inlet, etc.) and the outlet can be at least 10° (e.g., at least 20°, 30°, 40°, 50°, 60°, 70°, 80°, 90°, 100°, 110°, 120°, 130°, 140°, 150°, 160°, or 170°). In some embodiments, the angle between the inlet (e.g., first inlet, second inlet, third inlet, fourth inlet, fifth inlet, etc.) and the outlet is at most 180° (e.g., at most 170°, 160°, 150°, 140°, 130°, 120°, 110°, 100°, 90°, 80°, 70°, 60°, 50°, or 40°). In some embodiments, the angle between the inlet (e.g., a first inlet, a second inlet, a third inlet, a fourth inlet, a fifth inlet, etc.) and the outlet is about 40° to about 180° (e.g., 40° to about 160°, 60° to about 160°, 80° to about 160°, or about 100° to about 150°). In some embodiments, the angle between the inlet (e.g., a first inlet, a second inlet, a third inlet, a fourth inlet, a fifth inlet, etc.) and the second outlet is about 180°, about 170°, about 160°, about 150°, about 140°, about 130°, about 120°, about 110°, about 100°, about 90°, or about 80°.

[0079] In some embodiments, the flow rate of the lipid component into any of the inlets (e.g., the first inlet, the second inlet, the third inlet, the fourth inlet, etc.) may not exceed about 500 mL / min, 300 mL / min, 200 mL / min, 150 mL / min, 100 mL / min, 50 mL / min, 40 mL / min, 30 mL / min, 20 mL / min, 10 mL / min, or 5 mL / min. In some embodiments, the flow rate of the lipid component into any of the inlets (e.g., the first inlet, the second inlet, the third inlet, the fourth inlet, etc.) is at least 5 mL / min, 10 mL / min, 20 mL / min, 30 mL / min, 40 mL / min, 50 mL / min, 60 mL / min, or 70 mL / min. In some embodiments, the flow rate of the lipid component at any of the inlets (e.g., the first inlet, second inlet, third inlet, fourth inlet, etc.) is about 5 mL / min to about 100 mL / min, about 5 mL / min to about 80 mL / min, about 10 mL / min to about 80 mL / min, about 20 mL / min to about 80 mL / min, about 30 mL / min to about 80 mL / min, about 40 mL / min to about 80 mL / min, or about 50 mL / min to about 80 mL / min. In some embodiments, the flow rate of the lipid component into any of the inlets (e.g., the first inlet, second inlet, third inlet, fourth inlet, etc.) is about 50 mL / min to about 80 mL / min. Increased flow rates can be used to allow for adoption in larger-scale production.

[0080] In some embodiments, the flow rate of nucleic acid entering the first inlet may not exceed approximately 1200 mL / min, 1100 mL / min, 1000 mL / min, 900 mL / min, 800 mL / min, 700 mL / min, 500 mL / min, 300 mL / min, 200 mL / min, 150 mL / min, 100 mL / min, 50 mL / min, 40 mL / min, 30 mL / min, 20 mL / min, 10 mL / min, or 5 mL / min. In some embodiments, the flow rate of nucleic acid entering the first inlet may be at least 1 mL / min, 5 mL / min, 10 mL / min, 20 mL / min, 30 mL / min, 40 mL / min, 50 mL / min, or 100 mL / min. In some embodiments, the flow rate of nucleic acid entering the first inlet can be about 5 mL / min to about 300 mL / min, about 5 mL / min to about 200 mL / min, about 20 mL / min to about 200 mL / min, about 40 mL / min to about 200 mL / min, about 50 mL / min to about 200 mL / min, about 100 mL / min to about 200 mL / min, or about 120 mL / min to about 190 mL / min. In some embodiments, the flow rate of nucleic acid entering the first inlet is about 10 mL / min, as described in Table 5. In some embodiments, the flow rate of nucleic acid entering the first inlet is about 150 mL / min to about 160 mL / min, as described in Table 5. In some embodiments, the flow rate of nucleic acid entering the first inlet is about 150 mL / min, as described in Table 5 or Table 7. In some embodiments, the flow rate of nucleic acid entering the first inlet is about 200 mL / min to about 700 mL / min.

[0081] In some embodiments, the flow rate of the lipid component into the second inlet may not exceed about 1200 mL / min, 1100 mL / min, 1000 mL / min, 900 mL / min, 800 mL / min, 700 mL / min, 500 mL / min, 300 mL / min, 200 mL / min, 150 mL / min, 100 mL / min, 50 mL / min, 40 mL / min, 30 mL / min, 20 mL / min, 10 mL / min, or 5 mL / min. In some embodiments, the flow rate of the lipid component into the second inlet is at least 5 mL / min, 10 mL / min, 20 mL / min, 30 mL / min, 40 mL / min, 50 mL / min, 60 mL / min, 70 mL / min, 100 mL / min, 250 mL / min, 300 mL / min, 400 mL / min, 500 mL / min, 600 mL / min, 700 mL / min, or 800 mL / min. In some embodiments, the flow rate of the lipid component into the second inlet is about 5 mL / min to about 1200 mL / min, about 100 mL / min to about 1000 mL / min, about 5 mL / min to about 100 mL / min, about 5 mL / min to about 80 mL / min, about 10 mL / min to about 80 mL / min, about 20 mL / min to about 80 mL / min, about 30 mL / min to about 80 mL / min, about 40 mL / min to about 80 mL / min, or about 50 mL / min to about 80 mL / min. In some embodiments, the flow rate of the lipid component into the second inlet is about 50 mL / min to about 80 mL / min. In some embodiments, the flow rate of the lipid component into the second inlet is about 75 mL / min, as described in Tables 5 and 7. In some embodiments, the flow rate of the lipid component into the second inlet is about 55 mL / min, as described in Table 5. In some embodiments, the flow rate of the lipid component into the second inlet is about 5 mL / min, as described in Table 5. In some implementations, the flow rate of the lipid component into the second inlet is from about 50 mL / min to about 300 mL / min.

[0082] In some embodiments, the flow rate ratio of lipid components entering any two of the inlets provided herein (e.g., the first, second, third, fourth, fifth, etc.) is about 1:1 to about 1:10, about 1:1 to about 1:8, about 1:1 to about 1:7, about 1:1 to about 1:6, about 1:1 to about 1:3, or about 1:1 to about 1:4. In some embodiments, the flow rate ratio of lipid components entering any two of the inlets provided herein (e.g., the first, second, third, fourth, fifth, etc.) is at least about 1:1, 1:1.25, 1:1.5, 1:1.75, 1:2, 1:2.5, 1:3, or 1:4. In some embodiments, the flow rate ratio of lipid components entering any two of the inlets provided herein (e.g., the first, second, third, fourth, fifth, etc.) is at most about 1:10, 1:8, 1:6, 1:5, 1:4, 1:3, or 1:2. In some implementations, the ratio of the flow rates of lipid components entering any two of the inlets provided herein (e.g., the first, second, third, fourth, fifth, etc.) may be about 1:2, about 1:3, about 1:5, about 1:8, or about 1:10.

[0083] In some embodiments, the flow rate of the lipid component entering the second inlet to the flow rate of the nucleic acid entering the first inlet is about 1:1 to about 1:10, about 1:1 to about 1:8, about 1:1 to about 1:7, about 1:1 to about 1:6, about 1:1 to about 1:3, or about 1:1 to about 1:4. In some embodiments, the flow rate of the lipid component entering the second inlet to the flow rate of the nucleic acid entering the first inlet is at least about 1:1, 1:1.25, 1:1.5, 1:1.75, 1:2, 1:2.5, 1:3, or 1:4. In some embodiments, the flow rate of the lipid component entering the second inlet to the flow rate of the nucleic acid entering the first inlet is at most about 1:10, 1:8, 1:6, 1:5, 1:4, 1:3, or 1:2. In some implementations, the ratio of the flow rate of the lipid component entering the second inlet to the flow rate of the nucleic acid entering the first inlet can be approximately 1:2, approximately 1:3, approximately 1:5, approximately 1:8, or approximately 1:10.

[0084] An entry point for introducing nucleic acids. In some implementations, the first entry point can be configured to introduce a therapeutic agent, such as a nucleic acid. In some implementations, the first entry point can be configured to introduce a nucleic acid. In some implementations, the second entry point can be configured to introduce a therapeutic agent, such as a nucleic acid. In some implementations, the second entry point can be configured to introduce a nucleic acid. In some implementations, the third entry point can be configured to introduce a therapeutic agent, such as a nucleic acid. In some implementations, the third entry point can be configured to introduce a nucleic acid. In some implementations, the fourth entry point can be configured to introduce a therapeutic agent, such as a nucleic acid. In some implementations, the fourth entry point can be configured to introduce a nucleic acid. In some embodiments, nucleic acids may include small interfering RNA (siRNA), short hairpin RNA (shRNA), microRNA (miRNA), primary microRNA (pri-miRNA), long non-coding RNA (lncRNA), messenger RNA (mRNA), CRISPR-related nucleic acids, CRISPR-RNA (crRNA), unidirectional guide RNA (sgRNA), trans-activated CRISPR RNA (tracrRNA), plasmid deoxyribonucleic acid (pDNA), transfer RNA (tRNA), antisense oligonucleotide (ASO), antisense RNA (RNA), guide RNA, deoxyribonucleic acid (DNA), double-stranded deoxyribonucleic acid (dsDNA), single-stranded deoxyribonucleic acid (ssDNA), single-stranded ribonucleic acid (ssRNA), or double-stranded ribonucleic acid (dsRNA). In some embodiments, the first entry point may contain nucleic acids. In some embodiments, the first entry point may contain mRNA. In some embodiments, the second entry point may contain nucleic acids. In some embodiments, the second entry point may contain mRNA. In some embodiments, the third entry point may contain nucleic acid. In some embodiments, the third entry point may contain mRNA. In some embodiments, the fourth entry point may contain nucleic acid. In some embodiments, the fourth entry point may contain mRNA. In some embodiments, the mRNA is at least 15 mg (e.g., at least 15 mg, 20 mg, 30 mg, 40 mg, 50 mg, 60 mg, 80 mg, or 100 mg).

[0085] In some embodiments, the lipid nanoparticles comprise one or more nucleic acids present with cationic ionizable lipids in a weight ratio of about 5:1 to about 1:100. In some embodiments, the weight ratio of one or more nucleic acids to cationic ionizable lipids is at least 2:1, 1:1, 1:2, 1:5, 1:10, 1:20, 1:25, 1:30, 1:35, 1:40, 1:45, or 1:50. In some embodiments, the weight ratio of one or more nucleic acids to cationic ionizable lipids is at most 1:100, 1:90, 1:80, 1:70, 1:60, 1:50, 1:45, 1:40, 1:35, or 1:30. In some embodiments, the weight ratio of nucleic acid to cationic ionizable lipids is about 5:1, 2.5:1, 1:1, 1:5, 1:10, 1:15, 1:20, 1:25, 1:30, 1:35, 1:40, 1:45, 1:50, 1:60, 1:70, 1:80, 1:90, or 1:100, or any range thereof. In some embodiments, the weight ratio is about 1:25 or about 1:7. In some embodiments, the weight ratio is about 1:30 to about 1:40. In some embodiments, the weight ratio is about 1:30, 1:35, or about 1:40.

[0086] Inlet for introducing lipid components In some embodiments, any one of the first, second, third, fourth, fifth, sixth, seventh, eighth, ninth, or tenth inlets can be configured to introduce one or more lipid components of the lipid nanoparticle. The lipid nanoparticle may contain 2, 3, 4, 5, 6, or more components. In some embodiments, the lipid nanoparticle contains 2 components. In some embodiments, the lipid nanoparticle contains 3 components. In some embodiments, the lipid nanoparticle contains 4 components. In some embodiments, the lipid nanoparticle contains 5 components. In some embodiments, the lipid nanoparticle contains 6 (e.g., more) components. In some embodiments, the lipid nanoparticle contains one or more of a therapeutic agent (e.g., nucleic acid), cationic ionizable lipids, SORT lipids, phospholipids, steroids, and PEGylated lipids. In some embodiments, the lipid nanoparticle contains nucleic acid and one or more lipid components (e.g., cationic ionizable lipids, SORT lipids, phospholipids, steroids, and PEGylated lipids). In some embodiments, the first inlet can be configured to introduce one or more of a therapeutic agent (e.g., nucleic acid), cationic ionizable lipids, SORT lipids, phospholipids, steroids, or PEGylated lipids. In some embodiments, the second inlet may be configured to introduce one or more of a therapeutic agent (e.g., nucleic acid), cationic ionizable lipids, SORT lipids, phospholipids, steroids, or PEGylated lipids. In some embodiments, the third inlet may be configured to introduce one or more of a therapeutic agent (e.g., nucleic acid), cationic ionizable lipids, SORT lipids, phospholipids, steroids, or PEGylated lipids. In some embodiments, the fourth inlet may be configured to introduce one or more of a therapeutic agent (e.g., nucleic acid), cationic ionizable lipids, SORT lipids, phospholipids, steroids, or PEGylated lipids. In some embodiments, the fifth inlet may be configured to introduce one or more of a therapeutic agent (e.g., nucleic acid), cationic ionizable lipids, SORT lipids, phospholipids, steroids, or PEGylated lipids. In some embodiments, the sixth inlet may be configured to introduce one or more of a therapeutic agent (e.g., nucleic acid), cationic ionizable lipids, SORT lipids, phospholipids, steroids, or PEGylated lipids. In some embodiments, the seventh inlet may be configured to introduce one or more of a therapeutic agent (e.g., nucleic acid), cationic ionizable lipids, SORT lipids, phospholipids, steroids, or PEGylated lipids. In some embodiments, the eighth inlet may be configured to introduce one or more of a therapeutic agent (e.g., nucleic acid), a cationic ionizable lipid, a SORT lipid, a phospholipid, a steroid, or a PEGylated lipid. In some embodiments, the ninth inlet may be configured to introduce one or more of a therapeutic agent (e.g., nucleic acid), a cationic ionizable lipid, a SORT lipid, a phospholipid, a steroid, or a PEGylated lipid.In some implementations, the tenth inlet may be configured to introduce one or more of a therapeutic agent (e.g., nucleic acid), a cationic ionizable lipid, a SORT lipid, a phospholipid, a steroid, or a PEGylated lipid.

[0087] In some cases, the lipid nanoparticles provided herein comprise cationic ionizable lipids. Cationic ionizable lipids as described elsewhere in the art may be used herein. Examples of cationic ionizable lipids can be found, for example, in U.S. Patent Nos. 11,542,229, 11,247,968, 11,766,408, and 11,229,609, each of which is incorporated herein by reference in its entirety.

[0088] In some embodiments, the cationic ionizable lipids are present at a molar percentage of about 2% to about 60% of the total lipid component. In some embodiments, the molar percentage of the cationic ionizable lipids is about 5% to about 50%. In some embodiments, the molar percentage of the cationic ionizable lipids is about 5% to about 30%. In some embodiments, the molar percentage of the cationic ionizable lipids is about 7.5% to about 20%. In some embodiments, the molar percentage of the cationic ionizable lipids is at least 2%, 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, or 50%. In some embodiments, the molar percentage of the cationic ionizable lipids is at most 70%, 60%, 55%, 50%, 45%, 40%, 35%, 30%, or 25%.

[0089] Lipid nanoparticles may comprise steroids or steroid derivatives. In some embodiments, the steroid or steroid derivative includes any steroid or steroid derivative. As used herein, in some embodiments, the term "steroid" is a class of compounds having a tetracyclic 17-carbon ring structure, which may further comprise one or more substitutions, including alkyl, alkoxy, hydroxyl, oxo, acyl, or double bonds between two or more carbon atoms. Examples of steroids can be found in U.S. Patent Nos. 11,542,229, 11,247,968, 11,766,408, and 11,229,609, each of which is incorporated herein by reference in its entirety.

[0090] In some embodiments, the steroid or steroid derivative is present at a molar percentage of about 20% to about 60% of the total lipid component. In some embodiments, the steroid or steroid derivative is present at a molar percentage of about 30% to 50%. In some embodiments, the steroid or steroid derivative is present at a molar percentage of about 39% to about 46%. In some embodiments, the steroid or steroid derivative is present at a molar percentage of at least 20%, 25%, 30%, 35%, 40%, 45%, 50%, or 55%. In some embodiments, the steroid or steroid derivative is present at a molar percentage of up to 60%, 55%, 50%, 45%, 40%, 35%, 30%, or 25%.

[0091] In some embodiments, the lipid nanoparticles comprise PEG or PEGylated lipids. In some embodiments, this disclosure includes the use of any lipid with a PEG group attached. Examples of PEG or PEGylated lipids can be found in U.S. Patent Nos. 11,542,229, 11,247,968, 11,766,408, and 11,229,609, each of which is incorporated herein by reference in its entirety.

[0092] In some embodiments, PEG or PEGylated lipids are present at a molar percentage of about 0.1% to about 20% of the total lipid component. In some embodiments, PEG or PEGylated lipids are present at a molar percentage of about 0.5% to about 10%. In some embodiments, PEG or PEGylated lipids are present at a molar percentage of about 0.5% to about 5%. In some embodiments, PEG or PEGylated lipids are present at a molar percentage of about 2% to about 2.8%. In some embodiments, PEG or PEGylated lipids are present at a molar percentage of at least 0.1%, 0.2%, 0.5%, 1%, 2%, 3%, 4%, 5%, 6%, 7%, or 8%. In some embodiments, PEG or PEGylated lipids are present at a molar percentage of up to 10%, 9%, 8%, 7%, 6%, 5%, 4%, 3%, or 2%.

[0093] In some embodiments, the lipid nanoparticles comprise phospholipids. In some aspects of this disclosure, the polymer is mixed with one or more phospholipids to produce a composition. In some embodiments, any lipid also comprises a phosphate group. In some embodiments, the phospholipid is a C6-C phospholipid containing one or two long chains. 24The structure comprises an alkyl or alkenyl group, a glycerol or sphingosine group, one or two phosphate groups, and optionally contains a small organic molecule. Examples of phospholipids can be found in U.S. Patent Nos. 11,542,229, 11,247,968, 11,766,408, and 11,229,609, each of which is incorporated herein by reference in its entirety.

[0094] In some embodiments, phospholipids are present at a molar percentage of about 1% to about 40% of the total lipid component. In some embodiments, phospholipids are present at a molar percentage of about 10% to about 40% of the total lipid component. In some embodiments, phospholipids are present at a molar percentage of at least about 5%, 7.5%, 10%, 15%, 17%, 18%, 20%, 22%, or 25% of the total lipid component. In some embodiments, phospholipids are present at a molar percentage of at most about 40%, 38%, 35%, 33%, 30%, 28%, 25%, 22%, or 20% of the total lipid component.

[0095] In some embodiments, the lipid nanoparticles comprise one or more selective organ-targeting (SORT) compounds that cause the lipid nanoparticles to be selectively delivered to a specific organ. The compound may be a lipid, a small molecule therapeutic agent, a sugar, a vitamin, or a protein. Examples of SORT lipids can be found in U.S. Patent Nos. 11,766,408 and 11,229,609, which are incorporated herein by reference in their entirety.

[0096] In some embodiments, one or more SORT compounds are present in a molar percentage of about 5% to about 50% of the total lipid component. In some embodiments, one or more SORT compounds are present in a molar percentage of about 10% to about 45%. In some embodiments, one or more SORT compounds are present in an amount of about 20% to about 40%. In some embodiments, one or more SORT compounds are present in an amount of at least 5%, 7.5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, or 50%. In some embodiments, one or more SORT compounds are present in an amount of up to 50%, 45%, 40%, 35%, 30%, 25%, 20%, 15%, or 10%.

[0097] In some aspects, this disclosure provides one or more lipids having one or more hydrophobic components and permanent cationic groups. The permanent cationic lipids may contain groups that are positively charged regardless of pH. Permanent cationic lipids as described elsewhere in the art can be used. Examples of permanent cationic groups in some cases can be found in U.S. Patent Nos. 11,766,408 and 11,229,609, which are incorporated herein by reference in their entirety.

[0098] In some embodiments, the lipid nanoparticles may contain permanently cationic lipids in any suitable amount. Examples of permanently cationic lipids in some cases can be found in U.S. Patent Nos. 11,766,408 and 11,229,609, which are incorporated herein by reference in their entirety.

[0099] In some aspects, this disclosure provides one or more lipids having one or more hydrophobic components and permanent anionic groups. In some cases, examples of permanent anionic lipids can be found in U.S. Patent Nos. 11,766,408 and 11,229,609, which are incorporated herein by reference in their entirety.

[0100] Static mixer This disclosure provides a system including a static mixer. In some embodiments, the static mixer is downstream of the conduit. In some embodiments, the static mixer is upstream of the conduit. In some embodiments, the static mixer is parallel to the conduit.

[0101] The system may include a static mixer. The system may include a static mixer in which nucleic acids and one or more lipid components are mixed to generate a mixture fluid, and wherein the nucleic acids and one or more lipid components may not contact each other before entering the meeting site. In some embodiments, nucleic acids and one or more lipid components are mixed within a static mixer to generate a mixture fluid.

[0102] The static mixers described herein may include, for example, Figure 29A , Figure 29B or Figure 29C The design is illustrated. The static mixer described herein may include, for example: Figure 29A , Figure 29B , Figure 29C The design illustrated herein may include, or combinations thereof. The static mixers described herein may include, for example... Figure 29A The design is illustrated. The static mixer described herein may include, for example: Figure 29B The design is illustrated. The static mixer described herein may include, for example: Figure 29C The design shown in the diagram.

[0103] The static mixers described herein may include, for example, Figure 29A The design shown in Figure A1. The static mixer described herein may include, for example, Figure 29A The design shown in Figure A2. The static mixer described herein may include, for example, Figure 29A The design shown in Figure A3. The static mixer described herein may include, for example, Figure 29A The design shown in Figure A4. The static mixer described herein may include, for example, Figure 29A The design shown in Figure A5. The static mixer described herein may include, for example, Figure 29A The design shown in Figure A6. The static mixer described herein may include, for example, Figure 29A The illustrated design is B1. The static mixer described herein may include, for example, Figure 29A Design B2 is illustrated. The static mixer described herein may include, for example, Figure 29A The design shown in Figure B3. The static mixer described herein may include, for example, Figure 29A The design shown in Figure B4. The static mixer described herein may include, for example, Figure 29A The illustrated design is C1. The static mixer described herein may include, for example, Figure 29A The design shown is C2. The static mixer described herein may include, for example, Figure 29A The design shown is C3. The static mixer described herein may include, for example, Figure 29B The illustrated design is C4. The static mixer described herein may include, for example, Figure 29B The illustrated design is C5. The static mixer described herein may include, for example... Figure 29B The illustrated design is C6. The static mixer described herein may include, for example, Figure 29B The illustrated design is C7. The static mixer described herein may include, for example... Figure 29B The illustrated design is C8. The static mixer described herein may include, for example... Figure 29B The illustrated design is C9. The static mixer described herein may include, for example, Figure 29B The illustrated design is C10. The static mixer described herein may include, for example... Figure 29B The illustrated design is C11. The static mixer described herein may include, for example... Figure 29B The illustrated design is C12. The static mixer described herein may include, for example... Figure 29B The illustrated design is C13. The static mixer described herein may include, for example... Figure 29B The illustrated design is C14. The static mixer described herein may include, for example... Figure 29B The illustrated design is C15. The static mixer described herein may include, for example... Figure 29B The illustrated design is C16. The static mixer described herein may include, for example... Figure 29C The illustrated design is C17. The static mixer described herein may include, for example... Figure 29C The illustrated design is C18. The static mixer described herein may include, for example... Figure 29C The illustrated design is C18. The static mixer described herein may include, for example... Figure 29C The design shown is D1. The static mixer described herein may include, for example, Figure 29CThe design shown is D2. The static mixer described herein may include, for example, Figure 29C The design shown is D3. The static mixer described herein may include, for example, Figure 29C The design shown is D4. The static mixer described herein may include, for example, Figure 29C The design shown is D5. The static mixer described herein may include, for example, Figure 29C The design shown is D6. The static mixer described herein may include, for example, Figure 29C The design shown is D7. The static mixer described herein may include, for example, Figure 29C The illustrated design is D8. The static mixer described herein may include, for example... Figure 29C The design shown is D9. The static mixer described herein may include, for example, Figure 29C The design shown in the diagram is D10.

[0104] In some implementations, the static mixer described herein may include designs A1, A2, A3, A4, A5, A6, B1, B2, B3, B4, C1, C2, C3, C4, C5, C6, C7, C8, C9, C10, C11, C12, C13, C14, C15, C16, C17, C18, D1, D2, D3, D4, D5, D6, D7, D8, D9, D10, or any combination thereof.

[0105] In some embodiments, the static mixer may have a length less than about 1000 mm, 500 mm, 300 mm, 200 mm, 100 mm, 90 mm, 80 mm, 70 mm, 60 mm, 50 mm, 45 mm, 40 mm, 35 mm, 30 mm, 25 mm, 20 mm, 15 mm, 10 mm, 9 mm, 8 mm, 7 mm, 6 mm, 5 mm, 4 mm, 3 mm, 2 mm, or 1 mm. In some embodiments, the static mixer includes a length of at least 5 mm, 6 mm, 7 mm, 8 mm, 9 mm, 10 mm, 15 mm, 20 mm, 25 mm, or 30 mm. In some embodiments, the static mixer includes a length of about 5 mm to about 80 mm. In some embodiments, the static mixer includes a length of about 5 mm to about 40 mm. In some embodiments, the static mixer includes a length of about 10 mm to about 35 mm. In some embodiments, the static mixer includes a length of about 20 mm, such as... Figures 18A-18C As shown. In some embodiments, the static mixer comprises a length of approximately 30 mm, such as... Figures 19A-19C As shown. In some embodiments, the static mixer comprises a length of approximately 25 mm, such as... Figures 20A-20CAs shown. In some embodiments, the static mixer comprises a length of approximately 12 mm, such as... Figures 22A-22C As shown. In some embodiments, the static mixer may have a length of less than about 10 inches (in), 5 in, 4 in, 3 in, 2 in, 1.5 in, 1.2 in, 1 in, 0.9 in, 0.8 in, 0.7 in, 0.6 in, 0.5 in, 0.4 in, 0.3 in, 0.2 in, or 0.1 in. In some embodiments, the static mixer has a length of about 4.8 mm. In some embodiments, the static mixer may have a length of about 0.8 in, such as... Figures 18A-18C As shown. In some implementations, the static mixer can have a length of approximately 1.2 inches, such as... Figures 19A-19C As shown. In some implementations, the static mixer may have a length of about 1 in.

[0106] In some embodiments, the static mixer may have an inner diameter less than about 5 in, 4 in, 3 in, 2 in, 1 in, ¾ in, ½ in, 3 / 8 in, ¼ in, 3 / 16 in, 1 / 8 in, 1 / 16 in, or 1 / 32 in. In some embodiments, the static mixer includes an inner diameter less than about 127 mm, 102 mm, 76 mm, 50 mm, 25 mm, 19 mm, 13 mm, 9.5 mm, 6 mm, 5 mm, 4 mm, 3 mm, 2 mm, 1.5 mm, 1 mm, or 0.75 mm. In some embodiments, the static mixer includes an inner diameter of at least 0.5 mm, 1 mm, 1.5 mm, 2 mm, 2.5 mm, 3 mm, 4 mm, or 5 mm. In some embodiments, the static mixer includes an inner diameter from about 0.5 mm to about 20 mm. In some embodiments, the static mixer includes an inner diameter from about 1 mm to about 10 mm. In some embodiments, the static mixer includes an inner diameter from about 1 mm to about 5 mm. In some implementations, the static mixer includes an inner diameter of approximately 3 mm.

[0107] In some embodiments, the static mixer may have one element, two or more elements, four or more elements, six or more elements, eight or more elements, twelve or more elements, sixteen or more elements, twenty-four or more elements, or thirty-six or more elements. In some embodiments, the static mixer includes at least one element, at least two elements, at least three elements, at least five elements, at least eight elements, at least twelve elements, or at least twenty elements. In some embodiments, the static mixer includes up to 54 elements, up to 48 elements, up to 36 elements, up to 24 elements, up to 16 elements, or up to 12 elements. In some embodiments, the static mixer includes one to twelve elements. In some embodiments, the static mixer includes five to ten elements. In some embodiments, the static mixer includes eight elements.

[0108] In some embodiments, the system provided herein further includes a splitter insert, which can be arranged within the system in various ways. In some embodiments, a static mixer is inserted into the splitter insert, such as... Figure 8A and Figure 8B As shown. In some implementations, The components of a static mixer can be arranged in a variety of ways. In some implementations, a splitter insert can be inserted into the static mixer to split the flow before the mixing elements and ensure consistent mixing, such as... Figure 8A and Figure 8B As shown. In some embodiments, the shunt insert may have a length less than about 70 mm, 50 mm, 40 mm, 35 mm, 30 mm, 25 mm, 20 mm, 15 mm, 10 mm, 5 mm, or 1 mm. In some embodiments, the shunt insert includes a length of at least 1 mm, 5 mm, 10 mm, 15 mm, 20 mm, 25 mm, 30 mm, 35 mm, or 40 mm. In some embodiments, the shunt insert includes a length of about 1 mm to about 50 mm, about 10 mm to about 40 mm, or about 20 mm to about 40 mm. In some embodiments, the shunt insert includes a length of about 30 mm to about 40 mm. In some embodiments, the shunt insert includes a length of about 35 mm, such as... Figure 8A and Figure 8B As shown. In some implementations, the static mixer includes Figure 8A or Figure 8B The shunt insert.

[0109] In some embodiments, the shunt insert is a T-shaped conduit. In other embodiments, the shunt insert is a Y-shaped conduit. In a further embodiment, the shunt insert is an L-shaped conduit.

[0110] In some embodiments, any suitable number of components from the static mixer can be inserted into the shunt insert based on, for example, the length of the components and the length of the shunt insert. In some embodiments, at least one component of the static mixer is inserted into the shunt insert. In some embodiments, at least two, three, four, five, six, seven, or eight components of the static mixer can be inserted into the shunt insert. In some embodiments, up to 75% of the components of the static mixer can be inserted into the shunt insert. In some embodiments, up to 50% of the components of the static mixer can be inserted into the shunt insert. In some embodiments, up to 12, 11, 10, 9, 8, 7, 6, 5, 4, or three components of the static mixer can be inserted into the shunt insert.

[0111] In some embodiments, any suitable number of components in the static mixer can be inserted into the T-conduit based on, for example, the length of the components and the length of the T-conduit. In some embodiments, at least one component of the static mixer is inserted into the T-conduit. In some embodiments, at least two, three, four, five, six, seven, or eight components of the static mixer can be inserted into the T-conduit. In some embodiments, up to 75% of the components of the static mixer can be inserted into the T-conduit. In some embodiments, up to 50% of the components of the static mixer can be inserted into the T-conduit. In some embodiments, up to 12, 11, 10, 9, 8, 7, 6, 5, 4, or three components of the static mixer can be inserted into the T-conduit.

[0112] In some embodiments, two of the eight or more elements in the static mixer may be inserted into a T-shaped conduit preceding the static mixer. In some embodiments, six of the eight or more elements in the static mixer may be downstream of the outlet of the T-shaped conduit. In some embodiments, four of the twelve or more elements in the static mixer may be inserted into a T-shaped conduit preceding the static mixer. In some embodiments, eight of the twelve or more elements in the static mixer may be downstream of the outlet of the T-shaped conduit. In some embodiments, two of the sixteen or more elements in the static mixer may be inserted into a T-shaped conduit preceding the static mixer. In some embodiments, four of the sixteen or more elements in the static mixer may be inserted into a T-shaped conduit preceding the static mixer. In some embodiments, twelve of the sixteen or more elements in the static mixer may be downstream of the outlet of the T-shaped conduit. In some embodiments, fourteen of the sixteen or more elements in the static mixer may be downstream of the outlet of the T-shaped conduit.

[0113] In some embodiments, any suitable number of components in the static mixer can be inserted into the Y-conduit based on, for example, the length of the components and the length of the Y-conduit. In some embodiments, at least one component of the static mixer is inserted into the Y-conduit. In some embodiments, at least two, three, four, five, six, seven, or eight components of the static mixer can be inserted into the Y-conduit. In some embodiments, up to 75% of the components of the static mixer can be inserted into the Y-conduit. In some embodiments, up to 50% of the components of the static mixer can be inserted into the Y-conduit. In some embodiments, up to 12, 11, 10, 9, 8, 7, 6, 5, 4, or three components of the static mixer can be inserted into the Y-conduit.

[0114] In some embodiments, two of the eight or more elements in the static mixer may be inserted into a Y-shaped conduit preceding the static mixer. In some embodiments, six of the eight or more elements in the static mixer may be downstream of the outlet of the Y-shaped conduit. In some embodiments, four of the twelve or more elements in the static mixer may be inserted into a Y-shaped conduit preceding the static mixer. In some embodiments, eight of the twelve or more elements in the static mixer may be downstream of the outlet of the Y-shaped conduit. In some embodiments, two of the sixteen or more elements in the static mixer may be inserted into a Y-shaped conduit preceding the static mixer. In some embodiments, four of the sixteen or more elements in the static mixer may be inserted into a Y-shaped conduit preceding the static mixer. In some embodiments, twelve of the sixteen or more elements in the static mixer may be downstream of the outlet of the Y-shaped conduit. In some embodiments, fourteen of the sixteen or more elements in the static mixer may be downstream of the outlet of the Y-shaped conduit.

[0115] In some embodiments, any suitable number of components in the static mixer can be inserted into the L-shaped conduit based on, for example, the length of the components and the length of the L-shaped conduit. In some embodiments, at least one component of the static mixer is inserted into the L-shaped conduit. In some embodiments, at least 2, 3, 4, 5, 6, 7, or 8 components of the static mixer can be inserted into the L-shaped conduit. In some embodiments, up to 75% of the components of the static mixer can be inserted into the L-shaped conduit. In some embodiments, up to 50% of the components of the static mixer can be inserted into the L-shaped conduit. In some embodiments, up to 12, 11, 10, 9, 8, 7, 6, 5, 4, or 3 components of the static mixer can be inserted into the L-shaped conduit.

[0116] In some embodiments, two of the eight or more elements in the static mixer may be inserted into the L-shaped conduit preceding the static mixer. In some embodiments, six of the eight or more elements in the static mixer may be downstream of the outlet of the L-shaped conduit. In some embodiments, four of the twelve or more elements in the static mixer may be inserted into the L-shaped conduit preceding the static mixer. In some embodiments, eight of the twelve or more elements in the static mixer may be downstream of the outlet of the L-shaped conduit. In some embodiments, two of the sixteen or more elements in the static mixer may be inserted into the L-shaped conduit preceding the static mixer. In some embodiments, four of the sixteen or more elements in the static mixer may be inserted into the L-shaped conduit preceding the static mixer. In some embodiments, twelve of the sixteen or more elements in the static mixer may be downstream of the outlet of the L-shaped conduit. In some embodiments, fourteen of the sixteen or more elements in the static mixer may be downstream of the outlet of the L-shaped conduit.

[0117] In some embodiments, each element of the static mixer may have a length less than about 2 in, 1.5 in, 1.2 in, 1 in, 0.9 in, 0.8 in, 0.7 in, 0.6 in, 0.5 in, 0.4 in, 0.3 in, 0.2 in, 0.19 in, 0.18 in, 0.17 in, 0.16 in, 0.15 in, 0.14 in, 0.13 in, 0.12 in, 0.11 in, or 0.10 in. In some embodiments, each element of the static mixer comprises a length less than 50 mm, 40 mm, 30 mm, 25 mm, 20 mm, 15 mm, 10 mm, 5 mm, or 2.5 mm. In some embodiments, each element of the static mixer comprises a length of at least 1 mm, 1.5 mm, 2 mm, 2.5 mm, 3 mm, 3.5 mm, 4 mm, 5 mm, or 6 mm. In some embodiments, each element of the static mixer comprises a length from about 1 mm to about 5 mm. In some embodiments, each element of the static mixer comprises a length of approximately 1 mm to approximately 10 mm. In some embodiments, each element of the static mixer comprises a length of approximately 2.5 mm, such as... Figures 18A-18C As shown. In some embodiments, each element of the static mixer comprises a length of approximately 3.8 mm, such as... Figures 19A-19C As shown. In some embodiments, each element of the static mixer comprises a length of approximately 3.2 mm, such as... Figures 21A-21C As shown. In some embodiments, each element of the static mixer comprises a length of approximately 1.5 mm, such as... Figures 22A-22CAs shown. In some embodiments, each element of the static mixer comprises a length of approximately 4.8 mm, such as... Figures 23A-23C As shown.

[0118] In some embodiments, each element of the static mixer may have a 45° twist. In some embodiments, each element of the static mixer may have a 90° twist, such as... Figures 22A-22C As shown. In some embodiments, each element of the static mixer may have a 135° twist. In some embodiments, each element of the static mixer may have a 180° twist, such as... Figures 9A-9C As shown in Figures 25 and 28. In some embodiments, each element of the static mixer may have a 225° torsion. In some embodiments, each element of the static mixer may have a 270° torsion, such as... Figures 23A-23C As shown in Figures 26 and 27. In some embodiments, each element of the static mixer may have a 315° torsion. In some embodiments, each element of the static mixer may have a -45° torsion. In some embodiments, each element of the static mixer may have a -90° torsion. In some embodiments, each element of the static mixer may have a -135° torsion. In some embodiments, each element of the static mixer may have a -180° torsion. In some embodiments, each element of the static mixer may have a -225° torsion. In some embodiments, each element of the static mixer may have a -270° torsion. In some embodiments, each element of the static mixer may have a -315° torsion.

[0119] In some implementations, each element of the static mixer undergoes a 270° twist per 1 / 8 inch.

[0120] In some implementations, the static mixer may have a 90° directional mixer, such as Figures 22A-22C As shown. In some implementations, the static mixer may have a 270° directional mixer, such as... Figures 23A-23C As shown.

[0121] In some embodiments, each element of the static mixer may have a cross-sectional thickness of less than about 5 mm, 4 mm, 3 mm, 2 mm, 1 mm, 0.5 mm, 0.4 mm, 0.3 mm, 0.2 mm, or 0.1 mm. In some embodiments, each element of the static mixer includes a cross-sectional thickness of at least 0.1 mm, 0.2 mm, 0.3 mm, 0.5 mm, 0.75 mm, 1 mm, 1.1 mm, 1.2 mm, 1.3 mm, 1.4 mm, or 1.5 mm. In some embodiments, each element of the static mixer includes a cross-sectional thickness of about 0.1 mm to about 2 mm. In some embodiments, each element of the static mixer includes a cross-sectional thickness of about 1 mm. In other embodiments, each element of the static mixer includes a cross-sectional thickness of about 1 mm.

[0122] In some implementations, the static mixer may have one or more channel mixers. In some implementations, the static mixer may have a 3-channel mixer. In some implementations, the 3-channel mixer may be Y-shaped, such as... Figures 20A-20C As shown. In some implementations, the static mixer can have a 4-channel mixer. In some implementations, the 4-channel mixer can be X-shaped, such as... Figures 21A-21C As shown.

[0123] In some embodiments, the system described herein requires lower pressure compared to alternative systems such as a cross-shaped mixing system. This reduced pressure can be used to decrease the shear stress applied to the lipid nanoparticles and result in a lower back pressure in the pumping system. The reduced pressure can allow for adoption in larger-scale production. In some embodiments, the pressure can be a back pressure. In some embodiments, the system provided herein achieves a pressure of no more than 8 psig, while a cross-shaped mixing system can achieve pressures exceeding 20 psig (e.g., 23.3 psig as described in the examples). In some embodiments, the provided system achieves a pressure of no more than 20 psig (e.g., no more than 18 psig, 17 psig, 16 psig, 15 psig, 14 psig, 13 psig, 12 psig, 11 psig, 10 psig, 9 psig, or 8 psig). In some embodiments, the system pressure reaches at least 3 psig (e.g., at least 4 psig, 5 psig, 8 psig, 10 psig, 12 psig, 14 psig, or 16 psig). In some embodiments, the system pressure provided herein reaches from about 3 psig to about 20 psig. In some embodiments, the system pressure provided herein reaches from about 5 psig to about 15 psig, from about 5 psig to about 10 psig, or from about 6 psig to about 9 psig.

[0124] aisle This disclosure provides a system including a channel for accommodating a static mixer. In some embodiments, the channel may be downstream of the conduit. In some embodiments, the channel may be upstream of the conduit. In some embodiments, the channel may be parallel to the conduit.

[0125] The system may include channels. The system may include channels containing a static mixer. The system may include channels containing elements of a static mixer. The system may include channels containing multiple elements of a static mixer. The system may include channels containing elements. The system may include channels containing multiple elements. In some embodiments, the channels provide countercurrent. The system may include channels where nucleic acids and one or more lipid components are mixed to generate a mixture fluid. In some embodiments, nucleic acids and one or more lipid components are mixed within the channel to generate a mixture fluid.

[0126] In some embodiments, the channel may have a length of less than about 1000 mm, 500 mm, 300 mm, 200 mm, 100 mm, 90 mm, 80 mm, 70 mm, 60 mm, 50 mm, 45 mm, 40 mm, 35 mm, 30 mm, 25 mm, 20 mm, 15 mm, 10 mm, 9 mm, 8 mm, 7 mm, 6 mm, 5 mm, 4 mm, 3 mm, 2 mm, or 1 mm. In some embodiments, the channel includes a length of at least 5 mm, 6 mm, 7 mm, 8 mm, 9 mm, 10 mm, 15 mm, 20 mm, 25 mm, or 30 mm. In some embodiments, the channel includes a length of about 5 mm to about 80 mm. In some embodiments, the channel includes a length of about 5 mm to about 40 mm. In some embodiments, the channel includes a length of about 10 mm to about 35 mm. In some implementations, the channel may have a length of less than about 10 inches (in), 5 in, 4 in, 3 in, 2 in, 1.5 in, 1.2 in, 1 in, 0.9 in, 0.8 in, 0.7 in, 0.6 in, 0.5 in, 0.4 in, 0.3 in, 0.2 in, or 0.1 in. In some implementations, the channel has a length of about 4.8 mm.

[0127] In some embodiments, the channel may have an inner diameter less than about 5 in, 4 in, 3 in, 2 in, 1 in, ¾ in, ½ in, 3 / 8 in, ¼ in, 3 / 16 in, 1 / 8 in, 1 / 16 in, or 1 / 32 in. In some embodiments, the channel includes an inner diameter less than about 127 mm, 102 mm, 76 mm, 50 mm, 25 mm, 19 mm, 13 mm, 9.5 mm, 6 mm, 5 mm, 4 mm, 3 mm, 2 mm, 1.5 mm, 1 mm, or 0.75 mm. In some embodiments, the channel includes an inner diameter of at least 0.5 mm, 1 mm, 1.5 mm, 2 mm, 2.5 mm, 3 mm, 4 mm, or 5 mm. In some embodiments, the channel includes an inner diameter from about 0.5 mm to about 20 mm. In some embodiments, the channel includes an inner diameter from about 1 mm to about 10 mm. In some embodiments, the channel includes an inner diameter from about 1 mm to about 5 mm. In some embodiments, the channel includes an inner diameter of about 3 mm.

[0128] In some embodiments, the channel can be cylindrical, as shown in Figure 25. In some embodiments, the channel can be square, as shown in Figures 26-28. In some embodiments, the channel can be rectangular. In some embodiments, the channel can be of any shape.

[0129] In some embodiments, the channel may twist once every length less than about 2 in, 1.5 in, 1.2 in, 1 in, 0.9 in, 0.8 in, 0.7 in, 0.6 in, 0.5 in, 0.4 in, 0.3 in, 0.2 in, 0.19 in, 0.18 in, 0.17 in, 0.16 in, 0.15 in, 0.14 in, 0.13 in, 0.12 in, 0.11 in, or 0.10 in. In some embodiments, the channel may twist once every length less than 50 mm, 40 mm, 30 mm, 25 mm, 20 mm, 15 mm, 10 mm, 5 mm, or 2.5 mm. In some embodiments, the channel may twist once every length of at least 1 mm, 1.5 mm, 2 mm, 2.5 mm, 3 mm, 3.5 mm, 4 mm, 5 mm, or 6 mm. In some embodiments, the channel may twist once every length from about 1 mm to about 5 mm. In some implementations, the channel may twist once every approximately 1 mm to approximately 10 mm of its length. In some implementations, the channel may twist once every 1 / 8 in of its length.

[0130] In some embodiments, the channel may have multiple twists. In some embodiments, the channel may have a 45° twist. In some embodiments, the channel may have a 90° twist. In some embodiments, the channel may have a 135° twist. In some embodiments, the channel may have a 180° twist. In some embodiments, the channel may have a 225° twist. In some embodiments, the channel may have a 270° twist. In some embodiments, the channel may have a 315° twist. In some embodiments, the channel may have a -45° twist. In some embodiments, the channel may have a -90° twist. In some embodiments, the channel may have a -135° twist. In some embodiments, the channel may have a -180° twist, such as... Figure 26D , Figure 27D and Figure 28D As shown. In some embodiments, the channel may have a -225° twist. In some embodiments, the channel may have a -270° twist. In some embodiments, the channel may have a -315° twist.

[0131] In some implementations, the channel is square and twists by -180° every 1 / 8 inch.

[0132] pump This disclosure provides a system including a pump. The pump can be configured to deliver one or more components of lipid nanoparticles at a specified flow rate (e.g., flow rates described elsewhere herein). In some embodiments, the pump is configured to deliver nucleic acids at a specified flow rate. In some embodiments, the pump is configured to deliver one or more lipids at a specified flow rate. In some embodiments, the pump is configured to deliver cationic ionizable lipids at a specified flow rate. In some embodiments, the pump is configured to deliver phospholipids at a specified flow rate. In some embodiments, the pump is configured to deliver polymer-conjugated lipids at a specified flow rate. In some embodiments, the pump can be a peristaltic pump. In some embodiments, the pump can be a high-performance liquid chromatography (HPLC) pump. In some embodiments, the pump can be a Levitronix pump. In some embodiments, the pump can be a Knauer pump. In some embodiments, the pump can be a Knauer BlueShadow pump.

[0133] Generate lipid nanoparticles This disclosure provides systems and methods for generating lipid nanoparticles. Methods for preparing (generating) lipid nanoparticles using any of the systems provided herein are also provided.

[0134] In some embodiments, the methods provided herein include providing a system, such as the system provided elsewhere herein. In some embodiments, as described elsewhere herein, the system includes a conduit. In some cases, the conduit includes a first inlet. In some embodiments, the conduit includes a second inlet. In some embodiments, the conduit includes a third inlet. In some embodiments, the conduit includes a fourth inlet. In some embodiments, the conduit includes an outlet. In some embodiments, the system includes a static mixer. In some embodiments, the conduit includes a channel.

[0135] In some embodiments, the methods provided herein include introducing nucleic acids into a first inlet. In some embodiments, the methods provided herein include introducing one or more lipid components of lipid nanoparticles into a second inlet. A system or method may include allowing a solution containing nucleic acids (e.g., a first solution) to flow into a first inlet of a catheter, and allowing a solution containing one or more lipid components (e.g., a second solution) to flow into a second inlet of the catheter. In some embodiments, the first solution contains any nucleic acid described elsewhere herein. In some embodiments, the second solution contains one or more lipid components as described elsewhere herein.

[0136] In some embodiments, the methods provided herein include introducing nucleic acids into a first, second, third, or fourth inlet. In some embodiments, the methods provided herein include introducing one or more lipid components of lipid nanoparticles into a first, second, third, or fourth inlet. A system or method may include allowing a solution containing nucleic acids (e.g., a first) to flow into a first, second, third, or fourth inlet of a catheter, and allowing a solution containing one or more lipid components (e.g., a second) to flow into a first, second, third, or fourth inlet of a catheter. In some embodiments, the first solution contains any nucleic acid described elsewhere herein. In some embodiments, the second solution contains one or more lipid components as described elsewhere herein.

[0137] In some implementations, the methods provided herein include converging nucleic acids and one or more lipid components at an outlet. A first inlet and a second inlet may converge to form an outlet, such as the outlet described elsewhere herein, wherein the nucleic acid and one or more lipid components converge in the outlet.

[0138] In some embodiments, the system or method may further include a static mixer. In some embodiments, nucleic acids and one or more lipid components are mixed within the static mixer to generate lipid nanoparticles. In some embodiments, the system or method may further include a static mixer, such as the static mixer described elsewhere herein, wherein nucleic acids and one or more lipid components are mixed in a mixture fluid to generate lipid nanoparticles.

[0139] In some embodiments, the system or method may further include a channel. In some embodiments, nucleic acids and one or more lipid components are mixed within the channel to generate lipid nanoparticles. In some embodiments, the system or method may further include a channel, such as those described elsewhere herein, wherein nucleic acids and one or more lipid components are mixed in a mixture fluid to generate lipid nanoparticles.

[0140] The system and method can generate lipid nanoparticles with a low polydispersity index, wherein the polydispersity index may be no greater than about 0.2. The system and method can generate lipid nanoparticles with a size no greater than about 90 nanometers (nm). The system and method can generate mixture fluids with a Reynolds number no greater than about 1000. The system and method can have a flow rate ratio of approximately 1:2 between the lipid component and the nucleic acid inlet at the first inlet. The system and method can achieve an encapsulation efficiency of no less than about 90%.

[0141] The conduit may include a first inlet, a second inlet, and an outlet. The conduit may further include a junction downstream of the first and second inlets. The method may include providing a static mixer. The method may include providing a static mixer disposed distal to the junction. The method may further include introducing nucleic acids into the first inlet. The method may further include introducing one or more lipid components of lipid nanoparticles into the second inlet. The method may further include converging the nucleic acids and one or more lipid components at the outlet. The method may further include mixing the nucleic acids and one or more lipid components using the static mixer to generate a mixed fluid. The method may further include mixing the nucleic acids and one or more lipid components using the static mixer to generate a mixed fluid. The nucleic acids and one or more lipid components may not contact each other before entering the junction.

[0142] The conduit may include a first inlet, a second inlet, a third inlet, a fourth inlet, and an outlet. The method may include providing a static mixer. The method may further include introducing nucleic acids into the first, second, third, or fourth inlet. The method may further include introducing one or more lipid components of lipid nanoparticles into the first, second, third, or fourth inlet. The method may further include converging the nucleic acid and one or more lipid components at the outlet. The method may include providing a static mixer, wherein the static mixer can be configured to mix nucleic acids and one or more lipid components, wherein the static mixer includes multiple elements, wherein each element of the static mixer undergoes a 270° twist per 1 / 8 inch. The method may further include providing a channel that accommodates the static mixer configured to mix nucleic acids and one or more lipid components, wherein the channel is square and undergoes a -180° twist per 1 / 8 inch.

[0143] In some embodiments, the fluid mixture may have a polydispersity index (PDI) not greater than about 0.5, 0.4, 0.3, 0.25, 0.20, 0.19, 0.18, 0.17, 0.16, 0.15, 0.14, 0.13, 0.12, 0.11, 0.10, 0.09, 0.08, 0.07, 0.06, 0.05, 0.04, 0.03, 0.02, or 0.01. In some embodiments, the fluid mixture includes a polydispersity index (PDI) of at least 0.01, 0.02, 0.03, 0.04, 0.05, 0.06, 0.07, 0.08, 0.09, 0.10, 0.11, 0.12, 0.13, 0.14, or 0.15. In some embodiments, the PDI may be about 0.05 to about 0.5. In some embodiments, PDI can be from about 0.05 to about 0.25. In some embodiments, PDI can be from about 0.05 to about 0.2. In some embodiments, PDI can be from about 0.1 to about 0.5. In some embodiments, PDI can be from about 0.1 to about 0.25. In some embodiments, PDI can be from about 0.1 to about 0.2. In some embodiments, PDI can be from about 0.05 to about 0.16. In some embodiments, PDI can be from about 0.09 to about 0.12. PDI can be measured using light scattering techniques such as dynamic light scattering (DLS) or by electron microscopy (e.g., scanning electron microscopy or transmission electron microscopy).

[0144] In some embodiments, the fluid mixture may have a Reynolds number less than about 2500, 1500, 1200, 1000, 900, 800, 700, 600, 500, 400, 300, 200, or 100. In some embodiments, the fluid mixture may have a Reynolds number of at least 100, 200, 300, 400, 500, 600, 700, 800, 900, or 1000. In some embodiments, the Reynolds number is about 100 to about 1200. In some embodiments, the Reynolds number is about 100 to about 300. In some embodiments, the Reynolds number is about 600 to about 900. In some embodiments, the Reynolds number is about 600 to about 1000. In some embodiments, the Reynolds number is about 600 to about 700.

[0145] In some implementations, the Reynolds number is expressed using the formula R. e = (ρuL) / μ is calculated, where ρ is the fluid density, u is the flow velocity, L is the characteristic linear dimension, and μ is the dynamic viscosity of the fluid.

[0146] In some embodiments, increasing the fluid density ρ increases the Reynolds number. In some embodiments, decreasing the fluid density ρ decreases the Reynolds number. In some embodiments, increasing the fluid density ρ decreases the size of the resulting lipid nanoparticles. In some embodiments, decreasing the fluid density ρ increases the size of the resulting lipid nanoparticles. In some embodiments, increasing the pressure differential increases the fluid density ρ. In some embodiments, increasing the pressure differential increases the Reynolds number. In some embodiments, decreasing the pressure differential decreases the fluid density ρ. In some embodiments, increasing the pressure differential decreases the size of the resulting lipid nanoparticles. In some embodiments, decreasing the pressure differential increases the size of the resulting lipid nanoparticles.

[0147] In some embodiments, increasing the flow rate u increases the Reynolds number. In some embodiments, decreasing the flow rate u decreases the Reynolds number. In some embodiments, adjusting the flow rate u controls the size of the resulting lipid nanoparticles. In some embodiments, increasing the flow rate u decreases the size of the resulting lipid nanoparticles. In some embodiments, decreasing the flow rate u increases the size of the resulting lipid nanoparticles. In some embodiments, increasing the pressure differential increases the flow rate u. In some embodiments, increasing the pressure differential increases the Reynolds number. In some embodiments, decreasing the pressure differential decreases the flow rate u. In some embodiments, decreasing the pressure differential decreases the Reynolds number. In some embodiments, increasing the pressure differential decreases the size of the resulting lipid nanoparticles. In some embodiments, decreasing the pressure differential increases the size of the resulting lipid nanoparticles.

[0148] In some embodiments, increasing the characteristic linear size L increases the Reynolds number. In some embodiments, decreasing the characteristic linear size L decreases the Reynolds number. In some embodiments, increasing the characteristic linear size L decreases the size of the resulting lipid nanoparticles. In some embodiments, decreasing the characteristic linear size L increases the size of the resulting lipid nanoparticles. In some embodiments, changing the characteristic linear size L and changing the flow rate u maintains the Reynolds number. In some embodiments, the characteristic linear size L is the channel size.

[0149] In some embodiments, increasing the dynamic viscosity µ of the fluid decreases the Reynolds number. In some embodiments, decreasing the dynamic viscosity µ of the fluid increases the Reynolds number. In some embodiments, increasing the dynamic viscosity µ of the fluid increases the size of the resulting lipid nanoparticles. In some embodiments, decreasing the dynamic viscosity µ of the fluid decreases the size of the resulting lipid nanoparticles.

[0150] In some embodiments, increasing the Reynolds number decreases the particle size of the lipid nanoparticles. In some embodiments, decreasing the Reynolds number increases the particle size of the lipid nanoparticles. In some embodiments, increasing the Reynolds number increases the particle size of the lipid nanoparticles. In some embodiments, decreasing the Reynolds number decreases the particle size of the lipid nanoparticles. In some embodiments, the Reynolds number remains constant as the particle size of the lipid nanoparticles increases. In some embodiments, the Reynolds number remains constant as the particle size of the lipid nanoparticles decreases.

[0151] In some implementations, the particle size (e.g., diameter) of the lipid nanoparticles decreases with increasing Reynolds number, such as... Figure 3A As shown in the diagram. In some embodiments, the PDI of the lipid nanoparticles remains approximately constant with increasing Reynolds number, such as... Figure 3B As shown in the diagram. In some embodiments, this document provides methods for generating lipid nanoparticles, wherein the particle size is selected by increasing or decreasing the Reynolds number. In some embodiments, the method includes increasing the Reynolds number to decrease the particle size. In some embodiments, the method includes decreasing the Reynolds number to increase the particle size. In some embodiments, the relationship between the Reynolds number and the particle size is inversely proportional.

[0152] In some embodiments, the lipid nanoparticles may have a size not greater than 500 nanometers (nm), 400 nm, 300 nm, 200 nm, 100 nm, 90 nm, 80 nm, 70 nm, 60 nm, 50 nm, 40 nm, 30 nm, 20 nm, 10 nm, 5 nm, or 1 nm. In some embodiments, the lipid nanoparticles include sizes of at least 10 nm, 20 nm, 40 nm, 50 nm, 60 nm, 70 nm, 80 nm, 85 nm, 90 nm, 100 nm, 105 nm, 110 nm, 120 nm, 140 nm, 160 nm, 180 nm, or 200 nm. In some embodiments, the lipid nanoparticles include a size of about 50 nm to about 300 nm. In some embodiments, the lipid nanoparticles include a size of about 50 nm to about 100 nm. In some embodiments, the lipid nanoparticles include a size of about 100 nm to about 200 nm. In some implementations, the size of lipid nanoparticles is measured by light scattering techniques (e.g., dynamic light scattering) or by electron microscopy (e.g., scanning electron microscopy or transmission electron microscopy).

[0153] In some embodiments, such as shown in Figure 6, the particle size (e.g., diameter) remains unchanged after mixing in a static mixer and after dilution. In some embodiments, dilution includes dilution with an aqueous solvent. In other embodiments, dilution includes dilution with ethanol (e.g., to 12.5 v / v%).

[0154] In some embodiments, the method provided herein includes introducing ethanol after (e.g., after the first and second) solutions have entered and exited a static mixer. In some embodiments, particle size and polydispersity index (PDI) are influenced by the amount of ethanol introduced after the mixer. In some embodiments, the amount of ethanol introduced after the mixer is at least 10%. In some embodiments, the amount of ethanol introduced after the mixer is at least about 12%, 15%, 17%, 25%, 33%, 40%, 45%, 50%, or at least 55%. In some embodiments, the characteristics of particles obtained by introducing different amounts of ethanol after the mixer are shown in Table 4. In some embodiments, the polydispersity of lipid nanoparticles diluted with at least 25% ethanol is <0.15. In some embodiments, the polydispersity of lipid nanoparticles diluted with 17% or less ethanol after the mixer is about 0.2 or higher. In some embodiments, the relationship between particle size and ethanol amount is parabolic, exhibiting the smallest particle size after the introduction of 25% ethanol after the mixer, as described in Table 4.

[0155] In some embodiments, the encapsulation ratio may be not less than about 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99%. In some embodiments, the encapsulation ratio may be not greater than about 99.9%, 99.5%, 99%, 98%, 96%, 94%, 90%, or 85%. In some embodiments, the encapsulation ratio may be about 40% to about 99.9%, about 50% to about 99%, about 60% to about 99%, about 70% to about 99%, or about 80% to about 99%. In some embodiments, the encapsulation ratio is about 90% to about 99%, such as... Figure 7C As shown in the image.

[0156] In some embodiments, the lipid nanoparticles generated using the methods and systems provided herein are stable for at least 24 hours (e.g., at least 48 hours, 1 week, 1 month, 3 months, or at least 6 months). In some embodiments, the lipid nanoparticles are stable for about 24 hours to about 6 months, about 24 hours to about 3 months, about 1 week to about 6 months, or about 1 month to about 6 months. In some embodiments, the lipid nanoparticles are stable at a temperature of about 2°C to about 8°C. In some embodiments, the lipid nanoparticles are stable at a temperature of about -80°C.

[0157] In some implementations, the mixing time can be no less than approximately 5 milliseconds (ms), 10 ms, 15 ms, 20 ms, 25 ms, 30 ms, 35 ms, 40 ms, 45 ms, 50 ms, 55 ms, or 60 ms. In some implementations, the mixing time can be no greater than approximately 5 ms, 10 ms, 15 ms, 20 ms, 25 ms, 30 ms, 35 ms, 40 ms, 45 ms, 50 ms, 55 ms, or 60 ms. In some implementations, the mixing time can be from approximately 5 ms to approximately 40 ms, such as... Figures 17A-17B As shown in the image.

[0158] While various embodiments of this disclosure have been shown and described herein, it will be apparent to those skilled in the art that such embodiments are provided by way of example only. Many variations, modifications, and substitutions will occur to those skilled in the art without departing from this disclosure. It should be understood that various alternatives to the embodiments of this disclosure described herein may be employed.

[0159] As used herein and in the appended claims, unless the context clearly indicates otherwise, the singular forms “a,” “and,” and “the” include plural indicators. Thus, for example, reference to “agent” includes a variety of such agents, and reference to “cell” includes reference to one or more cells (or multiple cells) and their equivalents known to those skilled in the art, and so on. When used herein, ranges of physical properties such as molecular weight or chemical properties such as chemical formulas are intended to include the range and all combinations and sub-combinations of the specific embodiments therein. The term “about,” when referring to a range of numbers or numerical values, indicates that the range referred to is an approximation within experimental variability (or statistical experimental error), and thus the range of numbers or numerical values ​​may vary by a range between 1% and 15%. The term “comprising” (and related terms such as “comprise” or “comprises” or “having” or “including”) is not intended to exclude embodiments in which, for example, any of the material compositions, compositions, methods, or processes described herein may “consist of” or “substantially consist of” the described features.

[0160] Whenever the term "at least," "greater than," or "greater than or equal to" precedes the first value in a series of two or more values, the term "at least," "greater than," or "greater than or equal to" applies to each value in that series. For example, greater than or equal to 1, 2, or 3 is equivalent to greater than or equal to 1, greater than or equal to 2, or greater than or equal to 3.

[0161] When the terms "not greater than", "less than", or "less than or equal to" precede the first value in a series of two or more values, the terms "not greater than", "less than", or "less than or equal to" apply to every value in that series. For example, less than or equal to 3, 2, or 1 is equivalent to less than or equal to 3, less than or equal to 2, or less than or equal to 1.

[0162] Example Example 1: Static mixer for lipid nanoparticle production Cross-shaped four-way mixers are a mixing method that requires high energy input under turbulent conditions. Furthermore, high back pressure is exhibited when operating at high flow rates, necessitating the use of specific pumps to manage the increased pressure. Alternative methods utilizing lower flow rates and back pressures can be desirable for better control over the physicochemical properties of the drug product. Schemes employing lower flow rates and lower back pressures offer a wider range of pump options and allow for better control over lipid nanoparticle (LNP) formation. Static mixers have proven to be a suitable choice for the mixing process.

[0163] method The lipid components of the desired formulation were dissolved in ethanol to achieve the appropriate concentration. Further details regarding the lipid formulations are provided in Tables 8 and 11. For the “empty” LNP assay, the aqueous mRNA phase consisted of a 15 mM citrate pH 4 buffer without added mRNA. For assays using mRNA, preparations were performed according to Table 9. Static mixers of varying lengths, diameters, and architectures were purchased from Cole Palmer and are depicted in Figures 1A–1I. Each system was operated at different total flow rates (TFRs) at buffer:lipid flow rates (FRRs) of 2:1, 3:1, or 5:1, corresponding to the Reynolds number at the static mixer outlet. These TFRs are shown in Tables 1, 3, 5, and 6. Samples prepared at a 2:1 flow rate ratio were also diluted with the buffer at the same flow rate as the lipid flow rate. Some systems were also tested using food coloring dissolved in ethanol and water to simulate and visualize the mixing properties of each system. All Reynolds numbers were calculated using the diameter of the static mixer outlet.

[0164] Mixing was performed using three Chemyx Fusion 6000x syringe pumps and syringes ranging in size from 20 to 100 mL. For mRNA encapsulation formulations that underwent buffer replacement after water dilution, a Cytiva PD-10 column was used for buffer replacement. Each column was equilibrated four times with 4 mL of the formulation's storage buffer. 2.5 mL of the formulation was loaded onto each column and eluted with 3.5 mL of storage buffer. The formulation was concentrated to a target mRNA concentration of 1 mg / mL by ultracentrifugation using an Amicon Ultra-15 centrifuge filter and optionally diluted with buffer to a target formulation volume below 1 mg / mL. The formulation was then filtered using a single PES syringe filter.

[0165] Particle size distribution data were obtained using dynamic light scattering (DLS). Formulation samples were diluted 33-fold in 0.2X phosphate-buffered saline (PBS) to a nominal concentration of 0.03 mg / mL. Formulation samples during processing were run on a Wyatt DynaPro Plate ReaderIII. Particle size distribution data after overnight storage were measured on both the Wyatt Plate Reader and the Malvern Zetasizer Ultra-Red. Particle size (nm) and polydispersity index (PDI) values ​​from the Wyatt Plate Reader were reported as the average of three measurements, while no replicate measurements were performed on the Malvern Zetasizer.

[0166] Results and Discussion Mixer diagram Figures 1A-1I show schematic diagrams of each mixing system in the initial tests, where blue represents the organic lipid inlet and yellow represents the aqueous mRNA inlet. Systems A and B (Figures 1A-1B) both used the same mixing architecture, namely a Koflo 24 element 1 / 8” ID disposable static mixer with polypropylene tubing. System C (Figure 1C) used a Koflo 12 element 1 / 8” ID platinum-cured silica tubing. OD mixing elements. Systems D and E are both modifications of System B, with System D (Fig. 1D) having its mixing architecture partially pushed into a Y-shape, and System E (Fig. 1E) incorporating a simple shunt via a cable tie inserted into the Y-shape. These two customizations were made to minimize mixing occurring in the Y-shape, allowing for better testing of the actual mixing architecture's ability to form nanoparticles. System F is similar to System B but has only 12 mixing elements. System G (Fig. 1G) is a custom design with three 12-element 1 / 8" mixers housed adjacent to each other in a 3 / 16" silicone tube. Systems H and I (Fig. 1H-1I) are both custom systems that push the 1 / 8" mixers into flow connectors, causing the mixers to originate upstream of the fluid confluence point; H has a T-connector, and I has a Y-connector.

[0167] Visualizing mixing using food dyes Figure 2 Images of systems A, B, and C tested using food dye feeds are shown. Blue food dye was dissolved in ethanol, while yellow food dye was dissolved in MilliQ water to best illustrate lipid-mRNA mixing. Images of systems A and B are shown at adapter outlet Reynolds numbers of 25, 50, and 100, while system C is shown only at a Re of 100. It can be seen that the mixing quality of system C is significantly lower than that of systems A and B, and systems A and B appear to achieve a consistent green color after several mixing elements at all tested Re values. Notably, removing air from the mixing system is difficult, with air bubbles continuously passing through the mixer throughout the process. This is more problematic in smaller diameter mixers.

[0168] Day 1 System Operation On Day 1 of testing, systems A through E were tested using food dyes, and systems B, D, and E were run under various conditions after visual evaluation of mixing performance. The Reynolds number was varied by changing the total flow rate of the systems while maintaining a constant FRR of 1:2 lipid:buffer ratio. All results from the Day 1 tests of LNP 5 are shown in Tables 1A and 1B, showing a generally larger particle size compared to the control systems. Among the mixers tested on this day, system B (Re 621) and systems D and E (Re 276) performed well.

[0169] Table 1A Table 1B For system B, increasing the Reynolds number decreases the resulting LNP size. This trend is plotted on... Figures 3A-3B The trend follows an inverse relationship between flow rate and mixing time, with a low value of the latter typically associated with the formation of smaller nanoparticles. Particle sizes 15 minutes after mixing and immediately following dilution are shown in [Figure / Table / Illustration]. Figure 3A In the middle, and Figure 3A The PDI reading is shown in Figure 3B middle.

[0170] System operation on day 2 On day 2 of testing, the new system design and FRR (Frequency Rate of Buffer) different from the standard 1:2 lipid:buffer ratio were tested. To conserve materials, all tests except the last three were performed using the remaining LNP 3 lipids (a composition of five lipids). Tables 2A and 2B show all the results of this day's testing, including two control runs on a T-mixer (one at normal Re and the other at Re equivalent to most static mixer tests). System B was tested again at a higher online citrate ratio (1:5 instead of 1:2), resulting in higher PS (Power Requirement) than the previous test at 1:2 FRR. System B with 1:5 FRR and Re 621 was also tested with immediate water dilution instead of a 30-minute delayed water dilution, which showed that PS and PDI were independent of this change.

[0171] New systems with iterative designs, including systems F, G, and H, were also tested at a 1:2 FRR and Re621. In all three systems, F and H performed similarly well, outperforming any previously conducted static mixer tests. However, system F produced a high PDI after dilution, while system H did not. System H was also tested at a 1:3 FRR while maintaining a constant Re, showing no difference in PS but a slight increase in PDI.

[0172] Finally, based on the favorable results to date, systems F, H, and I were tested using LNP 5 (system I has not yet been tested, but it is a variant of the well-performing system H). All systems were tested using a 1:3 FRR, with system F performing the worst in both PS and PDI. Compared to other static mixing experiments, systems H and I performed relatively well, yielding diluted particle sizes of 115 nm and 102 nm, respectively, with PDI of 0.15 or lower. Notably, system I was also tested at a higher Re due to its smaller Y-shaped pore size. This difference in Re is likely due to the smaller PS compared to system H, resulting from higher mixing efficiency.

[0173] Table 2A Table 2B System operation on day 3 Based on the results of Day 1 and Day 2, follow-up experiments were conducted to optimize the design of the most promising system—System H (Figure 1H). Six new test systems were designed based on this system, one of which was a negative test, and these systems will be referred to as Systems J to O. All architectures used LNP 5 lipids and buffers, and the visual representations of these systems are shown in Figures 4A–4F. Although the same mixing architectures were tested in Systems J–N (Figures 4A–4E), the FRR, number of mixing elements, feed inlet orientation, and residence length were varied to observe their effects on particle size after mixing and dilution. Tables 3A and 3B summarize the experimental parameters and results of these tests.

[0174] Table 3A Table 3B When directly comparing the newly tested systems, it can be seen that systems J, L, and N (Figs. 4A, 4C, and 4E) achieved favorable performance. All three systems utilize a spiral mixer with approximately two mixing elements inserted into the mixing T-shape. All three systems also achieved a post-mixing EtOH concentration of 25%, although system L (Fig. 4C) reached this same EtOH percentage after initial mixing without subsequent online dilution. Systems J and N (Figs. 4A and 4E) performed similarly, even though the latter system had half the number of mixing elements. This result supports the hypothesis that the crucial emulsion formation occurs rapidly at the start of mixing. Higher flow rate ratios (system M (Fig. 4D)) resulted in larger particles and higher PDI. Overall, the optimal design of the static mixing system was able to simulate the T-mixer control with comparable PS and PDI at Re 1000, but this did require significantly higher flow rates due to the relatively larger pipe diameter.

[0175] Systems J and K (Figures 4A-4B) were tested for feed orientation, with the lipid inlet of system J located at the junction site and the lipid inlet of system K located at the T-shaped straight-through line. System J showed superior results compared to system K, with lower PS and comparable PDI. This result is likely due to the higher flow rate inlet of system J in the straight-through line, which has the potential to generate lower back pressure. Figures 5A-5B The particle diameter after dilution is shown. Figure 5A ) and diluted PDI ( Figure 5B (The bar charts for both.)

[0176] System operation on day 4 Following the testing on day 3, higher ethanol concentrations (ethanol (v / v) percentage) were tested at the static mixer outlet (before online dilution) to determine the optimal post-mixer ethanol concentration for the static mixing architecture. System J (Figure 4A) was used for these tests along with LNP 5 lipids and buffers, and a Reynolds number of approximately 1000 was maintained at the mixing outlet under all test conditions, assuming negligible changes in bulk viscosity and density with respect to the Reynolds number (actual Re range 920 to 1001). A peristaltic pump (Masterflex Model 77200-30) was used instead of the citrate dilution flow rate achievable with the Chemyx syringe pump. All relevant mixing parameters are shown in Table 4. All samples were diluted to 12.5 (v / v)% ethanol 30 minutes after mixing, and the citrate dilution flow rate was determined to maintain ethanol (v / v)% at 25% after online dilution. Some samples from Tables 3A and 3B are included in Tables 4A and 4B for comparison.

[0177] Table 4A Table 4B Table 4B also shows the particle size and PDI after mixing and dilution for all samples. Formulations with at least 25% ethanol after mixing generally have a low PDI (<0.15), while 17% ethanol after mixing results in a PDI of around 0.2. Particle size follows a parabolic relationship with the amount of ethanol after mixing, ranging from approximately 85 to 160 nm and reaching a minimum particle size at around 33% ethanol after mixing. A 1:2 FRR is advantageous, as this keeps the static mixer consistent with the previous mixer, since this 1:2 ratio has previously been found to be an advantageous mixing ratio for both T-type mixers and cross-shaped four-way mixers. Figure 6A The particle diameter is shown as plotted relative to the ethanol after mixing, and Figure 6B The PDI is shown.

[0178] System operation on day 5 Following the analysis of the results from the previous three sets of experiments, the design of System N (Figure 4E) was further analyzed, as it achieved small particle size and low PDI with fewer mixing elements required. System N was subsequently tested using an mRNA formulation instead of just lipids and buffers to evaluate encapsulation efficiency and storage stability parameters not previously examined on this architecture. LNP 5-CFTR was used, and flow ratios of 1:2 and 1:3 were tested for static mixing setups. A T-mixer control was also run using the same formulation and a 1:2 flow ratio, and all systems were run at a Re of 1000 at the mixing outlet. All experimental flow parameters are shown in Table 5.

[0179] Table 5 Each formulation was prepared and processed by small-scale buffer replacement (PD 10 column), subsequent centrifugation concentration (Amicon tube), and filtration. Finally, storage stability was tested by storing aliquots at 2–8°C or -80°C for more than 24 hours. Particle size and particle size distribution were analyzed after each processing and storage step, and the values ​​are reported in Tables 6A and 6B.

[0180] Table 6A Table 6B The control system consistently exhibited the lowest particle size, with a PS range of 61–65 nm and a PDI below 0.1. Static mixer tests with an FRR of 1:2 generally outperformed those with 1:3 FRR, achieving a PDI consistently of 0.1 or lower and a PDI range of 72–77 nm. Interestingly, the 1:3 FRR static mixer showed a steady increase in particle size during treatment, starting at 78 nm after mixing and increasing to 101 nm after concentration. After concentration, the particle size increased by 14 nm. Encapsulation efficiency is not shown in Tables 6A and 6B. Encapsulation efficiency was between 98% and 99% after storage under both control and 1:2 FRR static mixer conditions, while it was significantly lower under 1:3 FRR conditions, ranging from 66% to 68%. It is also noteworthy that the 1:3 FRR conditions had a different post-mixing ethanol concentration (20% instead of 25%) in this study, likely due to the presence of online citrate dilution. This is taken into account in the dilution step by diluting with less water to achieve the same 12.5% ​​diluted ethanol as achieved by a 1:1 dilution in the control and 1:2 FRR static mixer systems.

[0181] System operation on day 6 Following the conclusion in the aforementioned tests that the static mixer architecture of System N with a 1:2 FRR performed well using LNP 5-CFTR (PDI < 0.1, PS between 60 and 85 nm, and encapsulation > 97%), a final comparative test was conducted on the system with and without mixing elements. A second mixing system identical to System N (same tube length, accessories, and connectors) but without any static mixing elements was constructed. This second mixing system was referred to as the "mixer-free" system and was tested to verify that mixing occurred primarily due to the static mixing elements rather than due to fluid confluence (e.g., through jet impingement). Both systems were tested according to the flow parameters outlined in Table 7.

[0182] Table 7 Both systems were tested with the same flow parameters to identify the mixing characteristics of the systems with and without static mixing elements at Re = 1000. Samples were treated in the same manner as previously prepared samples (day 5 of testing), and the results are shown in Tables 8A and 8B. Encapsulation rates after storage for each formulation are not shown in Tables 8A or 8B. For the control system without static mixing elements, an encapsulation rate of 49–51% was achieved, while 96% was achieved using the 1:2 FRR static mixing system. It is noted that the 96% encapsulation rate is lower than that typically seen with this static mixing system and lower than that typically expected when using LNP 5-CFTR formulations.

[0183] Table 8A Table 8B As shown in Tables 8A and 8B, the control system without a mixer generally exhibited lower performance. Particle sizes ranged from 186 to 235 nm during processing and after storage, with the largest particle size observed after spin-concentration and the smallest after refrigeration. The PDI of the mixer-free system ranged from 0.09 to 0.22, which was generally higher compared to most mixing systems using LNP 5-CFTR. The static mixer performed better than the mixer-free system, with particle sizes ranging from 86 to 99 nm, with the largest particle size observed after mixing and gradually decreasing during processing. The static mixer samples showed the smallest particle size after refrigeration. The static mixer samples generally had a low PDI, ranging from 0.06 to 0.14 and peaking after spin-concentration. These values ​​are again less desirable than those seen in previous tests on the same formulations and conditions (larger particle size and PDI, and lower encapsulation). However, this test does demonstrate that mixing elements can directly improve the mixing performance of the system by significantly reducing particle size and increasing encapsulation.

[0184] System operation on day 7 Following the control test on day 6, which demonstrated a significant improvement in mixing performance when using LNP 5, other mRNA and lipid formulations were tested to evaluate the cross-platform performance of the static mixing architecture. For this purpose, five different formulations with two different payloads were tested. The precise lipid composition and mRNA batch size for each formulation used in these tests are shown in Table 11. The experimental parameters for these tests are listed in Table 9, which shows the formulations prepared using CFTR mRNA and two formulations using DNAI1 mRNA. All systems used the same mixing architecture (system N) and the same number of elements, as well as the same FRR, orifice outlet Reynolds number, and inlet flow rate. The main variations between systems were lipid composition (see Appendix A), lipid:mRNA ratio, lipid and mRNA feed concentrations, buffer strength, buffer pH, and final storage buffer composition.

[0185] Table 9 All size and distribution data are shown in Tables 10A and 10B. LNP 1-CFTR resulted in the largest particle size and widest particle size distribution across all formulations, ranging from 84 to 106 nm with a PDI ranging from 0.09 to 0.17, with the largest particle size after dilution and the largest PDI after mixing. LNP 5-CFTR also resulted in large particles, but smaller and less dispersible than LNP 1-CFTR. LNP 5 had a particle size range of 82 to 93 nm and a PDI ranging from 0.08 to 0.17 (the latter being the outlier value after rotary concentration). Minimum particle size was observed after storage. LNP 3-CFTR exhibited similar behavior to LNP 5-CFTR during processing, with a particle size range of 82 to 95 nm and a PDI ranging from 0.08 to 0.13. Both DNAI1 formulations outperformed all three CFTR formulations, with LNP 2-DNAI1 exhibiting a particle size range of 78–86 nm and a PDI range of 0.02–0.15. Finally, LNP 4-DNAI1 had the smallest particle size range among the five formulations tested, ranging from 63 to 73 nm, and a PDI range of 0.06 to 0.16.

[0186] This cross-platform comparison shows that the static mixer system can indeed produce feasible, albeit slightly larger, nanoparticles with low polydispersity (less than 0.2) and medium particle size (62–87 nm after storage). Encapsulation efficiency values ​​are not included in Tables 10A and 10B, but with a few exceptions, they are generally higher than 97%. First, the 93% encapsulation efficiency of LNP 3-CFTR after freeze-thaw is unusual, given its 98.6% encapsulation efficiency after refrigeration. Second, the 94% encapsulation efficiency of LNP 5-CFTR after refrigeration is also unusual, considering its 97.8% encapsulation efficiency after freeze-thaw. Finally, the encapsulation efficiency of LNP 2-DNAI1 is approximately 90% after both storage methods.

[0187] Table 10A Table 10B To facilitate the conclusions drawn from this cross-platform screening, it was crucial to compare these results with previous results using mixers of established quality. For this purpose, the post-storage particle size, PDI, and encapsulation efficiency of the static mixing system were compared with previously formulated compositions prepared using a cross-shaped four-way mixer. Notably, the LNP 4 formulations compared used a different mRNA (H1N1 instead of DNAI1), and LNP 1 used a tagged CFTR version. The graphical comparison is shown below. Figures 7A-7C It can be seen that the particle diameter made using the static mixing architecture is generally higher than that made using the cross-shaped four-way architecture. The PDI (partial density index) of the two mixing systems is generally comparable, with the static mixer showing a lower PDI in 5 out of 9 comparisons. Encapsulation efficiency is also comparable, with the largest discrepancy appearing between LNP 1 and LNP 2. LNP 1 exhibits a higher encapsulation efficiency when made using the static mixer, while LNP 2 exhibits a lower encapsulation efficiency when made using the static mixer.

[0188] in conclusion In this study, different static mixing architectures were tested and iterated to develop a novel mixing geometry to replace the cross-shaped four-way mixer. Ideally, this alternative should be scalable and should reduce the downstream particle aggregation seen with the current mixer. Overall, the initial static mixing system exhibited a larger particle size than the control run using a T-shaped mixer, even when the T-shaped mixer was running at a Reynolds number comparable to the static mixer. This is likely because mixing begins before the lipid and mRNA reserves meet the static mixer architecture, leading to designs for systems D, E, H, and I. Some of these systems did indeed produce smaller PS than the first-round design, particularly systems H and I, where the mixer in each system extends into the lipid inlet before merging with the buffer flow. This optimization reduced the particle size from approximately 200 nm to approximately 100 nm, a reduction of 50%.

[0189] These systems were then iterated to obtain System J-System O (Figs. 4A-4F), which yielded significantly better results compared to the previously tested static mixers at a Re of 1000. In these tests, favorable particle diameter and PDI were found when the aqueous inlet was passed through the straight section of the connector at a higher flow rate and the organic lipid inlets were merged at the confluence site at a 1:2 FRR. Negligible differences were found between the 8-element and 16-element mixing systems, highlighting the importance of initial mixing events for high-quality emulsion formation. In conclusion, the third round of static mixing tests showed great promise, with the only caveat being that they require operation at slightly higher Re / flow rates for good mixing.

[0190] After day 3 of mixer testing, the post-mixing ethanol concentration was probed, and a 1:2 mixing ratio was found to be favorable. It was subsequently decided to further test System N, as it achieved high performance with fewer components. LNP 5-CFTR was tested using System N for comparison with a control (T-shaped mixer), showing that the static mixing system performed favorably at a 1:2 lipid:mRNA flow rate ratio (FRR), while producing particles still slightly larger than those produced by the T-shaped mixer. On day 5 of testing, a true control system—with the same attachments, tube length, and connectors as System N, but without the static mixing element—was fabricated and tested to separate the mixing effect from the static mixing element and the flow path confluence. These tests revealed that the system may indeed require a static mixing element to properly produce particles smaller than 150 nm, and that without the mixing element, the mRNA encapsulation efficiency dropped below 60%.

[0191] Finally, the static mixing system (system N) was characterized on five different mRNA platforms: LNP 1-CFTR, LNP 2-DNAI1, LNP 3-CFTR, LNP 4-DNAI1, and LNP 5-CFTR. When the post-storage results of static mixing were compared with those of similar formulations prepared using a cross-shaped four-way mixing system, the static mixer generally produced particles with comparable encapsulation efficiency and PDI, but with an average particle diameter 14 nm higher.

[0192] Table 11 Example 2: Static Mixer Mixing Simulation Simulations of the mixing of ethanol and water using the Reynolds stress model show that the maximum shear stress and system pressure in a static mixer are lower than those in a cruciform mixer. Figures 15A-15C As shown. The static mixer is 1 inch long and has an inner diameter of approximately 1 / 8 inch. The static mixer comprises 8 elements, each approximately 1 / 8 inch long, and each element is twisted approximately 180°, as shown. Figure 15A As shown. The cross-sectional thickness of each component is approximately 0.0394 inches (1 mm), as... Figure 15A As shown. The ethanol flow rate was approximately 75.4 mL / min, and the water flow rate was approximately 150.8 mL / min. Figure 15B As shown. Figures 16A-16B A comparative system is shown, consisting of a cross-shaped mixer with a standard inner diameter of approximately 0.5 mm and three inlets. Two inlets have a water flow rate of approximately 40 mL / min, and one inlet has an ethanol flow rate of approximately 40 mL / min. The outlet inner diameter is approximately 1 / 16 in. Both systems were simulated in Ansys Fluent, and the results were used to extract shear stress, total system pressure, and ethanol mass fraction. Cross-sections were taken approximately every 0.1 mm perpendicular to the fluid travel direction, and the area-weighted mean shear stress and the standard deviation of the ethanol mass fraction were calculated at these cross-sections. The mean shear stress term was used to assess the shear stress exerted on the mixed fluid by each mixing architecture, and the standard deviation of the ethanol mass fraction was used to assess the homogeneity of the fluid; a low standard deviation represents high mixing / homogeneity. Time was calculated in milliseconds based on the fluid flow rate of each system and the cross-sectional area of ​​each evaluation cross-section. The time zero point for each mixing system was set at the starting point where the water-ethanol flows intersect. The results of these simulations are shown in... Figures 17A-17C The standard deviation of ethanol mass fraction was compared between two different mixers. Figure 17A The results show that the standard deviation of the cross-shaped mixer decreases more rapidly, indicating that its mixing process is faster compared to the simulated static mixing system. However, when comparing area-averaged shear stress ( Figure 17BThe results show that the cruciform mixer exhibits significantly higher shear stress during mixing, reaching a maximum of approximately 1000 Pa, which is more than five times the maximum shear stress achieved by the static mixing system. Furthermore, when comparing the maximum total system pressure of the two systems ( Figure 17C As can be seen, the cruciform mixing system reaches a pressure of approximately 23.3 psig, while the static mixing system reaches only approximately 7.7 psig. These results indicate that although the cruciform mixing system approaches a homogeneous system faster than the proposed static mixing system, the static mixing system is significantly improved due to its reduced shear stress on the simulated material and its lower system pressure, which should directly indicate a lower back pressure applied to the pumping system.

[0193] Example 3: Static Mixer Design A series of mixers were designed and 3D printed using Digital Light Processing (DLP), a resin-based additive manufacturing technology that offers high resolution and greater accuracy. Black FST Loctite 3955 was chosen as the mixer material due to its chemical resistance to ethanol. FST composite resins are also fire-resistant, smoke-resistant, and toxic.

[0194] A Koflo analogue design (Design 1, A1) was developed, modeled after the Koflo static mixer. The internal components are helical elements with a 180° twist. Figure 25A The outer housing includes two inlets with 1 / 8-inch barbs spaced 120° apart. Figure 25B It is wider than a typical 60° spaced Y-connector to allow space for pipe fittings and cable ties. The channel is cylindrical to accommodate the components. Figure 25C ).

[0195] Another design was developed (Design 2, No. D10), which included a helical element with a 270° twist. Figure 26A The outer casing includes two inlets (). Figure 26B And the channel is square. Figure 26C ) and includes -180° twist ( Figure 26D ).

[0196] Another design was developed (Design 3, No. D7), which included a helical element with a 270° twist. Figure 27A The outer casing includes four inlets (). Figure 27B And the channel is square. Figure 27C ) and includes -180° twist ( Figure 27D ).

[0197] Another design was developed (Design 5, No. D6), which included a helical element with a 180° twist. Figure 28A The outer casing includes four inlets (). Figure 28B And the channel is square. Figure 28C ) and includes -180° twist ( Figure 28D ).

[0198] These mixer designs (design numbers A1, D10, D7, D6) and the control 0.5 mm cross-shaped mixer were tested in simulation experiments to test total pressure and shear stress, as shown in Table 12.

[0199] Table 12 Design D7 produces low total pressure and shear stress. These values ​​are both lower than those simulated by the original static mixer design (Design A1). The mixing efficiency of Design D7 is also 124% higher than that of the Koflo analogue Design A1. The designed mixer has a throughput approximately eight times higher (both maximum and minimum) than a 0.5 mm cross-shaped mixer, allowing for a high flow rate of approximately 905 mL / min total flow rate.

[0200] A complete summary of the mixer design is shown in Table 13. The corresponding static mixer design described in Table 13 is shown in... Figures 29A-29C middle.

[0201] Table 13 In summarizing Table 13, all the above design conditions were evaluated and compared, with the goal of minimizing both back pressure and shear stress experienced by the reagent while maximizing the mixing rate. A back pressure cutoff of 10 psig was used to narrow down the results, as this is two-thirds of the maximum rated pressure of the low-shear pump system we wanted to use to drive the mixer flow. This cutoff was used to account for pressure increases caused by additional piping and possible unquantified inaccuracies in the CFD results. Among the designs with low back pressure, design number D7 had the highest simulated mixing rate and the lowest maximum mean shear stress, making it the leading candidate. Design number D6 was also considered because its design is similar to design number D7, but with a simulated back pressure nearly 2 psi lower. Design number D10 was considered because its mixer design is the same as design number D7, but with two inlets instead of four, simplifying the upstream connections. All three designs, as well as the Koflo analog design number A1, were successfully fabricated and tested. Of the four fabricated designs, design number D7 performed best at lower flow rates and was selected for testing at a higher simulated total flow rate of approximately 905 mL / min. At this rate, the measured back pressure was approximately 15 psi, significantly higher than the simulated back pressure of 6 psi, but this was somewhat expected because the simulated back pressure did not include contributions from upstream or downstream piping and connections.

[0202] Example 4: Initial testing of the manufactured static mixer Each of the selected manufactured static mixers was tested relative to both the cross-shaped and T-shaped mixers, with all tests performed at a buffer to lipid ratio of 3:1 (empty). Higher buffer pH can reduce particle size, so citrate buffers from pH 4 to pH 6 were tested. Buffer strength can also affect particle size, so the citrate buffer strength was varied and sodium chloride (NaCl) was added to alter charge shielding and promote particle formation. All conditions and tests performed for empty LNPs with an FRR (lipid:mRNA) ratio of 1:3 are shown in Table 14.

[0203] Table 14 Reynolds number based on initial SM control flow rate The results of the initial tests (Test 1-Test 7) ​​and the control comparison are shown in Table 15.

[0204] Table 15 Among these results, the cross-shaped mixer and the T-shaped mixer produced the smallest particle size (PS) and polydispersity index (PDI) compared to the static mixer. The best performing static mixer designs were design A1 and design D7.

[0205] Since design number D7 performed best compared to other non-Koflo designs, follow-up tests were conducted using design number D7 with different buffer compositions. The results are shown in Table 16.

[0206] Table 16 Based on the results and tables, design number D7 produced the best results among the non-Koflo equivalent static mixer designs, achieving a particle size of 88 nm after PD-10. Buffer strength, pH, and added NaCl did not show significant effects on particle size, with variations of only about 10 nm between conditions. In these experiments, design number D7 was run at one-quarter of its designed total flow rate. Testing the static mixer at higher flow rates could improve formulation performance.

[0207] Example 5: High-flow test of the manufactured static mixer on a peristaltic pump High-flow-rate tests were conducted on mixer design number D7 to achieve a simulated total flow rate of 904.8 mL / min. In the designs simulated at a total flow rate (TFR) of 904.8 mL / min, design number D7 exhibited the highest simulated mixing efficiency, and compared to designs D10 and D6, design number D7 produced smaller particle sizes at lower flow rates.

[0208] The peristaltic pump was tested for pressure measurement using design number D7 at a water / ethanol flow rate ratio (FRR) of 3:1. The peristaltic pump was chosen for ease of achieving scaled-up flow rates. As shown in Table 17, the results at different total flow rates indicate that the mRNA pump pressure was 15.4 psi at a total flow rate of 904.8 mL / min, thus demonstrating the feasibility of using a Levitronix pump at these flow rates.

[0209] Table 17 The RTX0051-empty formulation was tested at different total flow rates, as shown in Table 18. As the results in Table 18 show, only a total flow rate of 395.9 mL / min produced particles of 80 nm. Other total flow rates produced particles of 106–119 nm after PD-10. It is speculated that the particle size reduction at 395.6 mL / min is due to pulsation at 396 mL / min, rather than the effect of a total flow rate higher than 395.6 mL / min.

[0210] Table 18 The results showed that the D7 mixer could withstand a total flow rate of up to 904.8 mL / min with a maximum pressure of only 15.4 psig (mRNA pressure (psig)). Considering the flow rate, this pressure is considered extremely low. Particle size was larger at higher flow rates and smallest at the lowest flow rate tested (395.9 mL / min). At this flow rate, the diluted particle size was approximately 86 nm. It is speculated that the pulsation of the peristaltic mixer under high flow conditions led to suboptimal mixing conditions.

[0211] Example 6: High-flow rate test of the manufactured static mixer on an HPLC pump A high-performance liquid chromatography (HPLC) pump was used to observe whether it would produce particles smaller than those produced by a peristaltic pump at high flow rates. The desired flow rate was achieved using a Knauer BlueShadow 80P LC pump (1000 mL / min), and different parameters used in the peristaltic pump experiment were tested. Simulated flow parameters were a total flow rate of 904.8 mL / min, a maximum back pressure of 5.77 psig, and a mixing efficiency of 224% compared to the original static design. Table 19 shows the test conditions on the HPLC pump, which were set to mimic the test conditions on the peristaltic pump.

[0212] Table 19 The RTX0051-empty formulation was tested at different total flow rates. As shown in Table 20, the particles produced under the four test conditions were smaller than those produced using the peristaltic setting. The particle size range after PD-10 was 60-75 nm, with the highest flow rate condition producing the best particles in all sampling schemes. A minimal trend was observed in the total flow rate, with good empty particle production under all conditions.

[0213] Table 20 As the results show, the HPLC pump produces much smaller particles. Peristaltic fluctuations can significantly affect mixing efficiency at high flow rates. Empty particles smaller than 65 nm were achieved using the D7 mixer, as shown in Table 20. This represents a 20 nm reduction in particle size compared to the Koflo analog design A1, which produces particles of approximately 84 to 87 nm, as shown in Table 15.

[0214] Although preferred embodiments of this disclosure have been shown and described herein, it will be apparent to those skilled in the art that such embodiments are provided by way of example only. This disclosure is not intended to be limited to the specific examples provided herein. While this disclosure has been described with reference to the foregoing description, the description and illustration of embodiments herein are not intended to be construed in a limiting sense. Various variations, modifications, and substitutions will now occur to those skilled in the art without departing from this disclosure. Furthermore, it should be understood that all aspects of this disclosure are not limited to the specific depictions, configurations, or relative proportions set forth herein, and depend on various conditions and variables. It should be understood that various alternatives to the embodiments of this disclosure described herein may be employed in the practice of this disclosure. Therefore, it is contemplated that this disclosure should also cover any such alternatives, modifications, variations, or equivalents. The following claims are intended to define the scope of this disclosure and thereby cover the methods and structures within the scope of these claims and their equivalents.

[0215] Implementation Plan The following are exemplary implementations of the content disclosed herein: Implementation Scheme 1. A system for generating lipid nanoparticles, the system comprising: (a) A catheter, comprising: i. The first entry point, configured to introduce nucleic acids; ii. A second inlet, configured to introduce one or more lipid components of lipid nanoparticles; iii. Export, wherein nucleic acids and one or more lipid components converge in the export; and (b) A static mixer in which nucleic acid and one or more lipid components are mixed to generate a mixture fluid, and wherein the polydispersity index of the mixture fluid is not greater than about 0.25.

[0216] Implementation Scheme 2. The system as described in Implementation Scheme 1, wherein the catheter is T-shaped.

[0217] Implementation Scheme 3. The system as described in Implementation Scheme 1, wherein the catheter is Y-shaped.

[0218] Implementation Scheme 4. The system as described in Implementation Scheme 3, wherein the catheter further includes a cut ligature.

[0219] Implementation Scheme 5. The system as described in Implementation Scheme 1, wherein the conduit is L-shaped.

[0220] Implementation Scheme 6. The system as described in any of the preceding implementation schemes, wherein the length of the static mixer is less than about 40 millimeters (mm).

[0221] Implementation Scheme 7. The system as described in any of the preceding implementation schemes, wherein the length of the static mixer is less than about 10 mm.

[0222] Implementation Scheme 8. The system as described in any of the preceding implementation schemes, wherein the length of the static mixer is less than about 5 mm.

[0223] Implementation Scheme 9. The system as described in any of the preceding implementation schemes, wherein the length of the static mixer is approximately 4.8 mm.

[0224] Implementation Scheme 10. The system as described in any of the preceding implementation schemes, wherein the static mixer has an inner diameter of about 1 / 16 inch to about 1 / 2 inch.

[0225] Implementation Scheme 11. The system as described in Implementation Scheme 10, wherein the inner diameter is approximately ¼ inch.

[0226] Implementation Scheme 12. The system as described in Implementation Scheme 10, wherein the inner diameter is approximately 1 / 8 inch.

[0227] Implementation Scheme 13. The system as described in any of the preceding implementation schemes, wherein the polydispersity index is from about 0.05 to about 0.25.

[0228] Implementation Scheme 14. The system as described in Implementation Scheme 13, wherein the polydispersity index is about 0.1 to about 0.2.

[0229] Implementation Scheme 15. The system as described in any one of Implementation Schemes 1-12, wherein the polydispersity index is not greater than about 0.1.

[0230] Implementation Scheme 16. The system as described in any of the preceding implementation schemes, wherein the Reynolds number of the mixed fluid is about 150 to about 1000.

[0231] Implementation Scheme 17. The system as described in Implementation Scheme 16, wherein the Reynolds number is about 500 to about 1000.

[0232] Implementation Scheme 18. The system as described in Implementation Scheme 16, wherein the Reynolds number is approximately 1000.

[0233] Implementation Scheme 19. The system as described in any of the preceding implementation schemes, wherein the lipid nanoparticles are no larger than about 100 nanometers (nm).

[0234] Implementation Scheme 20. The system as described in Implementation Scheme 19, wherein the lipid nanoparticles are about 50 nm to about 100 nm.

[0235] Implementation Scheme 21. The system as described in Implementation Scheme 19, wherein the lipid nanoparticles are about no larger than about 50 nm.

[0236] Implementation Scheme 22. The system as described in any of the preceding implementation schemes, wherein the flow rate of the lipid component is in the ratio of about 1:2 to about 1:5 to the flow rate of the nucleic acid component.

[0237] Implementation Scheme 23. The system as described in Implementation Scheme 22, wherein the flow rate of the lipid component is approximately 1:2 to the flow rate of the nucleic acid component.

[0238] Implementation Scheme 24. The system as described in Implementation Scheme 22, wherein the flow rate of the lipid component is approximately 1:3 to the flow rate of the nucleic acid component.

[0239] Implementation Scheme 25. The system as described in any of the preceding embodiments, wherein nucleic acids and one or more lipid components are mixed to generate a mixture fluid, thereby encapsulating the nucleic acids in one or more lipid components to generate lipid nanoparticles.

[0240] Implementation Scheme 26. The system as described in any of the preceding implementation schemes, wherein the static mixer comprises eight or more elements.

[0241] Implementation Scheme 27. The system as described in any of the preceding implementation schemes, wherein the static mixer comprises 12 or more elements.

[0242] Implementation Scheme 28. The system as described in any of the preceding implementation schemes, wherein the static mixer comprises 16 or more elements.

[0243] Implementation Scheme 29. The system as described in any of the preceding implementation schemes, wherein the static mixer comprises 24 or more elements.

[0244] Implementation Scheme 30. The system as described in any of the preceding implementation schemes, wherein the static mixer is downstream of the conduit.

[0245] Implementation Scheme 31. A method for generating lipid nanoparticles, the method comprising: (a) Provide: i. A catheter, comprising: a. First entrance; b. Second entrance; c. Exports; and ii. Static mixer; (b) Introduce nucleic acid into the first entry point; (c) Introducing one or more lipid components of lipid nanoparticles into a second inlet; (d) To allow nucleic acids and one or more lipid components to converge at the outlet; and (e) Using a static mixer to mix nucleic acids and one or more lipid components to generate a mixture fluid, wherein the polydispersity index of the mixture fluid is not greater than about 0.25.

[0246] Implementation Scheme 32. The method as described in Implementation Scheme 31, wherein the catheter is T-shaped.

[0247] Implementation Scheme 33. The method as described in Implementation Scheme 31, wherein the catheter is Y-shaped.

[0248] Implementation Scheme 34. The method as described in Implementation Scheme 33, wherein the catheter further includes a cut ligature.

[0249] Implementation Scheme 35. The method as described in Implementation Scheme 31, wherein the catheter is L-shaped.

[0250] Implementation Scheme 36. The method of any one of Implementation Schemes 31-35, wherein the length of the static mixer is less than about 40 mm.

[0251] Implementation Scheme 37. The method of any one of Implementation Schemes 31-36, wherein the length of the static mixer is less than about 10 mm.

[0252] Implementation Scheme 38. The method of any one of Implementation Schemes 31-37, wherein the length of the static mixer is less than about 5 mm.

[0253] Implementation Scheme 39. The method of any one of Implementation Schemes 31-38, wherein the length of the static mixer is about 4.8 mm.

[0254] Implementation Scheme 40. The method of any one of Implementation Schemes 31-39, wherein the static mixer has an inner diameter of about 1 / 16 inch to about 1 / 2 inch.

[0255] Implementation Scheme 41. The method as described in Implementation Scheme 40, wherein the inner diameter is approximately ¼ inch.

[0256] Implementation Scheme 42. The method as described in Implementation Scheme 40, wherein the inner diameter is approximately 1 / 8 inch.

[0257] Implementation Scheme 43. The method of any one of Implementation Schemes 31-42, wherein the polydispersity index is about 0.05 to about 0.25.

[0258] Implementation Scheme 44. The method as described in Implementation Scheme 43, wherein the polydispersity index is about 0.1 to about 0.2.

[0259] Implementation Scheme 45. The method of any one of Implementation Schemes 31-42, wherein the polydispersity index is not greater than about 0.1.

[0260] Implementation Scheme 46. The method of any one of Implementation Schemes 31-45, wherein the Reynolds number of the mixed fluid is about 150 to about 1000.

[0261] Implementation Scheme 47. The method as described in Implementation Scheme 46, wherein the Reynolds number is about 500 to about 1000.

[0262] Implementation Scheme 48. The method as described in Implementation Scheme 46, wherein the Reynolds number is approximately 1000.

[0263] Implementation Scheme 49. The method of any one of Implementation Schemes 31-48, wherein the lipid nanoparticles are no larger than about 100 nm.

[0264] Implementation Scheme 50. The method as described in Implementation Scheme 49, wherein the lipid nanoparticles are about 50 nm to about 100 nm.

[0265] Implementation Scheme 51. The method as described in Implementation Scheme 49, wherein the lipid nanoparticles are about no larger than about 50 nm.

[0266] Implementation Scheme 52. The method of any one of Implementation Schemes 31-51, wherein the flow rate of the lipid component is in the ratio of about 1:2 to about 1:5 to the flow rate of the nucleic acid component.

[0267] Implementation Scheme 53. The method as described in Implementation Scheme 52, wherein the flow rate of the lipid component is approximately 1:2 to the flow rate of the nucleic acid component.

[0268] Implementation Scheme 54. The method as described in Implementation Scheme 52, wherein the flow rate of the lipid component is approximately 1:3 to the flow rate of the nucleic acid component.

[0269] Implementation Scheme 55. The method of any one of Implementation Schemes 31-54, wherein nucleic acids and one or more lipid components are mixed to generate a mixture fluid, thereby encapsulating the nucleic acids in one or more lipid components to generate lipid nanoparticles.

[0270] Implementation Scheme 56. The method of any one of Implementation Schemes 31-55, wherein the static mixer comprises eight or more elements.

[0271] Implementation Scheme 57. The method of any one of Implementation Schemes 31-56, wherein the static mixer comprises 12 or more elements.

[0272] Implementation Scheme 58. The method of any one of Implementation Schemes 31-57, wherein the static mixer comprises 16 or more elements.

[0273] Implementation Scheme 59. The method of any one of Implementation Schemes 31-58, wherein the static mixer comprises 24 or more elements.

[0274] Implementation Scheme 60. The method of any one of Implementation Schemes 31-59, wherein the static mixer is downstream of the conduit.

[0275] Implementation Scheme 61. A system for generating lipid nanoparticles, the system comprising: (a) A catheter, comprising: i. The first entry point, configured to introduce nucleic acids; ii. A second inlet, configured to introduce one or more lipid components of lipid nanoparticles; iii. The junction point where the first and second entrances intersect; and (b) A static mixer configured to mix nucleic acids and one or more lipid components, wherein the nucleic acids and one or more lipid components do not come into contact with each other before entering the junction site.

[0276] Implementation Scheme 62. The system as described in Implementation Scheme 61, wherein the catheter is T-shaped.

[0277] Implementation Scheme 63. The system as described in Implementation Scheme 61, wherein the catheter is Y-shaped.

[0278] Implementation Scheme 64. The system as described in Implementation Scheme 63, wherein the catheter further includes a cut ligature.

[0279] Implementation Scheme 65. The system as described in Implementation Scheme 61, wherein the conduit is L-shaped.

[0280] Implementation Scheme 66. The system of any one of Implementation Schemes 61-65, wherein the length of the static mixer is less than about 40 mm.

[0281] Implementation Scheme 67. The system of any one of Implementation Schemes 61-66, wherein the length of the static mixer is less than about 10 mm.

[0282] Implementation Scheme 68. The system of any one of Implementation Schemes 61-67, wherein the length of the static mixer is less than about 5 mm.

[0283] Implementation Scheme 69. The system of any one of Implementation Schemes 61-68, wherein the length of the static mixer is about 4.8 mm.

[0284] Implementation Scheme 70. The system of any one of Implementation Schemes 61-69, wherein the static mixer has an inner diameter of about 1 / 16 inch to about 1 / 2 inch.

[0285] Implementation Scheme 71. The system as described in Implementation Scheme 70, wherein the inner diameter is approximately ¼ inch.

[0286] Implementation Scheme 72. The system as described in Implementation Scheme 70, wherein the inner diameter is approximately 1 / 8 inch.

[0287] Implementation Scheme 73. The system of any one of Implementation Schemes 61-72, wherein the nucleic acid and one or more lipid components in (b) are mixed to generate a mixture fluid, and wherein the polydispersity index of the mixture fluid is from about 0.05 to about 0.25.

[0288] Implementation Scheme 74. The system as described in Implementation Scheme 73, wherein the polydispersity index is about 0.1 to about 0.2.

[0289] Implementation Scheme 75. The system as described in any one of Implementation Schemes 61-72, wherein the polydispersity index is not greater than about 0.1.

[0290] Implementation Scheme 76. The system of any one of Implementation Schemes 61-75, wherein the Reynolds number of the mixed fluid is about 150 to about 1000.

[0291] Implementation Scheme 77. The system as described in Implementation Scheme 76, wherein the Reynolds number is about 500 to about 1000.

[0292] Implementation Scheme 78. The system as described in Implementation Scheme 76, wherein the Reynolds number is approximately 1000.

[0293] Implementation Scheme 79. The system of any one of Implementation Schemes 61-78, wherein the lipid nanoparticles are no larger than about 100 nm.

[0294] Implementation Scheme 80. The system as described in Implementation Scheme 79, wherein the lipid nanoparticles are about 50 nm to about 100 nm.

[0295] Implementation Scheme 81. The system as described in Implementation Scheme 79, wherein the lipid nanoparticles are about no larger than about 50 nm.

[0296] Implementation Scheme 82. The system of any one of Implementation Schemes 61-81, wherein the flow rate of the lipid component is in the ratio of about 1:2 to about 1:5 to the flow rate of the nucleic acid component.

[0297] Implementation Scheme 83. The system as described in Implementation Scheme 82, wherein the flow rate of the lipid component is approximately 1:2 to the flow rate of the nucleic acid component.

[0298] Implementation Scheme 84. The system as described in Implementation Scheme 82, wherein the flow rate of the lipid component is approximately 1:3 to the flow rate of the nucleic acid component.

[0299] Implementation Scheme 85. The system of any one of Implementation Schemes 61-84, wherein nucleic acids and one or more lipid components are mixed to generate a mixture fluid, thereby encapsulating the nucleic acids in one or more lipid components to generate lipid nanoparticles.

[0300] Implementation Scheme 86. The system of any one of Implementation Schemes 61-85, wherein the static mixer comprises eight or more elements.

[0301] Implementation Scheme 87. The system of any one of Implementation Schemes 61-86, wherein the static mixer comprises 12 or more elements.

[0302] Implementation Scheme 88. The system of any one of Implementation Schemes 61-87, wherein the static mixer comprises 16 or more elements.

[0303] Implementation Scheme 89. The system of any one of Implementation Schemes 61-88, wherein the static mixer comprises 24 or more elements.

[0304] Implementation Scheme 90. The system of any one of Implementation Schemes 61-89, wherein the static mixer is downstream of the conduit.

[0305] Implementation Scheme 91. A method for generating lipid nanoparticles, the method comprising: (a) Provide: i. A catheter, comprising: a. First entrance; b. Second entrance; c. The junction point, downstream of the first and second inlets; and ii. A static mixer, wherein the static mixer is located at the distal end of the junction point; (b) Introduce nucleic acid into the first entry point; (c) Introducing one or more lipid components of lipid nanoparticles into a second inlet; (d) To allow nucleic acids and one or more lipid components to converge at the junction site; and (e) Using a static mixer to mix nucleic acids and one or more lipid components, wherein the nucleic acids and one or more lipid components do not come into contact with each other before entering the junction site.

[0306] Implementation Scheme 92. The method as described in Implementation Scheme 91, wherein the catheter is T-shaped.

[0307] Implementation Scheme 93. The method as described in Implementation Scheme 91, wherein the catheter is Y-shaped.

[0308] Implementation Scheme 94. The method as described in Implementation Scheme 93, wherein the catheter further includes a cut ligature.

[0309] Implementation Scheme 95. The method as described in Implementation Scheme 91, wherein the catheter is L-shaped.

[0310] Implementation Scheme 96. The method of any one of Implementation Schemes 91-95, wherein the length of the static mixer is less than about 40 mm.

[0311] Implementation Scheme 97. The method of any one of Implementation Schemes 91-96, wherein the length of the static mixer is less than about 10 mm.

[0312] Implementation Scheme 98. The method of any one of Implementation Schemes 91-97, wherein the length of the static mixer is less than about 5 mm.

[0313] Implementation Scheme 99. The method of any one of Implementation Schemes 91-98, wherein the length of the static mixer is about 4.8 mm.

[0314] Implementation Scheme 100. The method of any one of Implementation Schemes 91-99, wherein the static mixer has an inner diameter of about 1 / 16 inch to about 1 / 2 inch.

[0315] Implementation Scheme 101. The method as described in Implementation Scheme 100, wherein the inner diameter is approximately ¼ inch.

[0316] Implementation scheme 102. The method as described in implementation scheme 100, wherein the inner diameter is about 1 / 8 inch.

[0317] Implementation Scheme 103. The method of any one of Implementation Schemes 91-102, wherein the nucleic acid and one or more lipid components in I are mixed to generate a mixture fluid, and wherein the polydispersity index of the mixture fluid is from about 0.05 to about 0.25.

[0318] Implementation scheme 104. The method as described in implementation scheme 103, wherein the polydispersity index is about 0.1 to about 0.2.

[0319] Implementation Scheme 105. The method of any one of Implementation Schemes 91-102, wherein the polydispersity index is not greater than about 0.1.

[0320] Implementation Scheme 106. The method of any one of Implementation Schemes 91-105, wherein the Reynolds number of the mixed fluid is about 150 to about 1000.

[0321] Implementation scheme 107. The method as described in implementation scheme 106, wherein the Reynolds number is about 500 to about 1000.

[0322] Implementation scheme 108. The method as described in implementation scheme 106, wherein the Reynolds number is approximately 1000.

[0323] Implementation Scheme 109. The method of any one of Implementation Schemes 91-108, wherein the lipid nanoparticles are no larger than about 100 nm.

[0324] Implementation Scheme 110. The method as described in Implementation Scheme 109, wherein the lipid nanoparticles are about 50 nm to about 100 nm.

[0325] Implementation Scheme 111. The method as described in Implementation Scheme 109, wherein the lipid nanoparticles are about no larger than about 50 nm.

[0326] Implementation Scheme 112. The method of any one of Implementation Schemes 91-111, wherein the flow rate of the lipid component is in the ratio of about 1:2 to about 1:5 to the flow rate of the nucleic acid component.

[0327] Implementation Scheme 113. The method as described in Implementation Scheme 112, wherein the flow rate of the lipid component is approximately 1:2 to the flow rate of the nucleic acid component.

[0328] Implementation Scheme 114. The method as described in Implementation Scheme 112, wherein the flow rate of the lipid component is approximately 1:3 to the flow rate of the nucleic acid component.

[0329] Implementation Scheme 115. The method of any one of Implementation Schemes 91-114, wherein nucleic acids and one or more lipid components are mixed to generate a mixture fluid, thereby encapsulating the nucleic acids in one or more lipid components to generate lipid nanoparticles.

[0330] Implementation Scheme 116. The method of any one of Implementation Schemes 91-115, wherein the static mixer comprises eight or more elements.

[0331] Implementation Scheme 117. The method of any one of Implementation Schemes 91-116, wherein the static mixer comprises 12 or more elements.

[0332] Implementation Scheme 118. The method of any one of Implementation Schemes 91-117, wherein the static mixer comprises 16 or more elements.

[0333] Implementation Scheme 119. The method of any one of Implementation Schemes 91-118, wherein the static mixer comprises 24 or more elements.

[0334] Implementation Scheme 120. The method of any one of Implementation Schemes 91-119, wherein the static mixer is downstream of the conduit.

[0335] Implementation Scheme 121. A system for generating lipid nanoparticles, the system comprising: (a) A catheter, comprising: i. The first entry point, configured to introduce nucleic acids; ii. A second inlet, configured to introduce one or more lipid components of lipid nanoparticles; iii. Export, wherein nucleic acids and one or more lipid components converge in the export; and (b) A static mixer in which nucleic acid and one or more lipid components are mixed to generate a mixture fluid, and wherein the Reynolds number of the mixture fluid is not greater than about 1000.

[0336] Implementation scheme 122. The system as described in implementation scheme 121, wherein the catheter is T-shaped.

[0337] Implementation scheme 123. The system as described in implementation scheme 121, wherein the catheter is Y-shaped.

[0338] Implementation Scheme 124. The system as described in Implementation Scheme 123, wherein the catheter further includes a cut ligature.

[0339] Implementation Scheme 125. The system as described in Implementation Scheme 121, wherein the catheter is L-shaped.

[0340] Implementation Scheme 126. The system of any one of Implementation Schemes 121-125, wherein the length of the static mixer is less than about 40 mm.

[0341] Implementation Scheme 127. The system of any one of Implementation Schemes 121-126, wherein the length of the static mixer is less than about 10 mm.

[0342] Implementation Scheme 128. The system as described in any one of Implementation Schemes 121-127, wherein the length of the static mixer is less than about 5 mm.

[0343] Implementation Scheme 129. The system as described in any one of Implementation Schemes 121-128, wherein the length of the static mixer is about 4.8 mm.

[0344] Implementation Scheme 130. The system of any one of Implementation Schemes 121-129, wherein the static mixer has an inner diameter of about 1 / 16 inch to about 1 / 2 inch.

[0345] Implementation Scheme 131. The system as described in Implementation Scheme 130, wherein the inner diameter is approximately ¼ inch.

[0346] Implementation Scheme 132. The system as described in Implementation Scheme 130, wherein the inner diameter is approximately 1 / 8 inch.

[0347] Implementation Scheme 133. The system of any one of Implementation Schemes 121-132, wherein the polydispersity index of the mixed fluid is from about 0.05 to about 0.25.

[0348] Implementation scheme 134. The system as described in implementation scheme 133, wherein the polydispersity index is about 0.1 to about 0.2.

[0349] Implementation Scheme 135. The system as described in any one of Implementation Schemes 121-132, wherein the polydispersity index is not greater than about 0.1.

[0350] Implementation Scheme 136. The system as described in any one of Implementation Schemes 121-135, wherein the Reynolds number is about 150 to about 1000.

[0351] Implementation scheme 137. The system as described in implementation scheme 136, wherein the Reynolds number is about 500 to about 1000.

[0352] Implementation scheme 138. The system as described in implementation scheme 136, wherein the Reynolds number is approximately 1000.

[0353] Implementation Scheme 139. The system of any one of Implementation Schemes 121-138, wherein the lipid nanoparticles are no larger than about 100 nm.

[0354] Implementation Scheme 140. The system as described in Implementation Scheme 139, wherein the lipid nanoparticles are about 50 nm to about 100 nm.

[0355] Implementation Scheme 141. The system as described in Implementation Scheme 139, wherein the lipid nanoparticles are about no larger than about 50 nm.

[0356] Implementation Scheme 142. The system of any one of Implementation Schemes 121-141, wherein the flow rate of the lipid component is in the ratio of about 1:2 to about 1:5 to the flow rate of the nucleic acid component.

[0357] Implementation Scheme 143. The system as described in Implementation Scheme 142, wherein the flow rate of the lipid component is approximately 1:2 to the flow rate of the nucleic acid component.

[0358] Implementation Scheme 144. The system as described in Implementation Scheme 142, wherein the flow rate of the lipid component is approximately 1:3 to the flow rate of the nucleic acid component.

[0359] Implementation Scheme 145. The system of any one of Implementation Schemes 121-144, wherein nucleic acids and one or more lipid components are mixed to generate a mixture fluid, thereby encapsulating the nucleic acids in one or more lipid components to generate lipid nanoparticles.

[0360] Implementation Scheme 146. The system of any one of Implementation Schemes 121-145, wherein the static mixer comprises eight or more elements.

[0361] Implementation Scheme 147. The system of any one of Implementation Schemes 121-146, wherein the static mixer comprises 12 or more elements.

[0362] Implementation Scheme 148. The system of any one of Implementation Schemes 121-147, wherein the static mixer comprises 16 or more elements.

[0363] Implementation Scheme 149. The system of any one of Implementation Schemes 121-148, wherein the static mixer comprises 24 or more elements.

[0364] Implementation Scheme 150. The system as described in any one of Implementation Schemes 121-149, wherein the static mixer is downstream of the conduit.

[0365] Implementation Scheme 151. A method for generating lipid nanoparticles, the method comprising: (a) Provide: i. A catheter, comprising: a. First entrance; b. Second entrance; c. Exports; and ii. Static mixer; (b) Introduce nucleic acid into the first entry point; (c) Introducing one or more lipid components of lipid nanoparticles into a second inlet; (d) To allow nucleic acids and one or more lipid components to converge at the outlet; and (e) Using a static mixer to mix nucleic acids and one or more lipid components to generate a mixture fluid, wherein the Reynolds number of the mixture fluid is not greater than about 1000.

[0366] Implementation Scheme 152. The method as described in Implementation Scheme 151, wherein the catheter is T-shaped.

[0367] Implementation Scheme 153. The method as described in Implementation Scheme 151, wherein the catheter is Y-shaped.

[0368] Implementation Scheme 154. The method as described in Implementation Scheme 153, wherein the catheter further includes a cut ligature.

[0369] Implementation Scheme 155. The method as described in Implementation Scheme 151, wherein the catheter is L-shaped.

[0370] Implementation Scheme 156. The method of any one of Implementation Schemes 151-155, wherein the length of the static mixer is less than about 40 mm.

[0371] Implementation Scheme 157. The method of any one of Implementation Schemes 151-156, wherein the length of the static mixer is less than about 10 mm.

[0372] Implementation Scheme 158. The method of any one of Implementation Schemes 151-157, wherein the length of the static mixer is less than about 5 mm.

[0373] Implementation Scheme 159. The method of any one of Implementation Schemes 151-158, wherein the length of the static mixer is about 4.8 mm.

[0374] Implementation Scheme 160. The method of any one of Implementation Schemes 151-159, wherein the static mixer has an inner diameter of about 1 / 16 inch to abo½ 1 / 2 inch.

[0375] Implementation Scheme 161. The method as described in Implementation Scheme 160, wherein the inner diameter is abo¼ 1 / 4 inch.

[0376] Implementation Scheme 162. The method as described in Implementation Scheme 160, wherein the inner diameter is approximately 1 / 8 inch.

[0377] Implementation Scheme 163. The method of any one of Implementation Schemes 151-162, wherein the polydispersity index of the mixed fluid is from about 0.05 to about 0.25.

[0378] Implementation Scheme 164. The method as described in Implementation Scheme 163, wherein the polydispersity index is about 0.1 to about 0.2.

[0379] Implementation Scheme 165. The method of any one of Implementation Schemes 151-162, wherein the polydispersity index is not greater than about 0.1.

[0380] Implementation Scheme 166. The method of any one of Implementation Schemes 151-165, wherein the Reynolds number is about 150 to about 1000.

[0381] Implementation Scheme 167. The method as described in Implementation Scheme 166, wherein the Reynolds number is about 500 to about 1000.

[0382] Implementation scheme 168. The method as described in implementation scheme 166, wherein the Reynolds number is approximately 1000.

[0383] Implementation Scheme 169. The method of any one of Implementation Schemes 151-168, wherein the lipid nanoparticles are no larger than about 100 nm.

[0384] Implementation Scheme 170. The method as described in Implementation Scheme 169, wherein the lipid nanoparticles are about 50 nm to about 100 nm.

[0385] Implementation Scheme 171. The method as described in Implementation Scheme 169, wherein the lipid nanoparticles are about no larger than about 50 nm.

[0386] Implementation Scheme 172. The method of any one of Implementation Schemes 151-171, wherein the flow rate of the lipid component is in the ratio of about 1:2 to about 1:5 to the flow rate of the nucleic acid component.

[0387] Implementation Scheme 173. The method as described in Implementation Scheme 172, wherein the flow rate of the lipid component is approximately 1:2 to the flow rate of the nucleic acid component.

[0388] Implementation Scheme 174. The method as described in Implementation Scheme 172, wherein the flow rate of the lipid component is approximately 1:3 to the flow rate of the nucleic acid component.

[0389] Implementation Scheme 175. The method of any one of Implementation Schemes 151-174, wherein nucleic acids and one or more lipid components are mixed to generate a mixture fluid, thereby encapsulating the nucleic acids in one or more lipid components to generate lipid nanoparticles.

[0390] Implementation Scheme 176. The method of any one of Implementation Schemes 151-175, wherein the static mixer comprises eight or more elements.

[0391] Implementation Scheme 177. The method of any one of Implementation Schemes 151-176, wherein the static mixer comprises 12 or more elements.

[0392] Implementation Scheme 178. The method of any one of Implementation Schemes 151-177, wherein the static mixer comprises 16 or more elements.

[0393] Implementation Scheme 179. The method of any one of Implementation Schemes 151-178, wherein the static mixer comprises 24 or more elements.

[0394] Implementation Scheme 180. The method of any one of Implementation Schemes 151-179, wherein the static mixer is downstream of the conduit.

[0395] Implementation Scheme 181. A system for generating lipid nanoparticles, the system comprising: (a) A catheter, comprising: i. The first entry point, configured to introduce nucleic acids; ii. A second inlet, configured to introduce one or more lipid components of lipid nanoparticles; iii. Export, wherein nucleic acids and one or more lipid components converge in the export; and (b) A static mixer configured to mix nucleic acids and one or more lipid components, wherein the flow rate of the nucleic acids is not greater than about 200 mL / min.

[0396] Implementation Scheme 182. The system as described in Implementation Scheme 181, wherein the catheter is T-shaped.

[0397] Implementation Scheme 183. The system as described in Implementation Scheme 181, wherein the catheter is Y-shaped.

[0398] Implementation Scheme 184. The system as described in Implementation Scheme 183, wherein the catheter further includes a cut ligature.

[0399] Implementation Scheme 185. The system as described in Implementation Scheme 181, wherein the conduit is L-shaped.

[0400] Implementation Scheme 186. The system as described in any one of Implementation Schemes 181-185, wherein the length of the static mixer is less than about 40 mm.

[0401] Implementation Scheme 187. The system as described in any one of Implementation Schemes 181-186, wherein the length of the static mixer is less than about 10 mm.

[0402] Implementation Scheme 188. The system as described in any one of Implementation Schemes 181-187, wherein the length of the static mixer is less than about 5 mm.

[0403] Implementation Scheme 189. The system as described in any one of Implementation Schemes 181-188, wherein the length of the static mixer is about 4.8 mm.

[0404] Implementation Scheme 190. The system of any one of Implementation Schemes 181-189, wherein the static mixer has an inner diameter of about 1 / 16 inch to abo½ 1 / 2 inch.

[0405] Implementation Scheme 191. The system as described in Implementation Scheme 190, wherein the inner diameter is approximately ¼ inch.

[0406] Implementation scheme 192. The system as described in implementation scheme 190, wherein the inner diameter is about 1 / 8 inch.

[0407] Implementation Scheme 193. The system of any one of Implementation Schemes 181-192, wherein the nucleic acid and one or more lipid components in (b) are mixed to generate a mixture fluid, and wherein the polydispersity index of the mixture fluid is from about 0.05 to about 0.25.

[0408] Implementation scheme 194. The system as described in implementation scheme 193, wherein the polydispersity index is about 0.1 to about 0.2.

[0409] Implementation Scheme 195. The system as described in any one of Implementation Schemes 181-192, wherein the polydispersity index is not greater than about 0.1.

[0410] Implementation Scheme 196. The system of any one of Implementation Schemes 181-195, wherein the Reynolds number of the mixed fluid is about 150 to about 1000.

[0411] Implementation scheme 197. The system as described in implementation scheme 196, wherein the Reynolds number is about 500 to about 1000.

[0412] Implementation scheme 198. The system as described in implementation scheme 196, wherein the Reynolds number is approximately 1000.

[0413] Implementation Scheme 199. The system as described in any one of Implementation Schemes 181-198, wherein the lipid nanoparticles are no larger than about 100 nm.

[0414] Implementation Scheme 200. The system as described in Implementation Scheme 199, wherein the lipid nanoparticles are about 50 nm to about 100 nm.

[0415] Implementation Scheme 201. The system as described in Implementation Scheme 199, wherein the lipid nanoparticles are about no larger than about 50 nm.

[0416] Implementation Scheme 202. The system as described in any one of Implementation Schemes 181-201, wherein the flow rate of the lipid component is in the ratio of about 1:2 to about 1:5 to the flow rate of the nucleic acid component.

[0417] Implementation Scheme 203. The system as described in Implementation Scheme 202, wherein the flow rate of the lipid component is approximately 1:2 to the flow rate of the nucleic acid component.

[0418] Implementation Scheme 204. The system as described in Implementation Scheme 202, wherein the flow rate of the lipid component is approximately 1:3 to the flow rate of the nucleic acid component.

[0419] Implementation Scheme 205. The system of any one of Implementation Schemes 181-204, wherein nucleic acids and one or more lipid components are mixed to generate a mixture fluid, thereby encapsulating the nucleic acids in one or more lipid components to generate lipid nanoparticles.

[0420] Implementation Scheme 206. The system of any one of Implementation Schemes 181-205, wherein the static mixer comprises eight or more elements.

[0421] Implementation Scheme 207. The system of any one of Implementation Schemes 181-206, wherein the static mixer comprises 12 or more elements.

[0422] Implementation Scheme 208. The system of any one of Implementation Schemes 181-207, wherein the static mixer comprises 16 or more elements.

[0423] Implementation Scheme 209. The system of any one of Implementation Schemes 181-208, wherein the static mixer comprises 24 or more elements.

[0424] Implementation Scheme 210. The system as described in any one of Implementation Schemes 181-209, wherein the static mixer is downstream of the conduit.

[0425] Implementation Scheme 211. A method for generating lipid nanoparticles, the method comprising: (a) Provide: i. A catheter, comprising: a. First entrance; b. Second entrance; c. Exports; and ii. Static mixer; (b) Introduce nucleic acid into the first entry point; (c) Introducing one or more lipid components of lipid nanoparticles into a second inlet; (d) To allow nucleic acids and one or more lipid components to converge at the outlet; and (e) Use a static mixer to mix nucleic acids and one or more lipid components, wherein the flow rate of the nucleic acids is not greater than about 200 mL / min.

[0426] Implementation Scheme 212. The method as described in Implementation Scheme 211, wherein the catheter is T-shaped.

[0427] Implementation Scheme 213. The method as described in Implementation Scheme 211, wherein the catheter is Y-shaped.

[0428] Implementation Scheme 214. The method as described in Implementation Scheme 213, wherein the catheter further includes a cut ligature.

[0429] Implementation Scheme 215. The method as described in Implementation Scheme 211, wherein the catheter is L-shaped.

[0430] Implementation Scheme 216. The method of any one of Implementation Schemes 211-215, wherein the length of the static mixer is less than about 40 mm.

[0431] Implementation Scheme 217. The method of any one of Implementation Schemes 211-216, wherein the length of the static mixer is less than about 10 mm.

[0432] Implementation Scheme 218. The method of any one of Implementation Schemes 211-217, wherein the length of the static mixer is less than about 5 mm.

[0433] Implementation Scheme 219. The method of any one of Implementation Schemes 211-218, wherein the length of the static mixer is about 4.8 mm.

[0434] Implementation Scheme 220. The method of any one of Implementation Schemes 211-219, wherein the static mixer has an inner diameter of about 1 / 16 inch to about 1 / 2 inch.

[0435] Implementation Scheme 221. The method as described in Implementation Scheme 220, wherein the inner diameter is approximately ¼ inch.

[0436] Implementation scheme 222. The method as described in implementation scheme 220, wherein the inner diameter is about 1 / 8 inch.

[0437] Implementation Scheme 223. The method of any one of Implementation Schemes 211-222, wherein the nucleic acid and one or more lipid components are mixed to generate a mixture fluid, and wherein the polydispersity index of the mixture fluid is from about 0.05 to about 0.25.

[0438] Implementation Scheme 224. The method as described in Implementation Scheme 223, wherein the polydispersity index is about 0.1 to about 0.2.

[0439] Implementation Scheme 225. The method of any one of Implementation Schemes 211-222, wherein the polydispersity index is not greater than about 0.1.

[0440] Implementation Scheme 226. The method of any one of Implementation Schemes 211-225, wherein the Reynolds number of the mixed fluid is about 150 to about 1000.

[0441] Implementation Scheme 227. The method as described in Implementation Scheme 226, wherein the Reynolds number is about 500 to about 1000.

[0442] Implementation scheme 228. The method as described in implementation scheme 226, wherein the Reynolds number is approximately 1000.

[0443] Implementation Scheme 229. The method of any one of Implementation Schemes 211-228, wherein the lipid nanoparticles are no larger than about 100 nm.

[0444] Implementation Scheme 230. The method as described in Implementation Scheme 229, wherein the lipid nanoparticles are about 50 nm to about 100 nm.

[0445] Implementation Scheme 231. The method as described in Implementation Scheme 229, wherein the lipid nanoparticles are about no larger than about 50 nm.

[0446] Implementation Scheme 232. The method of any one of Implementation Schemes 211-231, wherein the flow rate of the lipid component is in the ratio of about 1:2 to about 1:5 to the flow rate of the nucleic acid component.

[0447] Implementation Scheme 233. The method as described in Implementation Scheme 232, wherein the flow rate of the lipid component is approximately 1:2 to the flow rate of the nucleic acid component.

[0448] Implementation Scheme 234. The method as described in Implementation Scheme 232, wherein the flow rate of the lipid component is approximately 1:3 to the flow rate of the nucleic acid component.

[0449] Implementation Scheme 235. The method of any one of Implementation Schemes 211-234, wherein nucleic acids and one or more lipid components are mixed to generate a mixture fluid, thereby encapsulating the nucleic acids in one or more lipid components to generate lipid nanoparticles.

[0450] Implementation Scheme 236. The method of any one of Implementation Schemes 211-235, wherein the static mixer comprises eight or more elements.

[0451] Implementation Scheme 237. The method of any one of Implementation Schemes 211-236, wherein the static mixer comprises 12 or more elements.

[0452] Implementation Scheme 238. The method of any one of Implementation Schemes 211-237, wherein the static mixer comprises 16 or more elements.

[0453] Implementation Scheme 239. The method of any one of Implementation Schemes 211-238, wherein the static mixer comprises 24 or more elements.

[0454] Implementation Scheme 240. The method of any one of Implementation Schemes 211-239, wherein the static mixer is downstream of the conduit.

[0455] Implementation Scheme 241. A system for generating lipid nanoparticles, the system comprising: (a) A catheter, comprising: i. The first entry point, configured to introduce nucleic acids; ii. A second inlet, configured to introduce one or more lipid components of lipid nanoparticles; iii. Export, wherein nucleic acids and one or more lipid components converge in the export; and (b) A static mixer configured to mix nucleic acids and one or more lipid components, wherein the lipid nanoparticles are no larger than about 150 nm.

[0456] Implementation Scheme 242. The system as described in Implementation Scheme 241, wherein the catheter is T-shaped.

[0457] Implementation Scheme 243. The system as described in Implementation Scheme 241, wherein the catheter is Y-shaped.

[0458] Implementation Scheme 244. The system as described in Implementation Scheme 243, wherein the catheter further includes a cut ligature.

[0459] Implementation Scheme 245. The system as described in Implementation Scheme 241, wherein the conduit is L-shaped.

[0460] Implementation Scheme 246. The system of any one of Implementation Schemes 241-245, wherein the length of the static mixer is less than about 40 mm.

[0461] Implementation Scheme 247. The system of any one of Implementation Schemes 241-246, wherein the length of the static mixer is less than about 10 mm.

[0462] Implementation Scheme 248. The system as described in any one of Implementation Schemes 241-247, wherein the length of the static mixer is less than about 5 mm.

[0463] Implementation Scheme 249. The system of any one of Implementation Schemes 241-248, wherein the length of the static mixer is about 4.8 mm.

[0464] Implementation Scheme 250. The system of any one of Implementation Schemes 241-249, wherein the static mixer has an inner diameter of about 1 / 16 inch to about 1 / 2 inch.

[0465] Implementation Scheme 251. The system as described in Implementation Scheme 250, wherein the inner diameter is approximately ¼ inch.

[0466] Implementation scheme 252. The system as described in implementation scheme 250, wherein the inner diameter is about 1 / 8 inch.

[0467] Implementation Scheme 253. The system of any one of Implementation Schemes 241-252, wherein the nucleic acid and one or more lipid components in (b) are mixed to generate a mixture fluid, and wherein the polydispersity index of the mixture fluid is from about 0.05 to about 0.25.

[0468] Implementation scheme 254. The system as described in implementation scheme 253, wherein the polydispersity index is about 0.1 to about 0.2.

[0469] Implementation scheme 255. The system as described in any one of implementation schemes 241-252, wherein the polydispersity index is not greater than about 0.1.

[0470] Implementation Scheme 256. The system of any one of Implementation Schemes 241-255, wherein the Reynolds number of the mixed fluid is about 150 to about 1000.

[0471] Implementation scheme 257. The system as described in implementation scheme 256, wherein the Reynolds number is about 500 to about 1000.

[0472] Implementation scheme 258. The system as described in implementation scheme 256, wherein the Reynolds number is approximately 1000.

[0473] Implementation Scheme 259. The system as described in any one of Implementation Schemes 241-258, wherein the lipid nanoparticles are no larger than about 100 nm.

[0474] Implementation Scheme 260. The system as described in Implementation Scheme 259, wherein the lipid nanoparticles are about 50 nm to about 100 nm.

[0475] Implementation Scheme 261. The system as described in Implementation Scheme 259, wherein the lipid nanoparticles are about no larger than about 50 nm.

[0476] Implementation Scheme 262. The system as described in any one of Implementation Schemes 241-261, wherein the flow rate of the lipid component is in the ratio of about 1:2 to about 1:5 to the flow rate of the nucleic acid component.

[0477] Implementation Scheme 263. The system as described in Implementation Scheme 262, wherein the flow rate of the lipid component is approximately 1:2 to the flow rate of the nucleic acid component.

[0478] Implementation Scheme 264. The system as described in Implementation Scheme 262, wherein the flow rate of the lipid component is approximately 1:3 to the flow rate of the nucleic acid component.

[0479] Implementation Scheme 265. The system of any one of Implementation Schemes 241-264, wherein nucleic acids and one or more lipid components are mixed to generate a mixture fluid, thereby encapsulating the nucleic acids in one or more lipid components to generate lipid nanoparticles.

[0480] Implementation Scheme 266. The system of any one of Implementation Schemes 241-265, wherein the static mixer comprises eight or more elements.

[0481] Implementation Scheme 267. The system of any one of Implementation Schemes 241-266, wherein the static mixer comprises 12 or more elements.

[0482] Implementation Scheme 268. The system of any one of Implementation Schemes 241-267, wherein the static mixer comprises 16 or more elements.

[0483] Implementation Scheme 269. The system of any one of Implementation Schemes 241-268, wherein the static mixer comprises 24 or more elements.

[0484] Implementation Scheme 270. The system as described in any one of Implementation Schemes 241-269, wherein the static mixer is downstream of the conduit.

[0485] Implementation Scheme 271. A method for generating lipid nanoparticles, the method comprising: (a) Provide: i. A catheter, comprising: a. First entrance; b. Second entrance; c. Exports; and ii. Static mixer; (b) Introduce nucleic acid into the first entry point; (c) Introducing one or more lipid components of lipid nanoparticles into a second inlet; (d) To allow nucleic acids and one or more lipid components to converge at the outlet; and (e) Use a static mixer to mix nucleic acids and one or more lipid components, wherein the lipid nanoparticles are no larger than about 150 nm.

[0486] Implementation Scheme 272. The method as described in Implementation Scheme 271, wherein the catheter is T-shaped.

[0487] Implementation Scheme 273. The method as described in Implementation Scheme 271, wherein the catheter is Y-shaped.

[0488] Implementation Scheme 274. The method as described in Implementation Scheme 273, wherein the catheter further includes a cut ligature.

[0489] Implementation Scheme 275. The method as described in Implementation Scheme 271, wherein the catheter is L-shaped.

[0490] Implementation Scheme 276. The method of any one of Implementation Schemes 271-275, wherein the length of the static mixer is less than about 40 mm.

[0491] Implementation Scheme 277. The method of any one of Implementation Schemes 271-276, wherein the length of the static mixer is less than about 10 mm.

[0492] Implementation Scheme 278. The method of any one of Implementation Schemes 271-277, wherein the length of the static mixer is less than about 5 mm.

[0493] Implementation Scheme 279. The method of any one of Implementation Schemes 271-278, wherein the length of the static mixer is about 4.8 mm.

[0494] Implementation Scheme 280. The method of any one of Implementation Schemes 271-279, wherein the static mixer has an inner diameter of about 1 / 16 inch to about 1 / 2 inch.

[0495] Implementation Scheme 281. The method as described in Implementation Scheme 280, wherein the inner diameter is approximately ¼ inch.

[0496] Implementation scheme 282. The method as described in implementation scheme 280, wherein the inner diameter is about 1 / 8 inch.

[0497] Implementation Scheme 283. The method of any one of Implementation Schemes 271-282, wherein the nucleic acid and one or more lipid components are mixed to generate a mixture fluid, and wherein the polydispersity index of the mixture fluid is from about 0.05 to about 0.25.

[0498] Implementation Scheme 284. The method as described in Implementation Scheme 283, wherein the polydispersity index is about 0.1 to about 0.2.

[0499] Implementation Scheme 285. The method of any one of Implementation Schemes 271-282, wherein the polydispersity index is not greater than about 0.1.

[0500] Implementation Scheme 286. The method of any one of Implementation Schemes 271-285, wherein the Reynolds number of the mixed fluid is about 150 to about 1000.

[0501] Implementation scheme 287. The method as described in implementation scheme 286, wherein the Reynolds number is about 500 to about 1000.

[0502] Implementation scheme 288. The method as described in implementation scheme 286, wherein the Reynolds number is approximately 1000.

[0503] Implementation Scheme 289. The method of any one of Implementation Schemes 271-288, wherein the lipid nanoparticles are no larger than about 100 nm.

[0504] Implementation Scheme 290. The method as described in Implementation Scheme 289, wherein the lipid nanoparticles are about 50 nm to about 100 nm.

[0505] Implementation Scheme 291. The method as described in Implementation Scheme 289, wherein the lipid nanoparticles are about no larger than about 50 nm.

[0506] Implementation Scheme 292. The method of any one of Implementation Schemes 271-291, wherein the flow rate of the lipid component is in the ratio of about 1:2 to about 1:5 to the flow rate of the nucleic acid component.

[0507] Implementation Scheme 293. The method as described in Implementation Scheme 292, wherein the flow rate of the lipid component is approximately 1:2 to the flow rate of the nucleic acid component.

[0508] Implementation Scheme 294. The method as described in Implementation Scheme 292, wherein the flow rate of the lipid component is approximately 1:3 to the flow rate of the nucleic acid component.

[0509] Implementation Scheme 295. The method of any one of Implementation Schemes 271-294, wherein nucleic acids and one or more lipid components are mixed to generate a mixture fluid, thereby encapsulating the nucleic acids in one or more lipid components to generate lipid nanoparticles.

[0510] Implementation Scheme 296. The method of any one of Implementation Schemes 271-295, wherein the static mixer comprises eight or more elements.

[0511] Implementation Scheme 297. The method of any one of Implementation Schemes 271-296, wherein the static mixer comprises 12 or more elements.

[0512] Implementation Scheme 298. The method of any one of Implementation Schemes 271-297, wherein the static mixer comprises 16 or more elements.

[0513] Implementation Scheme 299. The method of any one of Implementation Schemes 271-298, wherein the static mixer comprises 24 or more elements.

[0514] Implementation Scheme 300. The method of any one of Implementation Schemes 271-299, wherein the static mixer is downstream of the conduit.

[0515] Implementation Scheme 301. A system for generating lipid nanoparticles, the system comprising: (a) A catheter, comprising: i. The first entry point, configured to introduce nucleic acids; ii. A second inlet, configured to introduce one or more lipid components of lipid nanoparticles; iii. Export, wherein nucleic acids and one or more lipid components converge in the export; and (b) A static mixer configured to mix nucleic acids and one or more lipid components to encapsulate the nucleic acids in one or more lipid components to generate lipid nanoparticles.

[0516] Implementation scheme 302. The system as described in implementation scheme 301, wherein the catheter is T-shaped.

[0517] Implementation scheme 303. The system as described in implementation scheme 301, wherein the conduit is Y-shaped.

[0518] Implementation Scheme 304. The system as described in Implementation Scheme 303, wherein the catheter further includes a cut ligature.

[0519] Implementation scheme 305. The system as described in implementation scheme 301, wherein the conduit is L-shaped.

[0520] Implementation Scheme 306. The system of any one of Implementation Schemes 301-305, wherein the length of the static mixer is less than about 40 mm.

[0521] Implementation Scheme 307. The system as described in any one of Implementation Schemes 301-306, wherein the length of the static mixer is less than about 10 mm.

[0522] Implementation scheme 308. The system of any one of implementation schemes 301-307, wherein the length of the static mixer is less than about 5 mm.

[0523] Implementation Scheme 309. The system of any one of Implementation Schemes 301-308, wherein the length of the static mixer is about 4.8 mm.

[0524] Implementation Scheme 310. The system of any one of Implementation Schemes 301-309, wherein the static mixer has an inner diameter of about 1 / 16 inch to about 1 / 2 inch.

[0525] Implementation Scheme 311. The system as described in Implementation Scheme 310, wherein the inner diameter is approximately ¼ inch.

[0526] Implementation scheme 312. The system as described in implementation scheme 310, wherein the inner diameter is about 1 / 8 inch.

[0527] Implementation Scheme 313. The system of any one of Implementation Schemes 301-312, wherein the nucleic acid and one or more lipid components in (b) are mixed to generate a mixture fluid, and wherein the polydispersity index of the mixture fluid is from about 0.05 to about 0.25.

[0528] Implementation Scheme 314. The system as described in Implementation Scheme 313, wherein the polydispersity index is about 0.1 to about 0.2.

[0529] Implementation scheme 315. The system as described in any one of implementation schemes 301-312, wherein the polydispersity index is not greater than about 0.1.

[0530] Implementation Scheme 316. The system of any one of Implementation Schemes 301-315, wherein the Reynolds number of the mixed fluid is about 150 to about 1000.

[0531] Implementation scheme 317. The system as described in implementation scheme 316, wherein the Reynolds number is about 500 to about 1000.

[0532] Implementation scheme 318. The system as described in implementation scheme 316, wherein the Reynolds number is approximately 1000.

[0533] Implementation Scheme 319. The system of any one of Implementation Schemes 301-318, wherein the lipid nanoparticles are no larger than about 100 nm.

[0534] Implementation Scheme 320. The system as described in Implementation Scheme 319, wherein the lipid nanoparticles are about 50 nm to about 100 nm.

[0535] Implementation Scheme 321. The system as described in Implementation Scheme 319, wherein the lipid nanoparticles are about no larger than about 50 nm.

[0536] Implementation Scheme 322. The system as described in any one of Implementation Schemes 301-321, wherein the flow rate of the lipid component is in the ratio of about 1:2 to about 1:5 to the flow rate of the nucleic acid component.

[0537] Implementation Scheme 323. The system as described in Implementation Scheme 322, wherein the flow rate of the lipid component is approximately 1:2 to the flow rate of the nucleic acid component.

[0538] Implementation Scheme 324. The system as described in Implementation Scheme 322, wherein the flow rate of the lipid component is approximately 1:3 to the flow rate of the nucleic acid component.

[0539] Implementation Scheme 325. The system of any one of Implementation Schemes 301-324, wherein the static mixer comprises eight or more elements.

[0540] Implementation Scheme 326. The system of any one of Implementation Schemes 301-325, wherein the static mixer comprises 12 or more elements.

[0541] Implementation Scheme 327. The system of any one of Implementation Schemes 301-326, wherein the static mixer comprises 16 or more elements.

[0542] Implementation Scheme 328. The system of any one of Implementation Schemes 301-327, wherein the static mixer comprises 24 or more elements.

[0543] Implementation Scheme 329. The system of any one of Implementation Schemes 301-328, wherein the static mixer is downstream of the conduit.

[0544] Implementation Scheme 330. A method for generating lipid nanoparticles, the method comprising: (a) Provide: i. A catheter, comprising: a. First entrance; b. Second entrance; c. Exports; and ii. Static mixer; (b) Introduce nucleic acid into the first entry point; (c) Introducing one or more lipid components of lipid nanoparticles into a second inlet; (d) To allow nucleic acids and one or more lipid components to converge at the outlet; and (e) Using a static mixer to mix nucleic acids and one or more lipid components, thereby encapsulating the nucleic acids in one or more lipid components to generate lipid nanoparticles.

[0545] Implementation Scheme 331. The method as described in Implementation Scheme 330, wherein the catheter is T-shaped.

[0546] Implementation scheme 332. The method as described in implementation scheme 330, wherein the catheter is Y-shaped.

[0547] Implementation Scheme 333. The method as described in Implementation Scheme 332, wherein the catheter further includes a cut ligature.

[0548] Implementation scheme 334. The method as described in implementation scheme 330, wherein the catheter is L-shaped.

[0549] Implementation scheme 335. The method of any one of implementation schemes 330-334, wherein the length of the static mixer is less than about 40 mm.

[0550] Implementation scheme 336. The method of any one of implementation schemes 330-335, wherein the length of the static mixer is less than about 10 mm.

[0551] Implementation scheme 337. The method of any one of implementation schemes 330-336, wherein the length of the static mixer is less than about 5 mm.

[0552] Implementation Scheme 338. The method of any one of Implementation Schemes 330-337, wherein the length of the static mixer is about 4.8 mm.

[0553] Implementation Scheme 339. The method of any one of Implementation Schemes 330-338, wherein the static mixer has an inner diameter of about 1 / 16 inch to about 1 / 2 inch.

[0554] Implementation scheme 340. The method as described in implementation scheme 339, wherein the inner diameter is about ¼ inch.

[0555] Implementation scheme 341. The method as described in implementation scheme 339, wherein the inner diameter is about 1 / 8 inch.

[0556] Implementation Scheme 342. The method of any one of Implementation Schemes 330-341, wherein the nucleic acid and one or more lipid components are mixed to generate a mixture fluid, and wherein the polydispersity index of the mixture fluid is from about 0.05 to about 0.25.

[0557] Implementation scheme 343. The method as described in implementation scheme 342, wherein the polydispersity index is about 0.1 to about 0.2.

[0558] Implementation scheme 344. The method of any one of implementation schemes 330-341, wherein the polydispersity index is not greater than about 0.1.

[0559] Implementation Scheme 345. The method of any one of Implementation Schemes 330-344, wherein the Reynolds number of the mixed fluid is about 150 to about 1000.

[0560] Implementation Scheme 346. The method as described in Implementation Scheme 345, wherein the Reynolds number is about 500 to about 1000.

[0561] Implementation scheme 347. The method as described in implementation scheme 345, wherein the Reynolds number is approximately 1000.

[0562] Implementation scheme 348. The method of any one of implementation schemes 330-347, wherein the lipid nanoparticles are no larger than about 100 nm.

[0563] Implementation Scheme 349. The method as described in Implementation Scheme 348, wherein the lipid nanoparticles are about 50 nm to about 100 nm.

[0564] Implementation Scheme 350. The method as described in Implementation Scheme 348, wherein the lipid nanoparticles are about no larger than about 50 nm.

[0565] Implementation Scheme 351. The method of any one of Implementation Schemes 330-350, wherein the flow rate of the lipid component is in the ratio of about 1:2 to about 1:5 to the flow rate of the nucleic acid component.

[0566] Implementation Scheme 352. The method as described in Implementation Scheme 351, wherein the flow rate of the lipid component is approximately 1:2 to the flow rate of the nucleic acid component.

[0567] Implementation Scheme 353. The method as described in Implementation Scheme 351, wherein the flow rate of the lipid component is approximately 1:3 to the flow rate of the nucleic acid component.

[0568] Implementation Scheme 354. The method of any one of Implementation Schemes 330-353, wherein the static mixer comprises eight or more elements.

[0569] Implementation Scheme 355. The method of any one of Implementation Schemes 330-354, wherein the static mixer comprises 12 or more elements.

[0570] Implementation Scheme 356. The method of any one of Implementation Schemes 330-355, wherein the static mixer comprises 16 or more elements.

[0571] Implementation Scheme 357. The method of any one of Implementation Schemes 330-356, wherein the static mixer comprises 24 or more elements.

[0572] Implementation Scheme 358. The method of any one of Implementation Schemes 330-357, wherein the static mixer is downstream of the conduit.

[0573] Implementation Scheme 359. A system for generating lipid nanoparticles, the system comprising a static mixer wherein the system reaches a pressure of no more than 8 psig when nucleic acids and one or more lipid components are combined in the static mixer.

[0574] Implementation scheme 360. The system as described in implementation scheme 359, wherein the system further includes a first entry point configured to introduce nucleic acid.

[0575] Implementation Scheme 361. The system as described in Implementation Scheme 359 or 360, wherein the system further includes a second inlet configured to introduce one or more lipid components of lipid nanoparticles.

[0576] Implementation scheme 362. The system as described in any one of implementation schemes 359-361, wherein the length of the static mixer is less than about 40 mm.

[0577] Implementation scheme 363. The system as described in any one of implementation schemes 359-362, wherein the length of the static mixer is less than about 10 mm.

[0578] Implementation scheme 364. The system as described in any one of implementation schemes 359-363, wherein the length of the static mixer is less than about 5 mm.

[0579] Implementation Scheme 365. The system as described in any one of Implementation Schemes 359-364, wherein the length of the static mixer is about 4.8 mm.

[0580] Implementation Scheme 366. The system of any one of Implementation Schemes 359-365, wherein the static mixer has an inner diameter of about 1 / 16 inch to about 1 / 2 inch.

[0581] Implementation scheme 367. The system as described in implementation scheme 366, wherein the inner diameter is approximately ¼ inch.

[0582] Implementation scheme 368. The system as described in implementation scheme 366, wherein the inner diameter is approximately 1 / 8 inch.

[0583] Implementation Scheme 369. The system of any one of Implementation Schemes 359-368, wherein the nucleic acid and one or more lipid components in (b) are mixed to generate a mixture fluid, and wherein the polydispersity index of the mixture fluid is from about 0.05 to about 0.25.

[0584] Implementation scheme 370. The system as described in implementation scheme 369, wherein the polydispersity index is about 0.1 to about 0.2.

[0585] Implementation scheme 371. The system as described in any one of implementation schemes 369-370, wherein the polydispersity index is not greater than about 0.1.

[0586] Implementation Scheme 372. The system of any one of Implementation Schemes 359-371, wherein the Reynolds number of the mixed fluid is about 150 to about 1000.

[0587] Implementation scheme 373. The system as described in implementation scheme 372, wherein the Reynolds number is about 500 to about 1000.

[0588] Implementation scheme 374. The system as described in implementation scheme 372, wherein the Reynolds number is approximately 1000.

[0589] Implementation Scheme 375. The system as described in any one of Implementation Schemes 359-374, wherein the lipid nanoparticles are no larger than about 100 nm.

[0590] Implementation Scheme 376. The system as described in Implementation Scheme 375, wherein the lipid nanoparticles are about 50 nm to about 100 nm.

[0591] Implementation Scheme 377. The system as described in Implementation Scheme 375, wherein the lipid nanoparticles are about no larger than about 50 nm.

[0592] Implementation Scheme 378. The system as described in any one of Implementation Schemes 359-377, wherein the flow rate of the lipid component is in the ratio of about 1:2 to about 1:5 to the flow rate of the nucleic acid component.

[0593] Implementation Scheme 379. The system as described in Implementation Scheme 378, wherein the flow rate of the lipid component is approximately 1:2 to the flow rate of the nucleic acid component.

[0594] Implementation Scheme 380. The system as described in Implementation Scheme 378, wherein the flow rate of the lipid component is approximately 1:3 to the flow rate of the nucleic acid component.

[0595] Implementation Scheme 381. The system of any one of Implementation Schemes 359-380, wherein nucleic acids and one or more lipid components are mixed to generate a mixture fluid, thereby encapsulating the nucleic acids in one or more lipid components to generate lipid nanoparticles.

[0596] Implementation Scheme 382. The system as described in any one of Implementation Schemes 359-381, wherein the static mixer comprises eight or more elements.

[0597] Implementation Scheme 383. The system of any one of Implementation Schemes 359-382, wherein the static mixer comprises 12 or more elements.

[0598] Implementation Scheme 384. The system of any one of Implementation Schemes 359-383, wherein the static mixer comprises 16 or more elements.

[0599] Implementation Scheme 385. The system of any one of Implementation Schemes 359-384, wherein the static mixer comprises 24 or more elements.

Claims

1. A system for generating lipid nanoparticles, the system comprising: (a) Catheter; (b) A static mixer in which nucleic acids and one or more lipid components are mixed to generate a mixture fluid; as well as (c) High performance liquid chromatography (HPLC) pump.

2. A system for generating lipid nanoparticles, the system comprising a conduit and a static mixer, wherein nucleic acids and one or more lipid components are mixed to generate a mixture fluid, and wherein the system reaches a pressure not greater than 8 psig when the nucleic acids and the one or more lipid components converge in the static mixer.

3. The system of claim 1 or 2, wherein the conduit includes a first inlet configured to introduce the nucleic acid.

4. The system of any one of claims 1-3, wherein the catheter includes a second inlet configured to introduce one or more lipid components of the lipid nanoparticles.

5. The system of any one of claims 1-4, wherein the catheter includes an outlet, wherein the nucleic acid and the one or more lipid components converge in the outlet.

6. A system for generating lipid nanoparticles, the system comprising: (a) A catheter, said catheter comprising: (i) The first entry point, which is configured to introduce nucleic acids; (ii) A second inlet, which is configured to introduce one or more lipid components of the lipid nanoparticles; (iii) An outlet, wherein the nucleic acid and one or more lipid components converge in the outlet; and (b) A static mixer, wherein the nucleic acid and one or more lipid components are mixed to generate a mixture fluid, and wherein the polydispersity index of the mixture fluid is not greater than about 0.

25.

7. A system for generating lipid nanoparticles, the system comprising: (a) A catheter, said catheter comprising: (i) The first entry point, which is configured to introduce nucleic acids; (ii) A second inlet, which is configured to introduce one or more lipid components of the lipid nanoparticles; (iii) The intersection point, wherein the first entrance and the second entrance intersect; and (b) A static mixer configured to mix the nucleic acid and one or more lipid components, wherein the nucleic acid and one or more lipid components do not come into contact with each other before entering the intersection site.

8. A system for generating lipid nanoparticles, the system comprising: (a) A catheter, said catheter comprising: (i) The first entry point, which is configured to introduce nucleic acids; (ii) A second inlet, which is configured to introduce one or more lipid components of the lipid nanoparticles; (iii) An outlet, wherein the nucleic acid and one or more lipid components converge in the outlet; and (b) A static mixer, wherein the nucleic acid and one or more lipid components are mixed to generate a mixture fluid, and wherein the Reynolds number of the mixture fluid is not greater than about 1000.

9. A system for generating lipid nanoparticles, the system comprising: (a) A catheter, said catheter comprising: (i) The first entry point, which is configured to introduce nucleic acids; (ii) A second inlet, which is configured to introduce one or more lipid components of the lipid nanoparticles; (iii) An outlet, wherein the nucleic acid and one or more lipid components converge in the outlet; and (b) A static mixer configured to mix the nucleic acid and one or more lipid components, wherein the flow rate of the nucleic acid is not greater than about 200 mL / min.

10. A system for generating lipid nanoparticles, the system comprising: (a) A catheter, said catheter comprising: (i) The first entry point, which is configured to introduce nucleic acids; (ii) A second inlet, which is configured to introduce one or more lipid components of the lipid nanoparticles; (iii) An outlet, wherein the nucleic acid and one or more lipid components converge in the outlet; and (b) A static mixer configured to mix the nucleic acid and one or more lipid components, wherein the lipid nanoparticles are no larger than about 150 nm.

11. A system for generating lipid nanoparticles, the system comprising: (a) A catheter, said catheter comprising: (i) The first entry point, which is configured to introduce nucleic acids; (ii) A second inlet, which is configured to introduce one or more lipid components of the lipid nanoparticles; (iii) An outlet, wherein the nucleic acid and one or more lipid components converge in the outlet; and (b) A static mixer configured to mix the nucleic acid and one or more lipid components to encapsulate the nucleic acid in the one or more lipid components to generate the lipid nanoparticles.

12. A system for generating lipid nanoparticles, the system comprising: (i) A catheter, said catheter comprising: (a) The first entry point, which is configured to introduce nucleic acids; (b) A second inlet configured to introduce one or more lipid components of the lipid nanoparticles; (c) an outlet, wherein the nucleic acid and one or more lipid components converge in the outlet; and (ii) A static mixer configured to mix the nucleic acid and one or more lipid components. When nucleic acids and one or more lipid components are mixed in the static mixer, the system reaches a pressure of no more than 8 psig.

13. The system as claimed in any of the preceding claims, wherein the conduit includes a third inlet configured to introduce one or more lipid components of the nucleic acid or the lipid nanoparticle.

14. The system of any of the preceding claims, wherein the conduit includes a fourth inlet configured to introduce the nucleic acid or the lipid nanoparticles of one or more lipid components.

15. The system as claimed in any of the preceding claims, wherein the static mixer comprises a plurality of elements, wherein each element of the static mixer is twisted 270° per 1 / 8 inch.

16. The system as claimed in any of the preceding claims, wherein the system includes a channel that houses the static mixer configured to mix the nucleic acid and the one or more lipid components, wherein the channel is square and undergoes a -180° twist every 1 / 8 inch.

17. The system as claimed in any of the preceding claims, wherein the conduit is T-shaped.

18. The system of any one of claims 1-17, wherein the conduit is Y-shaped.

19. The system of any one of claims 1-17, wherein the conduit is L-shaped.

20. The system as claimed in any of the preceding claims, wherein the catheter further comprises a cut ties.

21. The system as claimed in any of the preceding claims, wherein the length of the static mixer is less than about 40 millimeters (mm).

22. The system as claimed in any of the preceding claims, wherein the length of the static mixer is less than about 10 mm.

23. The system as claimed in any of the preceding claims, wherein the length of the static mixer is less than about 5 mm.

24. The system as claimed in any of the preceding claims, wherein the length of the static mixer is about 4.8 mm.

25. The system as claimed in any of the preceding claims, wherein the static mixer has an inner diameter of about 1 / 16 inch to about 1 / 2 inch.

26. The system of claim 25, wherein the inner diameter is about ¼ inch.

27. The system of claim 25, wherein the inner diameter is about 1 / 8 inch.

28. The system as claimed in any of the preceding claims, wherein the polydispersity index of the mixture fluid is from about 0.05 to about 0.

25.

29. The system of claim 28, wherein the polydispersity index of the mixture fluid is from about 0.1 to about 0.

2.

30. The system of any one of claims 28, wherein the polydispersity index of the mixture fluid is not greater than about 0.

1.

31. The system as claimed in any of the preceding claims, wherein the Reynolds number of the mixture fluid is about 150 to about 1000.

32. The system of claim 31, wherein the Reynolds number is about 500 to about 1000.

33. The system of claim 31, wherein the Reynolds number is about 1000.

34. The system of any of the preceding claims, wherein the diameter of the lipid nanoparticles is not greater than about 100 nanometers (nm).

35. The system of claim 34, wherein the diameter of the lipid nanoparticles is about 50 nm to about 100 nm.

36. The system of claim 34, wherein the diameter of the lipid nanoparticles is not greater than about 50 nm.

37. The system of any one of claims 4-36, wherein the flow rate of the lipid component is in the ratio of the flow rate of the nucleic acid to about 1:2 to about 1:

5.

38. The system of claim 37, wherein the flow rate of the lipid component is in a ratio of approximately 1:2 to the flow rate of the nucleic acid.

39. The system of claim 37, wherein the flow rate of the lipid component is in a ratio of approximately 1:3 to the flow rate of the nucleic acid.

40. The system of any one of claims 4-39, wherein the nucleic acid and the one or more lipid components are mixed to generate the mixture fluid, thereby encapsulating the nucleic acid in the one or more lipid components to generate the lipid nanoparticles.

41. The system as claimed in any of the preceding claims, wherein the static mixer comprises eight or more elements.

42. The system as claimed in any of the preceding claims, wherein the static mixer comprises 12 or more elements.

43. The system as claimed in any of the preceding claims, wherein the static mixer comprises 16 or more elements.

44. The system as claimed in any of the preceding claims, wherein the static mixer comprises 24 or more elements.

45. The system as claimed in any of the preceding claims, wherein the static mixer is downstream of the conduit.

46. ​​The system of any one of claims 4-45, wherein the angle between the first inlet and the second inlet is not greater than 180°.

47. The system of any one of claims 4-46, wherein the angle between the first inlet and the outlet is at least 90°.

48. The system of any one of claims 5-46, wherein the angle between the second inlet and the outlet is at least 90°.

49. The system as claimed in any of the preceding claims, wherein the system achieves a pressure not exceeding 8 psig.

50. The system of any one of claims 6-49, further comprising a high-performance liquid chromatography (HPLC) pump configured to deliver the nucleic acid and the one or more lipid components at a specified flow rate.

51. A method for generating lipid nanoparticles, the method comprising: (a) Provide: (i) Catheter; as well as (ii) Static mixer; (b) Providing nucleic acid and one or more lipid components of the lipid nanoparticles to a high-performance liquid chromatography (HPLC) pump, the HPLC pump being configured to provide the nucleic acid and the one or more lipid components at a specified flow rate; (c) Introduce the nucleic acid into the first entry point; (d) Introducing one or more lipid components of the lipid nanoparticles into a second inlet; (e) To allow the nucleic acid and one or more lipid components to converge at the outlet; as well as (f) Using the static mixer, the nucleic acid and one or more lipid components are mixed to generate a mixture fluid containing the lipid nanoparticles.

52. The method of claim 51, wherein the catheter includes a first inlet.

53. The method of claim 51 or 52, wherein the catheter includes a second inlet.

54. The method of any one of claims 51-53, wherein the conduit includes an outlet.

55. A method for generating lipid nanoparticles, the method comprising: (a) Provide: (i) A catheter, said catheter comprising: (i) First entrance; (ii) Second entrance; (iii) Exports; and (ii) Static mixer; (b) Introduce nucleic acid into the first entry point; (c) Introducing one or more lipid components of the lipid nanoparticles into the second inlet; (d) To allow the nucleic acid and one or more lipid components to converge at the outlet; and (e) Using the static mixer, the nucleic acid and one or more lipid components are mixed to generate a mixture fluid, wherein the polydispersity index of the mixture fluid is not greater than about 0.

25.

56. A method for generating lipid nanoparticles, the method comprising: (a) Provide: (i) A catheter, said catheter comprising: (i) First entrance; (ii) Second entrance; (iii) The junction point, which is downstream of the first inlet and the second inlet; and (ii) A static mixer, wherein the static mixer is disposed at the distal end of the junction point; (b) Introduce nucleic acid into the first entry point; (c) Introducing one or more lipid components of the lipid nanoparticles into the second inlet; (d) To allow the nucleic acid and one or more lipid components to converge at the junction site; and (e) Using the static mixer, the nucleic acid and the one or more lipid components are mixed, wherein the nucleic acid and the one or more lipid components do not come into contact with each other before entering the junction site.

57. A method for generating lipid nanoparticles, the method comprising: (a) Provide: (i) A catheter, said catheter comprising: (i) First entrance; (ii) Second entrance; (iii) Exports; and (ii) Static mixer; (b) Introduce nucleic acid into the first entry point; (c) Introducing one or more lipid components of the lipid nanoparticles into the second inlet; (d) To allow the nucleic acid and one or more lipid components to converge at the outlet; and (e) Using the static mixer, the nucleic acid and one or more lipid components are mixed to generate a mixture fluid, wherein the Reynolds number of the mixture fluid is not greater than about 1000.

58. A method for generating lipid nanoparticles, the method comprising: (a) Provide: (i) A catheter, said catheter comprising: (i) First entrance; (ii) Second entrance; (iii) Exports; and (ii) Static mixer; (b) Introduce nucleic acid into the first entry point; (c) Introducing one or more lipid components of the lipid nanoparticles into the second inlet; (d) To allow the nucleic acid and one or more lipid components to converge at the outlet; and (e) Using the static mixer, the nucleic acid and one or more lipid components are mixed, wherein the flow rate of the nucleic acid is not greater than about 200 mL / min.

59. A method for generating lipid nanoparticles, the method comprising: (a) Provide: (i) A catheter, said catheter comprising: (i) First entrance; (ii) Second entrance; (iii) Exports; and (ii) Static mixer; (b) Introduce nucleic acid into the first entry point; (c) Introducing one or more lipid components of the lipid nanoparticles into the second inlet; (d) To allow the nucleic acid and one or more lipid components to converge at the outlet; and (e) Using the static mixer, the nucleic acid and one or more lipid components are mixed, wherein the lipid nanoparticles are no larger than about 150 nm.

60. A method for generating lipid nanoparticles, the method comprising: (a) Provide: (i) A catheter, said catheter comprising: (i) First entrance; (ii) Second entrance; (iii) Exports; and (ii) Static mixer; (b) Introduce nucleic acid into the first entry point; (c) Introducing one or more lipid components of the lipid nanoparticles into the second inlet; (d) To allow the nucleic acid and one or more lipid components to converge at the outlet; and (e) Using the static mixer, the nucleic acid and the one or more lipid components are mixed to encapsulate the nucleic acid in the one or more lipid components to generate the lipid nanoparticles.

61. A method for generating lipid nanoparticles, the method comprising: (a) Providing a system as described in any of the preceding claims; (b) Introduce nucleic acid into the first entry point; (c) Introducing one or more lipid components of the lipid nanoparticles into the second inlet; (d) To allow the nucleic acid and one or more lipid components to converge at the outlet; as well as (e) Using the static mixer, the nucleic acid and the one or more lipid components are mixed to encapsulate the nucleic acid within the one or more lipid components to generate the lipid nanoparticles. The particle size of the lipid nanoparticles is selected by adjusting the Reynolds number.

62. A method for generating lipid nanoparticles, the method comprising: (a) Provide: (i) A catheter, said catheter comprising: (i) First entrance; (ii) Second entrance; (iii) The junction point, which is downstream of the first inlet and the second inlet; and (ii) A static mixer, wherein the static mixer is disposed at the distal end of the junction point; (b) Introduce nucleic acid into the first entry point; (c) Introducing one or more lipid components of the lipid nanoparticles into the second inlet; (d) To allow the nucleic acid and one or more lipid components to converge at the junction site; and The nucleic acid and one or more lipid components are mixed using the static mixer, wherein the catheter and static mixer reach a pressure of no more than 8 psig.

63. The method of any one of claims 51-62, wherein the catheter includes a third inlet.

64. The method of any one of claims 51-63, wherein the catheter includes a fourth inlet.

65. The method of any one of claims 51-64, wherein the catheter is T-shaped.

66. The method of any one of claims 51-64, wherein the catheter is Y-shaped.

67. The method of any one of claims 51-64, wherein the catheter is L-shaped.

68. The method of any one of claims 51-67, wherein the catheter further comprises a cut ties.

69. The method of any one of claims 51-68, wherein the static mixer comprises a plurality of elements, wherein each element of the static mixer is twisted 270° per 1 / 8 inch.

70. The method of any one of claims 51-69, wherein the length of the static mixer is less than about 40 mm.

71. The method of any one of claims 51-70, wherein the length of the static mixer is less than about 10 mm.

72. The method of any one of claims 51-71, wherein the length of the static mixer is less than about 5 mm.

73. The method of any one of claims 51-72, wherein the length of the static mixer is about 4.8 mm.

74. The method of any one of claims 51-73, wherein the static mixer has an inner diameter of about 1 / 16 inch to about 1 / 2 inch.

75. The method of claim 74, wherein the inner diameter is about 1 / 4 inch.

76. The method of claim 75, wherein the inner diameter is about 1 / 8 inch.

77. The method of any one of claims 51-76, wherein the method comprises using a channel that accommodates the static mixer for mixing the nucleic acid and one or more lipid components, wherein the channel is square and undergoes a -180° twist every 1 / 8 inch.

78. The method of any one of claims 51-77, wherein the polydispersity index of the mixture fluid is from about 0.05 to about 0.

25.

79. The method of claim 78, wherein the polydispersity index of the mixture fluid is from about 0.1 to about 0.

2.

80. The method of claim 78, wherein the polydispersity index of the mixture fluid is not greater than about 0.

1.

81. The method of any one of claims 51-80, wherein the Reynolds number of the mixture fluid is about 150 to about 1000.

82. The method of claim 81, wherein the Reynolds number is about 500 to about 1000.

83. The method of claim 82, wherein the Reynolds number is about 1000.

84. The method of any one of claims 81-83, wherein the particle size is increased by reducing the Reynolds number.

85. The method of any one of claims 81-83, wherein the particle size is reduced by increasing the Reynolds number.

86. The method of any one of claims 81-85, wherein the diameter of the lipid nanoparticles is not greater than about 100 nm.

87. The method of claim 86, wherein the diameter of the lipid nanoparticles is about 50 nm to about 100 nm.

88. The method of claim 86, wherein the diameter of the lipid nanoparticles is not greater than about 50 nm.

89. The method of any one of claims 51-88, wherein the flow rate of the lipid component is in the ratio of about 1:2 to about 1:5 to the flow rate of the nucleic acid.

90. The method of claim 89, wherein the flow rate of the lipid component is in a ratio of approximately 1:2 to the flow rate of the nucleic acid.

91. The method of claim 89, wherein the flow rate of the lipid component is in a ratio of approximately 1:3 to the flow rate of the nucleic acid.

92. The method of any one of claims 51-91, wherein the nucleic acid and the one or more lipid components are mixed to generate the mixture fluid, thereby encapsulating the nucleic acid in the one or more lipid components to generate the lipid nanoparticles.

93. The method of any one of claims 51-92, wherein the static mixer comprises eight or more elements.

94. The method of any one of claims 51-93, wherein the static mixer comprises 12 or more elements.

95. The method of any one of claims 51-94, wherein the static mixer comprises 16 or more elements.

96. The method of any one of claims 51-95, wherein the static mixer comprises 24 or more elements.

97. The method of any one of claims 51-96, wherein the static mixer is downstream of the conduit.

98. The method of any one of claims 51-97, further comprising diluting the lipid nanoparticles.

99. The method of claim 98, wherein after dilution, the particle size of the lipid nanoparticles differs from the particle size of the lipid nanoparticles before dilution by less than 10%.

100. The method of any one of claims 55-99, further comprising providing the nucleic acid and one or more lipid components of the lipid nanoparticles to a high-performance liquid chromatography (HPLC) pump configured to provide the nucleic acid and the one or more lipid components at a specified flow rate.

Citation Information

Patent Citations

  • Compositions and methods for organ specific delivery of nucleic acids

    US11229609B2

  • Lipocationic dendrimers and uses thereof

    US11247968B2

  • Cationic sulfonamide amino lipids and amphiphilic zwitterionic amino lipids

    US11542229B2

  • Compositions and methods for organ specific delivery of nucleic acids

    US11766408B2